HUE034254T2 - Substituted condensed pyrimidine compounds - Google Patents

Substituted condensed pyrimidine compounds Download PDF

Info

Publication number
HUE034254T2
HUE034254T2 HUE14718916A HUE14718916A HUE034254T2 HU E034254 T2 HUE034254 T2 HU E034254T2 HU E14718916 A HUE14718916 A HU E14718916A HU E14718916 A HUE14718916 A HU E14718916A HU E034254 T2 HUE034254 T2 HU E034254T2
Authority
HU
Hungary
Prior art keywords
alkyl
mmol
compound
yield
nmr
Prior art date
Application number
HUE14718916A
Other languages
Hungarian (hu)
Inventor
Ingo Konetzki
Florian Jakob
Tobias Craan
Christian Hesslinger
Paul Ratcliffe
Antonio Nardi
Original Assignee
Gruenenthal Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gruenenthal Gmbh filed Critical Gruenenthal Gmbh
Publication of HUE034254T2 publication Critical patent/HUE034254T2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Description

Description [0001] The present invention relates to novel substituted, condensed pyrimidine compounds, and to their use as pharmaceuticals (medicaments).
[0002] Pharmaceutically active substituted pyrimidine compounds are known (cf. US 2008/070896 A, (which is also published as EP180371 A, orW02005/014558).
[0003] It is also known that certain pyrimidine compounds are suitable for inhibiting specific phosphodiesterases (abbreviated as PDEs). Phosphodiesterases, or more accurately 3’,5’-cyclonucleotide phosphodiesterases, are enzymes that catalyse the hydrolysis of the second messengers cAMP (cyclic adenosine monophosphate) and cGMP (cyclic guanosine monophosphate) to 5’-AMP (5’-adenosine monophosphate) and 5’-GMP (5’-guanosine monophosphate). Inhibition of phosphodiesterases thus represents a mechanism for modulating cellular processes and can be used to alleviate or cure disease conditions.
[0004] WO 95/01338 A1, for example, describes how suitable PDE inhibitors can be used to treat inflammatory respiratory diseases, dermatoses, and other proliferative, inflammatory and allergic skin diseases. WO 95/01338 A1 proposes, moreover, that such PDE inhibitors can find application in the treatment of diseases that are based on an excess release of TNF and leukotrienes, for example diseases from the arthritis spectrum (rheumatoid arthritis, rheumatoid spondylitis, osteoarthritis and other arthritic conditions). The international publication proposes, furthermore, the use of suitable PDE inhibitors as medicaments for diseases of the immune system (e.g. AIDS), symptoms of shock, as well as generalised inflammations in the gastrointestinal system (e.g. Crohn’s disease and ulcerative colitis), diseases based on allergic and/or chronic, immunological adverse reactions in the upper respiratory tract (lateral pharyngeal space, nose) and adjacent regions (sinuses, eyes), such as for example allergic rhinitis/sinusitis, chronic rhinitis/sinusitis, allergic conjunctivitis and nasal polyps, but also diseases of the heart that can be treated by PDE inhibitors, such as for example heart failure, or diseases that can be treated because of the tissue-relaxing effect of PDE inhibitors, such as for example renal and ureteric colic in conjunction with kidney stones.
[0005] Phosphodiesterases are a group of enzymes encompassing 11 gene families (PDE1-11), which differ inter alia through their affinity to cAMP and cGMP.
[0006] The inhibition of the individual gene families with suitable substances is the subject of wide-ranging research. A known PDE5 inhibitor is sildenafil, which is commercially available under the trade name Viagra*™) and which is used primarily for the treatment of erectile dysfunction.
[0007] The discovery that the second messenger cAMP plays an important role in many inflammatory processes and that PDE4 is strongly expressed in cells that control inflammation processes (see inter alia Schudt, C. et al. (1995). PDE isoenzymes as targets for anti-asthma drugs. European Respiratory Journal 8, 1179-1183), has led to the development of PDE4 inhibitors having an anti-inflammatory effect. One such PDE4 inhibitor having an anti-inflammatory effect is roflumilast for example (known under the trade name Daxas®), which was approved as a medicament for the treatment of COPD (chronic obstructive pulmonary disease). In addition to the desired anti-inflammatory efFect of roflumilast, however, side-effects such as for example nausea, diarrhoea and headaches are observed, which limit the dose in humans.
[0008] Undesired side-effects in humans were observed with other PDE4 inhibitors too, so the therapeutic range (therapeutic window) of such medicaments is relatively narrow. The provision of PDE4 inhibitors having side-effects and a better therapeutic window would therefore be desirable.
[0009] Phosphodiesterase4(PDE4) is cAMP-specific and encompasses 4 different subtypes (PDE4A, PDE4B, PDE4C and PDE4D). As described below, efforts are being made to find subtype-selective PDE4 inhibitors, above all PDE4B-selective inhibitors, that have less severe or no side-effects, such that the therapeutic range of these compounds is increased significantly.
[0010] The inhibition of PDE4D is associated with the occurrence of undesired side-effects, such as for example diarrhoea, vomiting and nausea (see in this regard Mori, F. et al. (2010). The human area postrema and other nuclei related to the emetic reflex express cAMP phosphodiesterases 4B and 4D. Journal of Chemical Neuroanatomy 40, 36-42; Press, N.J.; Banner K. H (2009). PDE4 inhibitors - A review of the current field. Progress in Medicinal Chemistry 47, 37-74; Robichaud, A. et al. (2002). Deletion of phosphodiesterase 4D in mice shortens a2-adrenoceptor-mediated anesthesia, a behavioral correlate of emesis. The Journal of Clinical Investigation 110, 1045-52; or Lee et al., (2007). Dynamic regulation of CFTR by competitive interactions of molecular adaptors. Journal of Biological Chemistry 282, 10414-10422); or Giembycz, M.A. (2002). 4D or not 4D - the emetogenic basis of PDE4 inhibitors uncovered? Trends in Pharmacological Sciences 23, 548).
[0011] In an article entitled "Discovery of selective PDE4B inhibitors" published in Bioorganic& Medicinal Chemistry Letters 19 (2009) p.3174-3176, Kenji et al. disclose thirty-five pyrimidine compounds that exhibit PDE4B selectivity. Some of the compounds listed are said to show a 10-times or even higher inhibitory activity against PDE4B than against PDE4D.
[0012] The compounds examined by Kenji et al. are substantially encompassed by the general formula described in US 2006/0293343A1. US 2006/0293343A1 discloses specific pharmaceutically effective PDE4-inhibiting pyrimidine compounds having an anti-inflammatory effect, of the following general formula: in which
Ar1 is optionally substituted furyl, thienyl, triazolyl, thiazolyl, oxazolyl or benzothiazolyl; E is a single bond or methylene;
Ar21 is an optionally substituted phenyl or naphthyl;
Ra and Rb in each case independently of one another is hydrogen or alkyl, alkenyl, alkynyl, alkoxy, thioalkyl, alkyl sulfinyl, alkyl sulfonyl, each of which can optionally be substituted; and Rc is hydrogen or optionally substituted alkyl.
[0013] In the article by Kenji et al. the authors describe the examination of various structure-activity relationships, discussing inter alia the influence of the substituents at the 5- and 6-position on the pyrimidine ring (the substituent at the 5-position corresponds to Rb in the general structural formula above, which was taken from US 2006/0293343A1, and the substituent at the 6-position corresponds to Ra). It can be inferred from the article that when an allyl, ethyl, cyano or formyl radical is bound at the 5-position of the pyrimidine ring, highly effective, selective PDE4B compounds were obtained. If, however, a larger radical is present at the same position, the inhibitory activity of the tested compounds decreases. With regard to possible modifications of the substituents at the 6-position of the pyrimidine ring, the authors ascertain that if methyl is replaced with ethyl at this position, the activity of the compound increases and the selectivity is lowered. Thus the authors reason that changes at the 5- and/or 6-position of the pyrimidine ring influence the activity and the selectivity of the pyrimidine compound. The authors allude to steric effects, without however giving any further information as to how the selectivity can be influenced without losing inhibitory activity.
[0014] Based on this prior art the object was now to find compounds that are preferably PDE4B-selective (i.e. to find active compounds that with a particular amount of active ingredient inhibit PDE4B but without inhibiting or only weakly inhibiting the PDE4D subtype). The advantage of such a PDE4B selectivity, as mentioned above, is that various side-effects do not (should not) occur or occur only to a small extent and that therefore a greater therapeutic range (= therapeutic window) of the pharmaceutical active ingredient is (should be) obtained. The therapeutic range of a pharmaceutical active ingredient or medicament describes the gap between its therapeutic dose and a dose that would lead to a toxic or undesired effect. The greater the therapeutic range, the rarer or more unlikely the occurrence of certain toxic or undesired side-effects and hence the safer and more tolerable the pharmaceutical active ingredient or medicament. The therapeutic range is often also referred to as the therapeutic window or therapeutic index. These names are used synonymously in the present application.
[0015] The inventors have now found pyrimidine compounds that display the desired inhibiting and PDE4B-selective property and are superior to the corresponding pyrimidine compounds of the prior art. They are therefore particularly suitable for the treatment of diseases and conditions in which inhibition of the PDE4 enzyme, in particular the PDE4B enzyme, is advantageous.
[0016] The invention thus relates to pyrimidine compounds of the following general formula (I)
in which G is a phenyl optionally substituted with at least one substituent Z or a 5- or 6-membered aromatic heterocycle optionally substituted with at least one substituent Z, wherein said phenyl or said aromatic heterocycle may be condensed with a 4-, 5-, 6- or 7-membered ring, being carbocyclic or heterocyclic, wherein said condensed ring may be saturated, partially unsaturated or aromatic and may be substituted with at least one substituent Z; G preferably is selected from thienyl, furanyl.thiazolyl, isothiazolyl.oxazolyl, isooxazolyl, .pyridinyl, pyrimidinyl, phenyl, benzothiophenyl, benzofuranyl, benzodioxolyl, indolyl, quinolinyl, isoquinolinyl (preferably from thienyl, furanyl, thi-azolyl, pyridinyl, pyrimidinyl, phenyl, benzothiophenyl, benzofuranyl, benzodioxolyl, indolyl, quinolinyl, isoquinolinyl), wherein each of aforementioned groups may be substituted with at least one substituent Z; G is preferably selected from one of the following optionally substituted groups G1 to G47
in which the site marked with an asterisk (*) indicates the binding site at position 2 of the pyrimidine ring; G particularly preferably is selected from G1, G2, G3, G4, G5, G6, G7, G8, G9, G10, G11, G12, G13, G14, G15, G16, G17, G26, G27, G28, G29, G30, G31, G34, G35, G36, G37, G38, G39, G40, G41, G42, G43, G44, G45, G46, and G47; G most particularly preferably is selected from G1, G2, G3, G4, G5, G6, G7, G8, G26, G27, G28, G29, G30, G31, G34, G35, G36, G37, G38, G39, G40, G41, G42, G43, G44, G45, G46, G47; or from G1, G5, G8, G26, G27, G28, G31, G34, and G35; Z independently of one another is (C.|-Cg) alkyl, (C-pCg) hydroxyalkyl, (C.|-Cg) alkoxy, (C-pCg) haloalkyl, (C-pCg) haloalkoxy, -S(C1-C6) alkyl, halogen, hydroxyl or cyano or is S02(C1-C6)alkyl, CONH2, NHS02(C1-C6)alkyl, NH-CO(CrC6)alkyl wherein aforementioned alkyls are branched or straight-chain and can be substituted; Z preferably independently of one another is CH3, OCH3, CF3, CHF2, CH2F, OCF3, OCHF2, OCH2F, SCH3, Br, Cl, F, OH or CN, or S02CH3, CONH2, NHS02CH3, or NHCOCH3; k is 0,1,2, 3 or 4; if G is thienyl, furanyl, thiazoly, pyrimidyl, pyrimidinyl, benzothienyl, benzofuranyl, benzodioxolyl, benzopyrrol, benzopyridinyl then k is preferably 0 or 1 ; if G is a phenyl, then k is preferably 1 or 2; T is CR1R2 or S(0)x or S(0)=NH; T preferably is CH2, S, SO, S02 or S(0)=NH; X is 0, 1 or 2; preferably 1 or 2; most preferably 2; R1 and R2 independently of one another are hydrogen, (C^Cg) alkyl, preferably (0Γ04) alkyl, (C-pCg) alkoxy, preferably (CrC4) alkoxy, (C1-C6) haloalkyl, preferably (CrC4) haloalkyl, halogen, hydroxyl or cyano, wherein the aforementioned alkyl chains are branched or straight-chain and can be substituted; preferably R1 and R2 stand for hydrogen; n is 1 or 2; preferably 1 ; K is (CrC6) alkyl, preferably (CrC4) alkyl, (C1-C6) alkoxy, preferably (CrC4) alkoxy, (C^-Cg) haloalkyl, preferably (C1-C4) haloalkyl, halogen, hydroxyl or cyano, wherein the aforementioned alkyl chains are branched or straight-chain and can be substituted; m is 0, 1,2, 3 or 4; preferably m is 0; X independently of one another is (C-pCg) alkyl, (C3-C6) cycloalkyl, (CrC6) alkoxy, (C3-C6) cycloalkoxy, (CrC6) haloalkyl, (CrC6) haloalkoxy, halogen, hydroxyl, cyano, carboxyl, C(0)-NH2, C(0)-NH(C1-C6)alkyl, C(0)-N((CrCg) alkyl)2, NH2, NH(C1-C6)alkyl, NtfC-i-Cg) alkyl)2, N-pyrrolidinyl, N-piperidinyl, N-morpholinyl, NH-CHO, NH-C(0)-(C1-C6)alkyl, S(0)2-NH2, S(C1-C6)alkyl, S(0)-(C1-C6)alkyl, S(0)2-(C1-C6)alkyl, 0-(CrC4)alkyl-CN (preferably OCH2CN), 0-(C1-C4)alkyl-NH-CHO, 0-(C1-C4)alkyl-NH-C(0)-(C1-C6)alkyl (preferably 0(CH2)2NCH3)3), or 0-(CrC4) alkyl-N((CrC6) alkyl)2, or is 0-(C1-C4)alkyl-0-(C1-C4)alkyl (preferably 0(CH2)20CH3), wherein the aforementioned alkyl chains are branched or straight-chain and can be substituted, or is a chemical grouping L-C02R3 or 0-(C1-C4)alkyl-C0-R4 (preferably 0-CH2-C0R4) or LCONR4; R3 is hydrogen, branched or straight-chain (CrC6) alkyl, preferably (CrC4)alkyl; R3 is preferably hydrogen or methyl; R4 is NH2, NHR5, NR5R6, (CrCg) alkoxy; R5 and R6 independently of one another is (CrC6) alkyl, (CrCg) hydroxyalkyl, (C3-C6) cycloalkyl (preferably as cyclopropyl), (C1-C6)alkyl(C3-C6)cycloalkyl (preferably CH2-cyclopropyl), (C3-C6) heterocycloalkyl (such asoxetanyl, tetrahydrofuran), or R5 and R6, together with the nitrogen atom to which they are bound form a saturated 3- to 6-membered heterocycle, optionally substituted with branched or straight-chain (C-j-Cg) alkyl or hydroxyl groups, which heterocycle can optionally have at least one further heteroatom selected from O, S, and N; preferably R5 and R6, together with the nitrogen atom to which they are bound, form azetidinyl, piperazinyl, morpholinyl, pyrrolidinyl which may be optionally substituted; preferably R4 is NH2, NHCH3, N(CH3)2, NHC2H5, NHCH(CH3)2, NHCH2CH2OH, OCH3 or one of the following groups
L is a bond, (CrC6) alkylene, (C2-C6) alkenylene, -0-(C.|-C4) alkylene, -NH-(Ci-C4) alkylene, or -NR3-(C.|-C4) alkylene, wherein aforementioned alkylenes or alkenylenes can each be substituted with one or more halogen atoms (in particular fluorine) or wherein aforementioned alkylenes or alkenylenes can be substituted with one or more (C^Cg) alkyl groups (preferably methyl or ethyl), or wherein in aforementioned alkylenes or alkenylenes a CH2 unit can be replaced by an oxygen atom; L preferably is a bond or methylene, wherein the methylene can be substituted with one or two halogen atoms (in particular fluorine); p is 1,2, 3 or 4; U~V is a chemical grouping wherein ~ stands for a single or double bond, U stands for a substituted or unsubstituted carbon atom, a substituted or unsubstituted nitrogen atom or a carbonyl group, and V stands for a substituted or unsubstituted carbon atom, a substituted or unsubstituted nitrogen atom, or an oxygen atom, preferably and in particular, the chemical grouping U~V is selected from CR7R8-CR7R8; CR7=CR7, N=CR7, CR7=N, N=N, C(=0)-CR7R8, and C(=0)-0; preferably is selected from CH2-CH2, CH=CH, N=CH, CH=N, N=N, C(=0)-CH2, and C(=0)-0; R7 and R8 independently of one another are hydrogen, (C.|-C4) alkyl, (C.|-C4) alkoxy, (C.|-C4) haloalkyl (preferably CHF, CH2F or CF3), (Ci-C4) hydroxyalkyl, halogen (preferably F, Cl, Br), hydroxyl or cyano, as well as pharmacologically tolerable salts, diastereomers, enantiomers, racemates, hydrates or solvates thereof.
[0017] Preferred compounds according to the invention have the following general formula (l-A) wherein p’ is 0, 1,2 or 3 and all substituents, chemical groupings and indices are as defined for the compounds according to formula (I)
(I-A) [0018] In principal, the group LC02R3 can be bound at any position at the aromatic carbocycle. The positions marked as α, ß, and γ are, however, preferred. If LC02R3 is bound to the ß-position, then the following general formula (l-A-1) can be drafted.
(I-A-1) [0019] Among the compounds according to the inventions having the general formula (l-A) or (l-A-1 ), compounds are preferred wherein L is a bond ora methylene group, G stands for optionally substituted G1, G2, G5and G6 or substituted G34 or G35 (preferably G stands for G5 or G35) and wherein T stands for CH2 or S(0)x with x being 0,1 or 2, preferably 1 or 2, and the chemical grouping U~V stands for CR7R8-CR7R8 (preferably CH2-CH2).
[0020] Among the compounds according to the inventions having the general formula (l-A) or (l-A-1), compounds are preferred wherein L is a bond ora methylene group, G stands for optionally substituted G1, G2, G5and G6 or substituted G34 or G35 (preferably G stands for G5 or G35) and wherein T stands for CH2 or S(0)x with x being 0,1 or 2, preferably 1 or 2, and the chemical grouping U~V stands for CR7=CR7 (preferably CH=CH).
[0021] Among the compounds according to the inventions having the general formula (l-A) or (l-A-1), compounds are preferred wherein L is a bond ora methylene group, G stands for optionally substituted G1, G2, G5and G6 or substituted G34 or G35 (preferably G stands for G5 or G35) and wherein T stands for CH2 or S(0)x with x being 0,1 or 2, preferably 1 or 2, and the chemical grouping U~V stands for N=CR7 (preferably N=CH) or CR7=N (preferably N=CH).
[0022] Among the compounds according to the inventions having the generals formula (l-A) or (l-A-1), compounds are preferred wherein L is a bond or a methylene group, G stands for optionally substituted G1, G2, G5 and G6 or substituted G34 or G35 (preferably G stands for G5 or G35) and wherein T stands for CH2 or S(0)x with x being 0, 1 or 2, preferably 1 or 2, and the chemical grouping U~V stands for N=N.
[0023] Among the compounds according to the inventions having the generals formula (l-A) or (l-A-1), compounds are preferred wherein L is a bond or a methylene group, G stands for optionally substituted G1, G2, G5 and G6 or substituted G34 or G35 (preferably G stands for G5 or G35) and wherein T stands for CH2 or S(0)x with x being 0, 1 or 2, preferably 1 or 2, and the chemical grouping U~V stands for C(=0)-CR7R8 (preferably C(=0)-CH2).
[0024] Among the compounds according to the inventions having the generals formula (l-A) or (l-A-1), compounds are preferred wherein L is a bond or a methylene group, G stands for optionally substituted G1, G2, G5 and G6 or substituted G34 or G35 (preferably G stands for G5 or G35) and wherein T stands for CH2 or S(0)x with x being 0, 1 or 2, preferably 1 or 2, and the chemical grouping U~V stands for C(=0)-0.
[0025] Further preferred compounds according to the invention have the following general formula (l-B) wherein p’ is 0,1,2 or 3 and all substituents, chemical groupings and indices are as defined for the compounds according to formula (1)
(I-B) [0026] In principal the group 0-(CrC4) alkyl-COR4 can be bound at any position at the aromatic carbocycle. The positions marked as α, ß, and γ are, however, preferred. A certain preference is given to the a- ory- position.
[0027] In an [embodiment 1], compounds according to the inventions having the general formula (l-B) are preferred wherein G stands for optionally substituted G1, G2, G5 and G6, substituted G34 or G35 (preferably G stands for G5 or G35) or stands for one of the following groups thienyl, furanyl, thiazolyl, pyridinyl, pyrimidinyl, phenyl, benzothiophenyl, benzofuranyl, benzodioxolyl, indolyl, quinolinyl, isoquinolinyl, which groups can be substituted with at least one substituent K, and wherein all other chemical groupings and indices including those for R4 from the chemical grouping -0-(0^04) alkyl-CO-R4 have the definitions as described in connection with general formula (I).
[0028] Among the compounds of [embodiment 1] compounds having the following formula (l-B-1) are preferred:
[0029] Among the compounds of formula (l-B-1) compounds are preferred wherein, the group 0-(0^04) alkyl-COR4 can be bound at any position at the aromatic carbocycle. The positions marked as α, ß, and γ are, however, preferred. A certain preference is given to the a- or γ- position.
[0030] In an [embodiment 2], compounds according to the invention having the general formula (I) are preferred wherein G stands for optionally substituted G1, G2, G5 and G6, substituted G34 or G35 (preferably G stands for G5 or G35) or stands for one of the following thienyl, furanyl, thiazolyl, pyridinyl, pyrimidinyl, phenyl, benzothiophenyl, benzo-furanyl, benzodioxolyl, indolyl, quinolinyl, isoquinolinyl, which groups can be substituted with at least one substituent K, wherein m is 0, n is 1, p is 1 with X being the group 0-(0^04) alkyl-COR4 or LC02R3, or X being the group 0-(C1-C4)alkyl-CN (preferably OCH2CN), 0-(C1-C4)alkyl-NH-C(0)-(C1-C6)alkyl (preferably 0(CH2)2NCH3)3), 0-(CrC4)alkyl-0-(C1-C4)alkyl (preferably 0(CH2)20CH3), wherein the aforementioned alkyl chains are branched or straight-chain and can be substituted, or is a chemical grouping LCONR4, and wherein the group X is bound at the α-, ß-, or γ-position (preferably if X stands for the group 0-(0^4) alkyl-COR4, this group is bound to the a- or γ- position, and if X stands for the LC02R3, this group is bound to the ß-position), and wherein the chemical grouping U~V stands for CR7R8-CR7R8 (preferably CH2-CH2) and wherein all other chemical groupings and indices have the definitions as described in connection with general formula (I).
[0031] Among the compounds of [embodiment 2], compounds are preferred wherein X is -C02H,-CH2C02H, or -OCH2CON(CH3)2 and wherein T stands for CH2 or S(0)x with x being 1 or 2, preferably 2.
[0032] In an [embodiment 3], compounds according to the invention having the general formula (I) are preferred wherein G stands for optionally substituted G1, G2, G5 and G6, substituted G34 or G35 (preferably G stands for G5 or G35) or stands for one of the following thienyl, furanyl, thiazolyl, pyridinyl, pyrimidinyl, phenyl, benzothiophenyl, benzo-furanyl, benzodioxolyl, indolyl, quinolinyl, isoquinolinyl, which groups can be substituted with at least one substituent K, wherein m is 0, n is 1, p is 1 with X being the group 0-(C1-C4) alkyl-COR4 or LC02R3, orX being the group 0-(C1-C4)alkyl-CN (preferably OCH2CN), 0-(C1-C4)alkyl-NH-C(0)-(C1-C6)alkyi (preferably 0(CH2)2NCH3)3), 0-(CrC4)alkyl-0-(Ci-C4)alkyl (preferably 0(CH2)20CH3), wherein the aforementioned alkyl chains are branched or straight-chain and can be substituted, or is a chemical grouping LCONR4, and wherein the group X is bound at the α-, β-, or γ-position (preferably if X stands for the group 0-(0.,-04) alkyl-COR4, this group is bound to the a- or γ- position, and if X stands for the LC02R3, this group is bound to the ß-position), and wherein the chemical grouping U~V stands for CR7=CR7 (preferably CH=CH) and wherein all other chemical groupings and indices have the definitions as described in connection with general formula (1).
[0033] Among the compounds of [embodiment 3], compounds are preferred wherein X is -C02H, CH2C02H, or -OCH2CON(CH3)2 and wherein T stands for CH2 or S(0)x with x being 1 or 2, preferably 2.
[0034] In an [embodiment 4], compounds according to the invention having the general formula (I) are preferred wherein G stands for optionally substituted G1, G2, G5 and G6, substituted G34 or G35 (preferably G stands for G5 or G35) or stands for one of the following thienyl, furanyl, thiazolyl, pyridinyl, pyrimidinyl, phenyl, benzothiophenyl, benzo-furanyl, benzodioxolyl, indolyl, quinolinyl, isoquinolinyl, which groups can be substituted with at least one substituent K, wherein m is 0, n is 1, p is 1 with X being the group 0-(C1-C4) alkyl-COR4 or LC02R3, orX being the group 0-(C1-C4)alkyl-CN (preferably OCH2CN), 0-(C1-C4)alkyl-NH-C(0)-(C1-C6)alkyi (preferably 0(CH2)2NCH3)3), 0-(CrC4)alkyl-0-(C1-C4)alkyl (preferably 0(CH2)20CH3), wherein the aforementioned alkyl chains are branched or straight-chain and can be substituted, or is a chemical grouping LCONR4, and wherein the group X is bound at the α-, β-, or γ-position (preferably if X stands for the group 0-(0Γ04) alkyl-COR4, this group is bound to the a- or γ- position, and if X stands for the LC02R3, this group is bound to the ß-position),, and wherein the chemical grouping U~V stands for N=CR7 (preferably N=CH) or CR7=N (preferably N=CH) and wherein all other chemical groupings and indices have the definitions as described in connection with general formula (I).
[0035] Among the compounds of [embodiment 4], compounds are preferred wherein X is -C02H,-CH2C02H, or -OCH2CON(CH3)2 and wherein T stands for CH2 or S(0)x with x being 1 or 2, preferably 2.
[0036] In an [embodiment 5], compounds according to the invention having the general formula (I) are preferred wherein G stands for optionally substituted G1, G2, G5 and G6, substituted G34 or G35 (preferably G stands for G5 or G35) or stands for one of the following thienyl, furanyl, thiazolyl, pyridinyl, pyrimidinyl, phenyl, benzothiophenyl, benzo-furanyl, benzodioxolyl, indolyl, quinolinyl, isoquinolinyl, which groups can be substituted with at least one substituent K, wherein m is 0, n is 1, p is 1 with X being the group 0-(CrC4) alkyl-COR4or LC02R3, orX being the group 0-(C1-C4)alkyl-CN (preferably OCH2CN), 0-(C1-C4)aikyi-NH-C(0)-(C1-C6)alkyl (preferably 0(CFI2)2NCFI3)3), 0-(CrC4)alkyl-0-(C.|-C4)alkyl (preferably 0(CH2)20CH3), wherein the aforementioned alkyl chains are branched or straight-chain and can be substituted, or is a chemical grouping LCONR4, and wherein the group X is bound at the α-, β-, or γ-position (preferably if X stands for the group 0-(C.|-C4) alkyl-COR4, this group is bound to the a- or γ- position, and if X stands for the LC02R3, this group is bound to the ß-position)" and wherein the chemical grouping U~V stands for N=N and wherein all other chemical groupings and indices have the definitions as described in connection with general formula (1).
[0037] Among the compounds of [embodiment 5], compounds are preferred wherein X is -C02H,-CH2C02H, or -OCH2CON(CH3)2 and wherein T stands for CH2 or S(0)x with x being 1 or 2, preferably 2.
[0038] In an [embodiment 6], compounds according to the invention having the general formula (I) are preferred wherein G stands for optionally substituted G1, G2, G5 and G6, substituted G34 or G35 (preferably G stands for G5 or G35) or stands for one of the following thienyl, furanyl, thiazolyl, pyridinyl, pyrimidinyl, phenyl, benzothiophenyl, benzo-furanyl, benzodioxolyl, indolyl, quinolinyl, isoquinolinyl, which groups can be substituted with at least one substituent K, wherein m isO, n is 1, p is 1 with X being the group 0-(CrC4) alkyl-COR4 or LC02R3, orX being the group 0-(C1-C4)alkyl-CN (preferably OCH2CN), 0-(C1-C4)alkyi-NH-C(0)-(C1-C6)alkyl (preferably 0(CH2)2NCH3)3), 0-(C1-C4)alkyl-0-(C1-C4)alkyl (preferably 0(CH2)20CH3), wherein the aforementioned alkyl chains are branched or straight-chain and can be substituted, or is a chemical grouping LCONR4, and wherein the group X is bound at the α-, β-, or γ-position (preferably if X stands for the group 0-(C1-C4) alkyl-COR4, this group is bound to the a- or γ- position, and if X stands for the LC02R3, this group is bound to the ß-position), and wherein the chemical grouping U~V stands for C(=0)-CR7R8 (preferably C(=0)-CH2) and wherein all other chemical groupings and indices have the definitions as described in connection with general formula (I).
[0039] Among the compounds of [embodiment 6], compounds are preferred wherein X is -C02H, CH2C02H, or -OCH2CON(CH3)2 and wherein T stands for CH2 or S(0)x with x being 1 or 2, preferably 2.
[0040] In an [embodiment 7], compounds according to the invention having the general formula (1) are preferred wherein G stands for optionally substituted G1, G2, G5 and G6, substituted G34 or G35 (preferably G stands for G5 or G35) or stands for one of the following thienyl, furanyl, thiazolyl, pyridinyl, pyrimidinyl, phenyl, benzothiophenyl, benzo-furanyl, benzodioxolyl, indolyl, quinolinyl, isoquinolinyl, which groups can be substituted with at least one substituent K, wherein m is 0, n is 1, p is 1 with X being the group 0-(C1-C4) alkyl-COR4 or LC02R3, orX being the group 0-(C.|-C4)alkyl-CN (preferably OCH2CN), 0-(C1-C4)alkyl-NH-C(0)-(C1-C6)alkyi (preferably 0(CH2)2NCH3)3), 0-(C1-C4)alkyl-0-(Ci-C4)alkyl (preferably 0(CH2)2OCH3), wherein the aforementioned alkyl chains are branched or straight-chain and can be substituted, or is a chemical grouping LCONR4, and wherein the group X is bound at the α-, β-, or γ-position (preferably if X stands for the group 0-(CrC4) alkyl-COR4, this group is bound to the a- or γ- position, and if X stands for the LC02R3, this group is bound to the ß-position), and wherein the chemical grouping U~V stands for C(=0)-0 and wherein all other chemical groupings and indices have the definitions as described in connection with general formula (I).
[0041] Among the compounds of [embodiment 7], compounds are preferred wherein X is -C02H,-CH2C02H, or -OCH2CON(CH3)2 and wherein T stands for CH2 or S(0)x with x being 1 or 2, preferably 2.
[0042] Unless otherwise specified, the term (C^Cg) alkyl is understood to mean branched and unbranched alkyl groups consisting of 1 to 6 hydrocarbon groups. Examples of (CrC6) alkyl radicals are methyl, ethyl, n-propyl, 1-methylethyl (isopropyl), n-butyl, 1-methylpropyl, 2-methylpropyl, 1,1-dimethylethyl (tert-butyl), n-pentyl, 1-methylbutyl, 2-methylbutyl, 3-methylbutyl, 1,1-dimethylpropyl, 1,2-dimethylpropyl, 2,2-dimethylpropyl, n-hexyl, 1-methylpentyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl. (CrC4) alkyl radicals are preferred, (CrC3) alkyl radicals being particularly preferred, in particular methyl, ethyl and propyl. Unless otherwise stated, the definitions of propyl, butyl, pentyl and hexyl encompass all possible isomeric forms of the individual radicals.
[0043] Unless otherwise specified, a haloalkyl radical is understood to bean alkyl radical in which at least one hydrogen is exchanged for a halogen atom, preferably fluorine, chlorine, bromine, particularly preferably fluorine. The haloalkyl radicals can be branched or unbranched and optionally mono- or polysubstituted. Preferred haloalkyl radicals are CHF2, CH2F, CF3, CFI2-CFI2F, CH2-CHF2, CFI2CF3. (Ci-C6) haloalkyl radicals are preferred, with (CrC4) haloalkyl radicals being particularly preferred and (CrC3) haloalkyl radicals most particularly preferred, in particular CHF2, CH2F, CF3, CH2-CH2F, CH2-CHF2 and CH2CF3.
[0044] Unless otherwise specified, a haloalkoxy radical is understood to be an alkoxy radical in which at least one hydrogen is exchanged for a halogen atom, preferably fluorine, chlorine, bromine, particularly preferably fluorine. The haloalkoxy radicals can be branched or unbranched and optionally mono- or polysubstituted. Preferred haloalkoxy radicals are OCFIF2, OCH2F, OCF3, OCFI2-CFFI2, OCH2-CF2FI, OCFI2CF3. (CrC6) haloalkoxy radicals are preferred, with (CrC4) haloalkoxy radicals being particularly preferred and (CrC3) haloalkoxy radicals most particularly preferred, in particular OCFIF2, OCFI2F, OCF3, OCFI2-CFFI2, OCFI2-CF2FI, OCFI2CF3.
[0045] Unless otherwise specified, the term (C2-C6) alkenyl is understood to mean branched and unbranched alkyl groups consisting of 2 to 6 hydrocarbon atoms and having at least one double bond. Examples of (C2-C6) alkenyls are ethenyl (also referred to as vinyl), prop-1-enyl, prop-2-enyl (also referred to as allyl), but-1-enyl, but-2-enyl, but-3-enyl, pent-1-enyl and hex-1-enyl. The designation (C2-C6) alkenyl includes all possible isomers, i.e. structural isomers (constitutional isomers) and stereoisomers ((Z) and (E) isomers).
[0046] Unless otherwise specified, the term carbocycle is understood to mean preferably 3- to 7-membered rings consisting of hydrocarbon groups, which rings may be saturated, partially unsaturated or aromatic.
[0047] Unless otherwise specified, the term heterocycle is understood to mean preferably 5- to 7-membered rings consisting of hydrocarbon groups, which can be saturated, partially unsaturated or aromatic and which contain one or more heteroatoms selected from the group comprising nitrogen, oxygen and sulfur, preferably nitrogen and/or oxygen. Examples of saturated heterocycles are 1,4-dioxane, tetrahydrofuran and 1,4-oxathiane. Examples of aromatic or partially unsaturated heterocycles are furán, thiophene, pyridine, pyrimidine, thiazole, isothiazole, oxazole, isoxazole, pyridazine, pyrazine, indole, indazole, quinoline, isoquinoline, phthalazine and quinazoline. Unsaturated aromatic heterocycles are also called heteroaromatics.
[0048] Unless otherwise specified, carbocylces and heterocycles may be condensed with a 4-, 5-, 6- or 7-membered ring, being carbocyclicor heterocyclic, wherein said condensed ring may be saturated, partially unsaturated or aromatic. Examples of such condensed ring systems are benzothiophenyl, benzofuranyl, benzodioxolyl, indolyl, quinolinyl and isoquinolinyl [0049] Owing to their excellent pharmacological activity, the compounds according to the invention of the general structure of formula (I) and of the substructures of formula (l-A), (l-A-1) (l-B), or (l-B-1) derived from formula (I) are suitable for the treatment of various diseases or conditions in which inhibition of the PDE4 enzyme is advantageous.
[0050] Such conditions and diseases are inter alia inflammatory diseases of the joints, in particular rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis (Bech-terew’s disease), gout, osteoarthritis; inflammatory diseases of the skin, in particular psoriasis, atopic dermatitis, lichen planus; inflammatory diseases of the eyes, in particular uveitis; gastrointestinal diseases and complaints, in particular inflammatory diseases of the digestive organs, above all Crohn’s disease, ulcerative colitis, and acute and chronic inflammations of the gall bladder and bile ducts, of pseudopolyps and juvenile polyps; inflammatory diseases of the internal organs, in particular SLE (systemic lupus erythematosus) including lupus nephritis, chronic prostatitis, interstitial cystitis; hyperplastic diseases, in particular benign prostatic hyperplasia; respiratory or lung diseases associated with elevated mucus production, inflammation and/or obstruction of the respiratory tract, in particular COPD (chronic obstructive pulmonary disease), chronic bronchitis, asthma, pulmonary fibrosis, allergic and non-allergic rhinitis, obstructive sleep apnoea, cystic fibrosis, chronic sinusitis, emphysema, cough, alveolitis, ARDS (acute respiratory distress syndrome), pulmonary oedema, bronchiectasis, pneumonia; diseases of the fibrotic spectrum, in particular hepatic fibrosis, systemic sclerosis, scleroderma; cancers, in particular haematopoietic cancers, inter alia B-cell lymphoma, T-cell lymphoma, in particular CLL and CML (chronic lymphatic and chronic myeloid leukaemia), ALL and AML (acute lymphatic and acute myeloid leukaemia), and gliomas; metabolic diseases, in particular type 2 diabetes, metabolic syndrome, obesity/adiposity, fatty liver disease (not alcohol-induced), and cardiovascular diseases, in particular arteriosclerosis, PAH (pulmonary arterial hypertension); psychological disorders, in particular schizophrenia, depression, in particular bipolar or manic depression, dementia, memory loss, generalised anxiety disorder (GAD); and diseases ofthe peripheralor central nervous system, in particular Parkinson’s disease, multiple sclerosis, Alzheimer’s disease, stroke, ALS (amyotrophic lateral sclerosis).
[0051] One ofthe advantages ofthe compounds according to the invention ofthe general structure of formula (I) and of a substructure of formula (l-A), (l-A-1) (l-B), or (l-B-1) derived from formula (I) is that they are selective PDE4B inhibitors. The advantage of this selectivity lies in the fact that the PDE4D enzyme for example is not inhibited or is only partly inhibited, and hence the use of such selective PDE4B inhibitors gives rise to no side-effects or to markedly reduced side-effects. Undesired side-effects are for example emesis and nausea, in particular indisposition, vomiting and sickness. The therapeutic range ofthe compounds according to the invention is therefore advantageous.
[0052] The invention therefore also provides a pharmaceutical composition (medicament) containing at least one compound according to the invention ofthe general structure of formula (I) or of a substructure of formula (l-A), (l-A-1) (l-B), or (l-B-1) derived from formula (I) in the presented form or in the form of its acids or bases or in the form ofthe pharmaceutically safe, in particular physiologically tolerable salts, or in the form of its solvates, in particular hydrates, optionally in the form of its racemates, its pure stereoisomers, in particular enantiomers or diastereomers, or in the form of mixtures of stereoisomers, in particular enantiomers or diastereomers, in any mixing ratio.
[0053] The invention therefore also provides a compound according to the invention of the general structure of formula (I) or of a substructure of formula (l-A), (l-A-1 ) (l-B), or (l-B-1) derived from formula (I) in the presented form or in the form of its acids or bases or in the form of the pharmaceutically safe, in particular physiologically tolerable salts, or in the form of its solvates, in particular hydrates, optionally in the form of its racemates, its pure stereoisomers, in particular enantiomers or diastereomers, or in the form of mixtures of stereoisomers, in particular enantiomers or diastereomers, in any mixing ratio for use as a medicament, in particular for the treatment of conditions or diseases that can be treated by inhibition of the PDE4 enzyme, in particular the PDE4B enzyme.
[0054] The invention also provides a compound according to the invention of the general structure of formula (I) or of a substructure of formula (l-A), (l-A-1) (l-B), or (l-B-1) derived from formula (I) in the presented form or in the form of its acids or bases or in the form of the pharmaceutically safe, in particular physiologically tolerable salts, or in the form of its solvates, in particular hydrates, optionally in the form of its racemates, its pure stereoisomers, in particular enantiomers or diastereomers, or in the form of mixtures of stereoisomers, in particular enantiomers or diastereomers, in any mixing ratio for use as a medicament for the treatment of inflammatory diseases of the joints, in particular rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis (Bechterew’s disease), gout, osteoarthritis; and/or inflammatory diseases of the skin, in particular psoriasis, atopic dermatitis, lichen planus; and/or inflammatory diseases of the eyes, in particular uveitis; gastrointestinal diseases and complaints, in particular inflammatory diseases of the digestive organs, above all Crohn’s disease, ulcerative colitis, and acute and chronic inflammations of the gall bladder and bile ducts, of pseudopolyps and juvenile polyps; inflammatory diseases of the internal organs, in particular SLE (systemic lupus erythematosus) including lupus nephritis, chronic prostatitis, interstitial cystitis; and/or hyperplastic diseases, in particular benign prostatic hyperplasia; respiratory or lung diseases associated with elevated mucus production, inflammation and/or obstruction of the respiratory tract, in particular COPD (chronic obstructive pulmonary disease), chronic bronchitis, asthma, pulmonary fibrosis, allergic and non-allergic rhinitis, obstructive sleep apnoea, cystic fibrosis, chronic sinusitis, emphysema, cough, alveolitis, ARDS (acute respiratory distress syndrome), pulmonary oedema, bronchiectasis, pneumonia; diseases of the fibrotic spectrum, in particular hepatic fibrosis, systemic sclerosis, scleroderma; cancers, in particular haematopoietic cancers, inter alia B-cell lymphomas, T-cell lymphomas, in particular CLL and CML (chronic lymphatic and chronic myeloid leukaemia), ALL and AML (acute lymphatic and acute myeloid leukaemia), and gliomas; metabolic diseases, in particular type 2 diabetes, metabolic syndrome, obesity/adiposity, fatty liver disease (not alcohol-induced), and cardiovascular diseases, in particular arteriosclerosis, PAH (pulmonary arterial hypertension); psychological disorders, in particular schizophrenia, depression, in particular bipolar or manic depression, dementia, memory loss, generalised anxiety disorder (GAD); and/or diseases of the peripheral or central nervous system, in particular Parkinson’s disease, multiple sclerosis, Alzheimer’s disease, stroke, ALS (amyotrophic lateral sclerosis).
[0055] The invention also provides a compound according to the invention of the general structure of formula (I) or of a substructure of formula (l-A), (l-A-1) (l-B), or (l-B-1) derived from formula (I) in the presented form or in the form of its acids or bases or in the form of the pharmaceutically safe, in particular physiologically tolerable salts, or in the form of its solvates, in particular hydrates, optionally in the form of its racemates, its pure stereoisomers, in particular enantiomers or diastereomers, or in the form of mixtures of stereoisomers, in particular enantiomers or diastereomers, in any mixing ratio for use as a medicament for the treatment of inflammatory diseases of the joints (in particular rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis (Bechterew’s disease), gout, osteoarthritis), the skin (in particular psoriasis, atopic dermatitis, lichen planus) or the eyes (in particular uveitis), of respiratory or lung diseases associated with elevated mucus production, inflammation and/or obstruction of the respiratory tract, in particular COPD (chronic obstructive pulmonary disease), chronic bronchitis, asthma, pulmonary fibrosis, allergic and non-allergic rhinitis, obstructive sleep apnoea, cystic fibrosis, chronic sinusitis, emphysema, cough, alveolitis, ARDS (acute respiratory distress syndrome), pulmonary oedema, bronchiectasis, pneumonia; of metabolicdiseases, in particulartype 2 diabetes, metabolicsyndrome, obesity/adiposity, fatty liver disease (not alcohol-induced), and/or cardiovascular diseases, in particular arteriosclerosis, PAH (pulmonary arterial hypertension).
[0056] The invention also provides a compound according to the invention of the general structure of formula (I) or of a substructure of formula (l-A), (l-A-1) (l-B), or (l-B-1) derived from formula (I) in the presented form or in the form of its acids or bases or in the form of the pharmaceutically safe, in particular physiologically tolerable salts, or in the form of its solvates, in particular hydrates, optionally in the form of its racemates, its pure stereoisomers, in particular enantiomers or diastereomers, or in the form of mixtures of stereoisomers, in particular enantiomers or diastereomers, in any mixing ratio for use as a medicament for the treatment of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis (Bechterew’s disease), psoriasis, COPD (chronic obstructive pulmonary disease), asthma, type 2 diabetes and/or metabolic syndrome.
[0057] The invention also provides the use of a compound according to the invention of the general structure of formula (I) or of a substructure of formula (l-A), (l-A-1) (l-B), or (l-B-1) derived from formula (I) in the presented form or in the form of its acids or bases or in the form of the pharmaceutically safe, in particular physiologically tolerable salts, or in the form of its solvates, in particular hydrates, optionally in the form of its racemates, its pure stereoisomers, in particular enantiomers or diastereomers, or in the form of mixtures of stereoisomers, in particular enantiomers or diastereomers, in any mixing ratio to produce a medicament for the treatment of inflammatory diseases of the joints, in particular rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis (Bechterew’s disease), gout, osteoarthritis; inflammatory diseases of the skin, in particular psoriasis, atopic dermatitis, lichen planus; inflammatory diseases of the eyes, in particular uveitis; gastrointestinal diseases and complaints, in particular inflammatory diseases of the digestive organs, above all Crohn’s disease, ulcerative colitis, and acute and chronic inflammations of the gall bladder and bile ducts, of pseudopolyps and juvenile polyps; inflammatory diseases of the internal organs, in particular SLE (systemic lupus erythematosus) including lupus nephritis, chronic prostatitis, interstitial cystitis; hyperplastic diseases, in particular benign prostatic hyperplasia; respiratory or lung diseases associated with elevated mucus production, inflammation and/or obstruction of the respiratory tract, in particular COPD (chronic obstructive pulmonary disease), chronic bronchitis, asthma, pulmonary fibrosis, allergic and non-allergic rhinitis, obstructive sleep apnoea, cystic fibrosis, chronic sinusitis, emphysema, cough, alveolitis, ARDS (acute respiratory distress syndrome), pulmonary oedema, bronchiectasis, pneumonia; diseases of the fibrotic spectrum, in particular hepatic fibrosis, systemic sclerosis, scleroderma; cancers, in particular haematopoietic cancers, inter alia B-cell lymphomas, T-cell lymphomas, in particular CLL and CML (chronic lymphatic and chronic myeloid leukaemia), ALL and AML (acute lymphatic and acute myeloid leukaemia), and gliomas; metabolic diseases, in particular type 2 diabetes, metabolic syndrome, obesity/adiposity, fatty liverdisease (not alcohol-induced), and cardiovascular diseases, in particular arteriosclerosis, PAH (pulmonary arterial hypertension); psychological disorders, in particular schizophrenia, depression, in particular bipolar or manic depression, dementia, memory loss, generalised anxiety disorder (GAD); and/or diseases of the peripheral or central nervous system, in particular Parkinson’s disease, multiple sclerosis, Alzheimer’s disease, stroke, ALS (amyotrophic lateral sclerosis).
[0058] Preferred according to the invention is the use of a compound according to the invention of the general structure of formula (I) or of a compound of the general structure of formula (l-A), (l-A-1) (l-B), or (l-B-1) derived from formula (I) in the presented form or in the form of its acids or bases or in the form of the pharmaceutically safe, in particular physiologically tolerable salts, or in the form of its solvates, in particular hydrates, optionally in the form of its racemates, its pure stereoisomers, in particular enantiomers ordiastereomers, or in the form of mixtures of stereoisomers, in particular enantiomers or diastereomers, in any mixing ratio to produce a medicament for the treatment of inflammatory diseases of the joints (in particular rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis (Bechterew’s disease), gout, osteoarthritis), skin (in particular psoriasis, atopic dermatitis, lichen planus) or eyes (in particular uveitis).
[0059] Preferred according to the invention is the use of a compound according to the invention of the general structure of formula (I) or of a compound of the general structure of formula (l-A), (l-A-1) (l-B), or (l-B-1) derived from formula (I) in the presented form or in the form of its acids or bases or in the form of the pharmaceutically safe, in particular physiologically tolerable salts, or in the form of its solvates, in particular hydrates, optionally in the form of its racemates, its pure stereoisomers, in particular enantiomers or diastereomers, or in the form of mixtures of stereoisomers, in particular enantiomers or diastereomers, in any mixing ratio to produce a medicament for the treatment of gastrointestinal diseases and complaints, in particular inflammatory diseases of the digestive organs, above all Crohn’s disease, ulcerative colitis, and acute and chronic inflammations of the gall bladder and bile ducts, of pseudopolyps and juvenile polyps.
[0060] Preferred according to the invention is the use of a compound according to the invention of the general structure of formula (I) or of a compound of the general structure of formula formula (l-A), (l-A-1) (l-B), or (l-B-1) derived from formula (I) in the presented form or in the form of its acids or bases or in the form of the pharmaceutically safe, in particular physiologically tolerable salts, or in the form of its solvates, in particular hydrates, optionally in the form of its racemates, its pure stereoisomers, in particular enantiomers or diastereomers, or in the form of mixtures of stereoisomers, in particular enantiomers or diastereomers, in any mixing ratio to produce a medicament for the treatment of inflammatory diseases of the internal organs, in particular SLE (systemic lupus erythematosus) including lupus nephritis, chronic prostatitis, interstitial cystitis.
[0061] Preferred according to the invention is the use of a compound according to the invention of the general structure of formula (I) or of a compound of the general structure of formula (l-A), (l-A-1) (l-B), or (l-B-1) derived from formula (I) in the presented form or in the form of its acids or bases or in the form of the pharmaceutically safe, in particular physiologically tolerable salts, or in the form of its solvates, in particular hydrates, optionally in the form of its racemates, its pure stereoisomers, in particular enantiomers ordiastereomers, or in the form of mixtures of stereoisomers, in particular enantiomers or diastereomers, in any mixing ratio to produce a medicament for the treatment of hyperplastic diseases, in particular benign prostatic hyperplasia.
[0062] Preferred according to the invention is the use of a compound according to the invention of the general structure of formula (I) or of a compound of the general structure of formula (l-A), (l-A-1) (l-B), or (l-B-1) in the presented form or in the form of its acids or bases or in the form of the pharmaceutically safe, in particular physiologically tolerable salts, or in the form of its solvates, in particular hydrates, optionally in the form of its racemates, its pure stereoisomers, in particular enantiomers or diastereomers, or in the form of mixtures of stereoisomers, in particular enantiomers or diastereomers, in any mixing ratio to produce a medicament for the treatment of respiratory or lung diseases associated with elevated mucus production, inflammation and/or obstruction of the respiratory tract, in particular COPD (chronic obstructive pulmonary disease), chronic bronchitis, asthma, pulmonary fibrosis, allergic and non-allergic rhinitis, obstructive sleep apnoea, cystic fibrosis, chronic sinusitis, emphysema, cough, alveolitis, ARDS (acute respiratory distress syndrome), pulmonary oedema, bronchiectasis, pneumonia.
[0063] Preferred according to the invention is the use of a compound according to the invention of the general structure of formula (I) or of a compound of the general structure of formula (l-A), (l-A-1) (l-B), or (l-B-1) in the presented form or in the form of its acids or bases or in the form of the pharmaceutically safe, in particular physiologically tolerable salts, or in the form of its solvates, in particular hydrates, optionally in the form of its racemates, its pure stereoisomers, in particular enantiomers or diastereomers, or in the form of mixtures of stereoisomers, in particular enantiomers or dias-tereomers, in any mixing ratio to produce a medicament for the treatment of diseases of the fibrotic spectrum, in particular hepatic fibrosis, systemic sclerosis, scleroderma.
[0064] Preferred according to the invention is the use of a compound according to the invention of the general structure of formula (I) or of a compound of the general structure of formula (l-A), (l-A-1) (l-B), or (l-B-1) in the presented form or in the form of its acids or bases or in the form of the pharmaceutically safe, in particular physiologically tolerable salts, or in the form of its solvates, in particular hydrates, optionally in the form of its racemates, its pure stereoisomers, in particular enantiomers or diastereomers, or in the form of mixtures of stereoisomers, in particular enantiomers or diastereomers, in any mixing ratio to produce a medicament for the treatment of cancers, in particular haematopoietic cancers, inter alia B-cell lymphomas, T-cell lymphomas, in particular CLL and CML (chronic lymphatic and chronic myeloid leukaemia), ALL and AML (acute lymphatic and acute myeloid leukaemia), and gliomas.
[0065] Preferred according to the invention is the use of a compound according to the invention of the general structure of formula (I) or of a compound of the general structure of formula (l-A), (1-A-1) (l-B), or (l-B-1) the presented form or in the form of its acids or bases or in the form of the pharmaceutically safe, in particular physiologically tolerable salts, or in the form of its solvates, in particular hydrates, optionally in the form of its racemates, its pure stereoisomers, in particular enantiomers or diastereomers, or in the form of mixtures of stereoisomers, in particular enantiomers or diastereomers, in any mixing ratio to produce a medicament for the treatment of metabolic diseases, in particular type 2 diabetes, metabolic syndrome, obesity/adiposity, fatty liver disease (not alcohol-induced), and cardiovascular diseases, in particular arteriosclerosis, PAH (pulmonary arterial hypertension).
[0066] Preferred according to the invention is the use of a compound according to the invention of the general structure of formula (I) or of a compound of the general structure of formula (l-A), (l-A-1) (l-B), or (l-B-1) the presented form or in the form of its acids or bases or in the form of the pharmaceutically safe, in particular physiologically tolerable salts, or in the form of its solvates, in particular hydrates, optionally in the form of its racemates, its pure stereoisomers, in particular enantiomers or diastereomers, or in the form of mixtures of stereoisomers, in particular enantiomers or diastereomers, in any mixing ratio to produce a medicament for the treatment of psychological disorders, in particular schizophrenia, depression, in particular bipolar or manic depression, dementia, memory loss, generalised anxiety disorder (GAD).
[0067] Preferred according to the invention is the use of a compound according to the invention of the general structure of formula (I) or of a compound of the general structure of formula (l-A), (l-A-1) (l-B), or (l-B-1) the presented form or in the form of its acids or bases or in the form of the pharmaceutically safe, in particular physiologically tolerable salts, or in the form of its solvates, in particular hydrates, optionally in the form of its racemates, its pure stereoisomers, in particular enantiomers or diastereomers, or in the form of mixtures of stereoisomers, in particular enantiomers or diastereomers, in any mixing ratio to produce a medicament for the treatment of diseases of the peripheral or central nervous system, in particular Parkinson’s disease, multiple sclerosis, Alzheimer’s disease, stroke, ALS (amyotrophic lateral sclerosis).
[0068] Particularly preferred is the use of a compound according to the invention of the general structure of formula (I) or of a compound of the general structure of formula (l-A), (l-A-1) (l-B), or (l-B-1) the presented form or in the form of its acids or bases or in the form of the pharmaceutically safe, in particular physiologically tolerable salts, or in the form of its solvates, in particular hydrates, optionally in the form of its racemates, its pure stereoisomers, in particular enantiomers or diastereomers, or in the form of mixtures of stereoisomers, in particular enantiomers or diastereomers, in any mixing ratio to produce a medicament for the treatment of one or more of the following diseases or conditions: rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis (Bechterew’s disease), psoriasis, COPD (chronic obstructive pulmonary disease) and asthma.
[0069] The invention also provides a method for the treatment of inflammatory diseases of the joints, in particular rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis (Bechterew’s disease), gout, osteoarthritis; inflammatory diseases of the skin, in particular psoriasis, atopic dermatitis, lichen planus; inflammatory diseases of the eyes, in particular uveitis; gastrointestinal diseases and complaints, in particular inflammatory diseases of the digestive organs, above all Crohn’s disease, ulcerative colitis, and acute and chronic inflammations of the gall bladder and bile ducts, of pseudopolyps and juvenile polyps; inflammatory diseases of the internal organs, in particular SLE (systemic lupus erythematosus) including lupus nephritis, chronic prostatitis, interstitial cystitis; hyperplastic diseases, in particular benign prostatic hyperplasia; respiratory or lung diseases associated with elevated mucus production, inflammation and/or obstruction of the respiratory tract, in particular COPD (chronic obstructive pulmonary disease), chronic bronchitis, asthma, pulmonary fibrosis, allergic and non-allergic rhinitis, obstructive sleep apnoea, cystic fibrosis, chronic sinusitis, emphysema, cough, alveolitis, ARDS (acute respiratory distress syndrome), pulmonary oedema, bronchiectasis, pneumonia; diseases of the fibrotic spectrum, in particular hepatic fibrosis, systemic sclerosis, scleroderma; cancers, in particular haematopoietic cancers, inter alia B-cell lymphomas, T-cell lymphomas, in particular CLL and CML (chronic lymphatic and chronic myeloid leukaemia), ALL and AML (acute lymphatic and acute myeloid leukaemia), and gliomas; metabolic diseases, in particular type 2 diabetes, metabolic syndrome, obesity/adiposity, fatty liver disease (not alcohol-induced), and cardiovascular diseases, in particular arteriosclerosis, PAH (pulmonary arterial hypertension); psychological disorders, in particular schizophrenia, depression, in particular bipolar or manic depression, dementia, memory loss, generalised anxiety disorder (GAD); and/or diseases of the peripheral or central nervous system, in particular Parkinson’s disease, multiple sclerosis, Alzheimer’s disease, stroke, DLS (amyotrophic lateral sclerosis) in a human, which is characterised in that a therapeutically effective amount of at least one compound according to the invention of the general structure of formula (I) or of a substructure of formula (l-A), (l-A-1) (l-B), or (l-B-1) derived from formula (I) in the presented form or in the form of its acids or bases or in the form of the pharmaceutically safe, in particular physiologically tolerable salts, or in the form of its solvates, in particular hydrates, optionally in the form of its racemates, its pure stereoisomers, in particular enantiomers or diastereomers, or in the form of mixtures of stereoisomers, in particular enantiomers or diastereomers, in any mixing ratio, is administered.
[0070] A method for the treatment of inflammatory diseases of the joints (in particular rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis (Bechterew’s disease), gout, osteoarthritis), skin (in particular psoriasis, atopic dermatitis, lichen planus) or eyes (in particular uveitis) in a human is preferred which is characterised in that a therapeutically effective amount of at least one compound according to the invention of the general structure of formula (I) or of a substructure of formula (l-A), (l-A-1) (l-B), or (l-B-1) derived from formula (I) in the presented form or in the form of its acids or bases or in the form of the pharmaceutically safe, in particular physiologically tolerable salts, or in the form of its solvates, in particular hydrates, optionally in the form of its racemates, its pure stereoisomers, in particular enantiomers or diastereomers, or in the form of mixtures of stereoisomers, in particular enantiomers or diastereomers, in any mixing ratio, is administered.
[0071] A method for the treatment of gastrointestinal diseases and complaints, in particular inflammatory diseases of the digestive organs, above all Crohn’s disease, ulcerative colitis, and acute and chronic inflammations of the gall bladder and bile ducts, of pseudopolyps and juvenile polyps, in a human is preferred which is characterised in that a therapeutically effective amount of at least one compound according to the invention of the general structure of formula (I) or of a substructure of formula (l-A), (l-A-1) (1-B), or (l-B-1) derived from formula (I) in the presented form or in the form of its acids or bases or in the form of the pharmaceutically safe, in particular physiologically tolerable salts, or in the form of its solvates, in particular hydrates, optionally in the form of its racemates, its pure stereoisomers, in particular enantiomers or diastereomers, or in the form of mixtures of stereoisomers, in particular enantiomers or diastereomers, in any mixing ratio, is administered.
[0072] A method for the treatment of inflammatory diseases of the internal organs, in particular SLE (systemic lupus erythematosus) including lupus nephritis, chronic prostatitis and/or interstitial cystitis, in a human is preferred which is characterised in that a therapeutically effective amount of at least one compound according to the invention of the general structure of formula (I) or of a substructure of formula (l-A), (l-A-1) (l-B), or (l-B-1) derived from formula (I) in the presented form or in the form of its acids or bases or in the form of the pharmaceutically safe, in particular physiologically tolerable salts, or in the form of its solvates, in particular hydrates, optionally in the form of its racemates, its pure stereoisomers, in particular enantiomers or diastereomers, or in the form of mixtures of stereoisomers, in particular enantiomers or diastereomers, in any mixing ratio, is administered.
[0073] A method for the treatment of hyperplastic diseases, in particular benign prostatic hyperplasia, in a human is preferred which is characterised in that a therapeutically effective amount of at least one compound according to the invention of the general structure of formula (I) or of a substructure of formula (l-A), (l-A-1) (l-B), or (l-B-1) derived from formula (I) in the presented form or in the form of its acids or bases or in the form of the pharmaceutically safe, in particular physiologically tolerable salts, or in the form of its solvates, in particular hydrates, optionally in the form of its racemates, its pure stereoisomers, in particular enantiomers ordiastereomers, or in the form of mixtures of stereoisomers, in particular enantiomers ordiastereomers, in any mixing ratio, is administered.
[0074] A method for the treatment of respiratory or lung diseases associated with elevated mucus production, inflammation and/or obstruction of the respiratory tract, in particular COPD (chronic obstructive pulmonary disease), chronic bronchitis, asthma, pulmonary fibrosis, allergic and non-allergic rhinitis, obstructive sleep apnoea, cystic fibrosis, chronic sinusitis, emphysema, cough, alveolitis, ARDS (acute respiratory distress syndrome), pulmonary oedema, bronchiectasis and/or pneumonia in a human is preferred which is characterised in that a therapeutically effective amount of at least one compound according to the invention of the general structure of formula (I) or of a substructure of formula (l-A), (I-A-1) (l-B), or (l-B-1) derived from formula (I) in the presented form or in the form of its acids or bases or in the form of the pharmaceutically safe, in particular physiologically tolerable salts, or in the form of its solvates, in particular hydrates, optionally in the form of its racemates, its pure stereoisomers, in particular enantiomers or diastereomers, or in the form of mixtures of stereoisomers, in particular enantiomers or diastereomers, in any mixing ratio, is administered.
[0075] A method for the treatment of diseases of the fibrotic spectrum, in particular hepatic fibrosis, systemic sclerosis and/or scleroderma, in a human is preferred which is characterised in that a therapeutically effective amount of at least one compound according to the invention of the general structure of formula (l-A), (l-A-1) (l-B), or (l-B-1) derived from formula (I) in the presented form or in the form of its acids or bases or in the form of the pharmaceutically safe, in particular physiologically tolerable salts, or in the form of its solvates, in particular hydrates, optionally in the form of its racemates, its pure stereoisomers, in particular enantiomers ordiastereomers, or in the form of mixtures of stereoisomers, in particular enantiomers ordiastereomers, in any mixing ratio, is administered.
[0076] A method for the treatment of cancers, in particular haematopoietic cancers, inter alia B-cell lymphomas, T-cell lymphomas, in particular CLL and CML (chronic lymphatic and chronic myeloid leukaemia), ALL and AML (acute lymphatic and acute myeloid leukaemia), and gliomas in a human is preferred which is characterised in that a therapeutically effective amount of at least one compound according to the invention of the general structure of formula (I) or of a substructure of formula (l-A), (l-A-1) (l-B), or (l-B-1) derived from formula (I) in the presented form or in the form of its acids or bases or in the form of the pharmaceutically safe, in particular physiologically tolerable salts, or in the form of its solvates, in particular hydrates, optionally in the form of its racemates, its pure stereoisomers, in particular enantiomers or diastereomers, or in the form of mixtures of stereoisomers, in particular enantiomers or diastereomers, in any mixing ratio, is administered.
[0077] A method for the treatment of metabolic diseases, in particular type 2 diabetes, metabolic syndrome, obesi-ty/adiposity, fatty liver disease (not alcohol-induced), and cardiovascular diseases, in particular arteriosclerosis, PDH (pulmonary arterial hypertension), in a human is preferred which is characterised in that a therapeutically effective amount of at least one compound according to the invention of the general structure of formula (I) or of a substructure of formula (l-A), (l-A-1) (l-B), or (l-B-1) derived from formula (I) in the presented form or in the form of its acids or bases or in the form of the pharmaceutically safe, in particular physiologically tolerable salts, or in the form of its solvates, in particular hydrates, optionally in the form of its racemates, its pure stereoisomers, in particular enantiomers or diastereomers, or in the form of mixtures of stereoisomers, in particular enantiomers ordiastereomers, in any mixing ratio, is administered.
[0078] A method for the treatment of psychological disorders, in particular schizophrenia, depression, in particular bipolar or manic depression, dementia, memory loss and/or generalised anxiety disorder (GDD), in a human is preferred which is characterised in that a therapeutically effective amount of at least one compound according to the invention of the general structure of formula (I) or of a substructure of formula (l-A), (l-A-1) (l-B), or (l-B-1) derived from formula (I) in the presented form or in the form of its acids or bases or in the form of the pharmaceutically safe, in particular physiologically tolerable salts, or in the form of its solvates, in particular hydrates, optionally in the form of its racemates, its pure stereoisomers, in particular enantiomers or diastereomers, or in the form of mixtures of stereoisomers, in particular enantiomers ordiastereomers, in any mixing ratio, is administered.
[0079] A method for the treatment of diseases of the peripheral or central nervous system, in particular Parkinson’s disease, multiple sclerosis, Alzheimer’s disease, stroke and/or ALS (amyotrophic lateral sclerosis), in a human is preferred which is characterised in that a therapeutically effective amount of at least one compound according to the invention of the general structure of formula (I) or of a substructure of formula (l-A), (l-A-1) (l-B), or (l-B-1) derived from formula (I) in the presented form or in the form of its acids or bases or in the form of the pharmaceutically safe, in particular physiologically tolerable salts, or in the form of its solvates, in particular hydrates, optionally in the form of its racemates, its pure stereoisomers, in particular enantiomers ordiastereomers, or in the form of mixtures of stereoisomers, in particular enantiomers ordiastereomers, in any mixing ratio, is administered.
[0080] A method for the treatment of one or more of the following diseases or conditions: rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis (Bechterew’s disease), psoriasis, COPD (chronic obstructive pulmonary disease), asthma and also type 2 diabetes and metabolic syndrome in a human is preferred which is characterised in that a therapeutically effective amount of at least one compound according to the invention of the general structure of formula (1) or of a substructure of formula (l-A), (l-A-1) (l-B), or (l-B-1) derived from formula (I) in the presented form or in the form of its acids or bases or in the form of the pharmaceutically safe, in particular physiologically tolerable salts, or in the form of its solvates, in particular hydrates, optionally in the form of its racemates, its pure stereoisomers, in particular enantiomers or diastereomers, or in the form of mixtures of stereoisomers, in particular enantiomers or diastereomers, in any mixing ratio, is administered.
[0081] The amount of active ingredient to be administered to the person or patient varies and is dependent on the patient’s weight, age and medical history and on the type of administration, the indication and the severity of the illness. Generally 0.01 to 500 mg/kg, in particular 0.05 to 50 mg/kg, preferably 0.1 to 25 mg/kg of body weight of at least one compound according to the invention of the general structure of formula (I) or of a substructure of formula (l-A), (l-A-1) (l-B), or (l-B-1) derived from formula (I) are administered.
[0082] The compounds according to the invention can be produced in the manner described here or in an analogous manner.
[0083] The compounds according to the invention can be synthesized according to general knowledge in the field of organic chemistry or in a manner as described here (cf. reaction schemes below) or analogously. The reaction conditions in the synthesis routes described herein are known to the skilled person and are for some cases exemplified in the synthesis examples herein. i) Formation of 4-hydroxypyrimidine compound of formula (IV) [0084] (Reaction scheme 1)
ii) Chlorination of the 4-hydroxypyrimidine compound of formula (IV) with a chlorinating agent to form a compound (VII) [0085] (Reaction scheme 2)
ill) Transition metal catalyzed reaction of the 4-chloropyrimidine compound of formula (VII) witn a compouna orrormula (VIII) to form a compound of formula (IX) [0086] (Reaction scheme 3)
[0087] In cases where the chemical grouping U~V stands for CR7R8-CR7R8(e.g. CH2-CH2) or N=CR7 (e.g. N=CH), the so-called Buchwald reaction is employed using a palladium catalyst.
[0088] In cases where the chemical grouping U~V stands for CR7=CR7 (e.g. CH=CH) the reaction takes place in the presence of a copper catalyst. iv) If U~V stands for C(=Q)-CR7R8 (e.g. C(=0)-CH2) the following 2-step process towards the formation of compound of formula (IX) starting from 4-chloropyrimidine compound of formula (VII) can be employed [0089] (Reaction scheme 4)
[0090] Buchwald reaction of the amine compound of formula (X) with the 4-chloropyrimidine compound of formula (VII) followed by an intramolecular amidation reaction (reagents: trifluoroacetic anhydride and a base like diisopropyl-ethylamine). v) If U~V stands for CR7=N (e.g. CH=N) the following 3- step process towards the formation of compound of formula (IX) starting from 4-chloropyrimidine compound of formula (VII) can be employed [0091] (Reaction scheme 5)
[0092] Buchwald reaction of the amine compound of formula (XII) with the 4-chloropyrimidine compound of formula (VII). Next, the nitro group in the compound of formula (XIII) is reduced and the product (XIV) is reacted with a formic acid derivate (e.g. triethyl orthoform iate) to afford the compound of formula (IX) wherein U~V stands for CR7=N (CH=N). vi) If U~V stands for C(=Q)-Oa 2-steep process towards the formation of compound of formula (IX) starting from 4-chloropyrimidine compound of formula (VII) can be employed [0093] (Reaction scheme 6)
[0U34J bucnwald reaction of tne amine compound of formula (XV) with the 4-chloropyrimidine compound of formula (VII) followed by reaction with a phosgene equivalent like 1,1’-carbonyldiimidazole (CDI) to a compound of formula (IX) where U~V stands for C(=0)-0. vii) Synthesis of the target compound of formula (XVIII) by acid or basic ester cleavage of the compound of formula (XVII) [0095] (Reaction scheme 7)
viii) Oxidation of the thioether compound of formula (XIX) towards the corresponding sulfoxide (XX) [0096] (Reaction scheme 8)
ix) Oxidation of the thioether compound of formula (XIX) towards the corresponding sulfone (XXI) [0097] (Reaction scheme 9)
x) Reaction of a compound of formula (XXII) with a compound of formula (VIII) to form a compound of formula (XXIII) wherein U~V stands for CR7R8-CR7R8(e.g. CH2-CH2) [0098] (Reaction scheme 10) ,,
V
[0099] Unless otherwise specified, the radicals Rx in the general formulae of the compounds that are used or reacted in the aforementioned methods are defined as follows:
Rx is (C-|-Cg) alkyl, preferably methyl.
[0100] The compounds according to the invention are specified in the table below, without limiting the invention thereto.
[0101] In the tables the following abbreviations were used: Me = methyl, Et = ethyl, site = binding site of the LC02R3 group (table 1) or the OCH2COR4 group (table 2),
Table 1
(continued)
(continued)
Table 2:
(continued)
(continued)
(continued)
(continued)
(continued)
(continued)
Table 3:
[0102] The medicaments, drugs and pharmaceutical compositions according to the invention can take the form of and be administered as liquid, semi-solid or solid dosage forms and as for example injection solutions, drops, juices, syrups, sprays, suspensions, granules, tablets, pellets, transdermal therapeutic systems, capsules, plasters, suppositories, ointments, creams, lotions, gels, emulsions or aerosols and contain, in addition to at least one compound according to the invention of the general structure of formula (I) or of a substructure of formula (l-A), (l-A-1) (l-B), or (l-B-1) derived from formula (I), according to the pharmaceutical form and depending on the administration route, pharmaceutical auxiliary substances such as for example carrier materials, fillers, solvents, diluting agents, surface-active substances, dyes, preservatives, disintegrants, slip additives, lubricants, flavourings and/or binders. These auxiliary substances can be, for example: water, ethanol, 2-propanol, glycerol, ethylene glycol, propylene glycol, polyethyleneglycol, polypropylene glycol, glucose, fructose, lactose, sucrose, dextrose, molasses, starch, modified starch, gelatine, sorbitol, inositol, mannitol, microcrystalline cellulose, methyl cellulose, carboxymethyl cellulose, cellulose acetate, shellac, cetyl alcohol, polyvinyl pyrrolidone, paraffins, waxes, natural and synthetic rubbers, acacia gum, alginates, dextran, saturated and unsaturated fatty acids, stearic acid, magnesium stearate, zinc stearate, glyceryl stearate, sodium lauryl sulfate, edible oils, sesame oil, coconut oil, groundnut oil, soya bean oil, lecithin, sodium lactate, polyoxyethylene and polyoxypropylene fatty acid esters, sorbitan fatty acid esters, sorbic acid, benzoic acid, citric acid, ascorbic acid, tannic acid, sodium chloride, potassium chloride, magnesium chloride, calcium chloride, magnesium oxide, zinc oxide, silicon dioxide, titanium oxide, titanium dioxide, magnesium sulfate, zinc sulfate, calcium sulfate, potash, calcium phosphate, dicalcium phosphate, potassium bromide, potassium iodide, talc, kaolin, pectin, crospovidone, agar and bentonite.
[0103] The choice of auxiliary substances and the amounts thereof to use depends on whether the medicament/drug is to be administered by oral, subcutaneous, parenteral, intravenous, vaginal, pulmonary, intraperitoneal, transdermal, intramuscular, nasal, buccal or rectal means or locally, for example for infections of the skin, mucous membranes and eyes. Preparations in the form of inter alia tablets, pastilles, capsules, granules, drops, juices and syrups are suitable for oral administration; solutions, suspensions, easily reconstitutable powders for inhalation and sprays are suitable for parenteral, topical and inhalative administration. Compounds according to the invention of the general structure (I) in a depot formulation, in dissolved form or in a plaster, optionally with addition of agents promoting skin penetration, are suitable preparations for percutaneous administration. Preparation forms that are suitable for rectal, transmucosal, parenteral, oral or percutaneous administration can deliver the compounds according to the invention of the general structure (I) on a delayed release basis.
[0104] Preparation of the medicaments and pharmaceutical compositions according to the invention takes place using agents, equipment, methods and procedures that are well-known from the prior art of pharmaceutical formulation, such as are described for example in "Remington’s Pharmaceutical Sciences", Ed. A.R. Gennaro, 17th edition, Mack Publishing Company, Easton PD (1985), in particular in part 8, chapters 76 to 93.
[0105] Thus, for example, for a solid formulation such as a tablet, the active ingredient of the medicament, i.e. a compound of the general structure of formula (I) or of a substructure of formula (l-A), (l-A-1) (l-B), or (l-B-1) derived from formula (I) or of one of its pharmaceutically acceptable salts is granulated with a pharmaceutical carrier, e.g. conventional tablet ingredients such as corn starch, lactose, sucrose, sorbitol, talc, magnesium stearate, dicalcium phosphate or pharmaceutically acceptable rubbers, and pharmaceutical diluting agents such as water for example, to form a solid composition containing a compound according to the invention or a pharmaceutically acceptable salt thereof in a homogeneous distribution. A homogeneous distribution is understood here to mean that the active ingredient is evenly distributed throughout the entire composition so that the composition can be readily divided into identically effective single-unit dosage forms such as tablets, pills or capsules. The solid composition is then divided into single-unit dosage forms. The tablets or pills of the medicament according to the invention or of the compositions according to the invention can also be coated or compounded in another way so as to provide a delayed-release dosage form. Suitable coating agents are inter alia polymeric acids and mixtures of polymeric acids with materials such as for example shellac, cetyl alcohol and/or cellulose acetate.
[0106] The amount of active ingredient to be administered to the patient varies and is dependent on the patient’s weight, age and medical history and on the type of administration, the indication and the severity of the illness. Conventionally 0.01 to 500 mg/kg, in particular 0.05 to 50 mg/kg, preferably 0.1 to 25 mg/kg of body weight of at least one compound according to the invention of the general structure of formula (I) or of a substructure of formula (l-A), (l-A-1) (l-B), or (l-B-1) derived from formula (I) are administered.
[0107] The following abbreviations are used in the descriptions of the experiments: eq. = equivalent; calc. = calculated; BINAP = 2,2’-bis(diphenylphosphino)-1 ,Τ-binaphthyl; BOP = (benzotriazol-1-yloxy)tris(dimethylamino)phosphonium hexafluorophosphate; CDI = carbonyldiimidazole; dba = dibenzylidene-acetone; DMAP = N,N-dimethylpyridin-4-amine; DME = 1,2-dimethoxyethane; DMF = Ν,Ν-dimethylformamide; DMSO = dimethylsulfoxide; EDCI = 1-ethyl-3-(3-dimeth-ylaminopropyl)carbodiimid hydrochloride, f. = found; d = day; HATU = (1-[bis(dimethylamino)methylene]-1H-1,2,3-tria-zolo[4,5-b]pyridinium 3-oxid hexafluorophosphate); HOBt = hydroxybenzotriazole; h = hour; min = minute; MMPP = magnesium monoperoxyphthalate hexahydrate; NMP = N-methyl-2-pyrrolidone; Rt = retention time; TBTU = Ν,Ν,Ν’,Ν’-tetramethyl-0-(benzotriazol-1-yl)uronium tetrafluoroborate; tBuXPhos = 2-di-tert-butylphosphino-2,4,6-triisopropyl-1,1-biphenyl; tert = tertiary; THF = tetrahydrofuran; TOFMS = time-of-flight mass spectrometer; ES-MS = electrospray mass spectrometry (ES-MS); APCI = atmospheric pressure chemical ionization.
The following analytical HPLC/MS methods were used:
Method 1 : [0108]
Column: Ascentis Express C18, 2.7 μηι, 3 cm x 2.1 mm; Column temperature: 30 °C; Injection volume: 1 μΙ; Dead time system: 0.2 min Detection: MM-ES + APCI + DAD (254 nm)
Mobile phase A: water / 0.1 % formic acid Mobile phase B: methanol / 0.1 % formic acid Gradient:
Method 2:
[0109]
Hardware: coupled Agilent 1290 Infinity UHPLC-TOF system; UV: 190 - 400 nm;
Column: Agilent Zorbax SB-C18, Rapid Resolution HD, 1.8 μηι; Column temperature: 80 °C
Detection: time-of-flight mass spectrometer Agilent 6224; Ion source: dual ESI
Mobile phase A: water / 0.1 % formic acid
Mobile phase B: acetonitrile / 0.1 % formic acid
Gradient:
Method 3:
[0110]
Column: XBridge C18 (150 mm x 4.6 mm, 5.0 μηι)
Column temperature: 35°C Flow rate: 1.0 mL/min Injection volume: 3 μΙ Detection: 215 and 254 nm Mobile phase A: acetonitrile
Mobile phase B: 10 mM ammonium acetate in water Gradient:
(continued)
Synthesis example No. 1: 2-(1-(2-(3-Fluoro-4-methoxyphenyl)-6,7-dihydro-5H-cyclopenta[d]-pyrimidin-4-yl)in-dolin-5-yl)acetic acid (compound No. 1-01) la) 2-(3-Fluoro-4-methoxyphenyl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-amine [0111] Potassium t-butylate (160 mg, 1.43 mmol) was added to a solution of 3-fluoro-4-methoxybenzonitrile (1.0 g, 6.62 mmol) and adiponitrile (0.85 ml, 7.48 mmol) in mesitylene (5 ml) and the mixture was stirred at 130 °C for 1 h. The reaction mixture was then cooled and diluted with water (10 ml). The solid which had precipitated out was filtered off, washed with water (3 x 5 ml) and diethyl ether (3 x 5 ml) and dried. Beige-coloured solid. Yield: 1.29 g (75 % of theory) 13C-NMR (101 MHz, DMSO-d6, δ ppm): 21.4, 26.8, 33.6, 56.0, 113.16, 113.17, 113.3, 114.3, 114.5, 123.80, 123.84, 131.69, 131.76, 148.3, 148.4, 150.0, 152.4, 160.0, 160.57, 160.60, 171.2 lb) 2-(3-Fluoro-4-methoxyphenyl)-6,7-dihydro-3H-cyclopenta[d1pyrimidin-4(5H)-one [0112] Sodium nitrite (2.4 g, 34.79 mmol) was added to a solution of the product obtained in the preceding instructions 1a) (3.0 g, 11.57 mmol) in a mixture of water and acetic acid (15 ml of each) at room temperature and the mixture was then stirred at 90 °Cfor 30 min. The mixture was cooled and water (100 ml) was added. The solid which had precipitated out was filtered off, washed with water (3x5 ml) and diethyl ether (3x5 ml) and then dried. Beige-coloured solid. Yield: 2.17 g (72 % of theory) 13C-NMR (101 MHz, DMSO-d6, δ ppm): 20.7, 27.0, 34.3, 56.2, 113.56, 113.57, 114.8, 115.0, 121.8, 124.54, 124.56, 125.0, 149.66, 149.76, 149.82, 152.2, 155.3, 160.9, 169.2 lc) 4-Chloro-2-(3-fluoro-4-methoxyphenyl)-6,7-dihydro-5H-cyclopentafd1pyrimidine [0113] A suspension of the pyrimidine obtained according to instructions 1b) (1.0 g, 3.84 mmol) in phosphorus oxychloride (5 ml, 14.0 mmol) was stirred at 100 °C for 2 h. The cooled reaction solution was then poured on to ice (50 g) and extracted with methylene chloride (4 x 20 ml). The combined organic extracts were filtered over silica gel and concentrated. Beige-coloured solid. Yield: 815 mg (76 % of theory) 13C-NMR (101 MHz, CDCI3, δ ppm): 21.4, 28.9, 34.8, 56.2, 112.74, 112.76, 115.9, 116.1, 124.68, 124.71, 129.92, 129.99, 131.0, 150.0, 150.1, 151.1, 153.5, 156.9, 163.02, 163.05, 176.6 ld) 2-(1-(2-(3-Fluoro-4-methoxyphenyl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)indolin-5-yl)acetic acid methyl ester [0114] Caesium carbonate (391 mg, 1.27 mmol), BINAP (48 mg, 0.08 mmol) and palladium(ll) acetate (18 mg, 0.08 mmol) were added to the chlorine compound from 1c) (388 mg, 1.39 mmol) and 2-(indolin-5-yl)acetic acid methyl ester (242 mg, 1.27 mmol) in anhydrous 1,4-dioxane (5 ml) under argon. The reaction mixture was stirred at 95 °C for 1 h and then purified by column chromatography [silica gel 60; cyclohexane/ethyl acetate 3 :1]. Pale yellow solid. Yield: 146 mg (26 % of theory) LC-MS (method 1): Rt = 3.7 min, m/z: [M+H]+ = 434.2 13C-NMR (101 MHz, CDCI3, δ ppm): 22.2, 28.5, 31.1, 34.2, 40.7, 50.6, 52.0, 56.2, 110.0, 112.8, 115.5, 115.8, 116.0, 116.3, 124.5, 125.6, 127.8, 128.1, 132.1, 143.3, 149.5, 151.0, 153.5, 157.4, 172.3 le) 2-(1-(2-(3-Fluoro-4-methoxyphenyl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)indolin-5-yl)acetic acid [0115] 1 N sodium hydroxide solution (1.08 ml, 1.08 mmol) was added to a suspension of the methyl ester from 1d) (146 mg, 0.34 mmol) in methanol (5 ml) and 1,4-dioxane (5 ml) and the mixture was stirred at 95 °C (oil temperature) for 20 min. 1 N hydrochloric acid (1.35 ml) was added and the mixture was concentrated on a rotary evaporator. The solid which thereby precipitated out was filtered off, washed with water (3x2 ml) and dried in vacuo. Colourless solid. Yield: 123 mg (86 % of theory). Melting range: 195 - 200 °C LC-MS (method 1): Rt = 3.5 min, m/z: [M+H]+ = 420.3 13C-NMR(101 MHz, DMSO-d6, δ ppm): 21.5, 27.9, 30.2, 33.9, 40.2, 49.9, 56.0,113.5,114.4,114.6,115.3,115.4,124.0, 125.7, 127.5, 128.4, 131.2, 131.3, 132.0, 142.7, 148.7, 148.8, 150.0, 152.5, 156.9, 159.7, 159.8, 172.9, 174.4
Synthesis example No. 2: 2-(1-(2-(4-Methoxyphenyl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)indolin-5-yl)acetic acid (compound No. 1-03) 2a) 2-(4-Methoxyphenyl)-6,7-dihydro-5H-cyclopenta[dlpyrimidin-4-amine [0116] Synthesis analogous to instructions 1a) from 4-methoxybenzonitrile(5.00g, 37.60 mmol) and adiponitrile (4.82 ml, 4.59 g, 42.40 mmol). The target compound was obtained as a beige solid.
Yield: 5.68 g (63 % of theory) LC-MS (method 1): Rt = 2.5 min, m/z: [M+H]+ = 242.3 13C-NMR(101 MHz, CDCI3, δ ppm): 21.0, 26.8, 33.7, 55.1, 112.8, 113.3, 128.9, 131.1, 159.9, 160.5, 161.7, 171.1 2b) 2-(4-Methoxyphenyl)-6,7-dihydro-3H-cyclopenta[d1pyrimidin-4(5H)-one [0117] The target compound was prepared analogously to instructions 1b) from 2-(4-methoxyphenyl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-amine (5.65 g, 23.41 mmol). Yellow solid. Yield: 3.21 g (57 % of theory) LC-MS (method 1): Rt = 3.15 min, m/z: [M+H]+ = 243.2 13C-NMR (101 MHz, DMSO-d6, δ ppm): 20.7, 27.0, 34.4, 55.4, 113.9, 121.3, 124.6, 129.3, 156.2, 160.9, 161.7, 169.2 2c) 4-Chloro-2-(4-methoxyphenyl)-6,7-dihydro-5H-cyclopentafd1pyrimidine [0118] The pyrimidone from 2b) (3.21 g, 13.25 mmol) and phosphorus oxychloride (17 ml, 28.36 g, 188.0 mmol) were stirred at 100 °C (oil bath temperature) for 2 h. Ice-water (300 ml) was added in portions to the reaction mixture, while cooling, and the mixture was stirred for 20 min. It was extracted with methylene chloride and the combined organic phases were dried with magnesium sulfate, filtered and concentrated by evaporation in vacuo. Brown solid. Yield: 3.07 g (89 % of theory) LC-MS (method 1): Rt = 4.05 min, m/z: [M+H]+ = 261.2 13C-NMR (101 MHz, CDCI3, δ ppm): 21.4, 28.8, 34.6, 55.4, 113.9, 128.4, 130.2, 130.8, 157.5, 162.3, 163.4, 175.8 2d) 2-(1-(2-(4-Methoxyphenyl)-6,7-dihydro-5H-cyclopenta|d1pyrimidin-4-yl)indolin-5-yl)acetic acid methyl ester [0119] The target compound was prepared analogously to instructions 1d) from 4-chloro-2-(4-methoxyphenyl)-6,7-dihydro-5H-cyclopenta[d]pyrimidine (203 mg, 0.78 mmol) and 2-(indolin-5-yl)acetic acid methyl ester (150 mg, 0.78 mmol). Beige solid. Yield: 275 mg (85 % of theory) LC-MS (method 1): Rt = 3.5 min, m/z: [M+H]+ = 416.3 13C-NMR (101 MHz, CDCI3, δ ppm): 22.1, 28.5, 31.0, 34.4, 40.7, 50.5, 52.0, 55.3, 113.7, 114.9, 116.2, 125.4, 127.3, 128.0, 129.7, 130.9, 131.9, 143.6, 157.4, 161.3, 162.0, 172.4, 174.6 2e) 2-(1-(2-(4-Methoxyphenyl)-6,7-dihydro-5H-cyclopenta[d1pyrimidin-4-yl)indolin-5-yl)acetic acid
[0120] Preparation from the methyl ester obtained under 2d) (253 mg, 0.61 mmol) by means of saponification analogously to instructions 1e). Colourless solid. Yield: 223 mg (91% of theory); Melting range: 220-222 °C LC-MS (method 1): Rt = 3.3 min, m/z: [M+H]+ = 402.3 13C-NMR (101 MHz, DMSO-d6, δ ppm): 21.5, 27.9, 30.2, 33.9,40.1,49.8, 55.2,113.8,114.7,115.4,125.6,127.6,128.2, 129.0, 130.6, 131.9, 142.9, 156.9, 160.8, 160.9, 172.9, 174.3
Synthesis example No. 3: 2-(1-(2-(5-Chlorothiophen-2-yl)-6,7-dihydro-5H-cyclopenta[d]-pyrimidin-4-yl)indolin- 5-yl)acetic acid (compound No. 1-13) 3a) 2-(1-(2-(5-Chlorothiophen-2-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)indolin-5-yl)acetic acid methyl ester [0121] Preparation analogously to instructions 1d) from 2-(indolin-5-yl)acetic acid methyl ester (95.6 mg, 0.5 mmol) and 4-chloro-2-(5-chlorothiophen-2-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidine (135.6 mg, 0.5 mmol). Yellow solid. Yield: 89 mg (41 % of theory) 13C-NMR (101 MHz, CDCI3, δ ppm): 22.1, 28.5, 29.8, 31.2, 34.1,40.7, 50.4, 52.0, 109.5, 115.3, 116.8, 125.1, 125.5, 125.6, 127.4, 128.1, 128.1, 130.3, 143.1, 157.1, 172.3 3b) 2-(1 -(2-(5-Chlorothiophen-2-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)indolin-5-yl)acetic acid
[0122] 1 N sodium hydroxide solution (0.23 ml) was added to the ester from 3a) (83.6 mg, 0.2 mmol) in methanol (2 ml) and the mixture was stirred at 70 °C for 4 h. 1 N hydrochloric acid (0.23 ml) was added to the reaction mixture. The solid which had precipitated out was filtered off, washed with water and methanol and dried. Pale brown solid. Yield: 63 mg (78 % of theory); Melting range: 185-191 °C 13C-NMR (101 MHz, DMSO-d6, δ ppm): 21.4, 27.8, 30.4, 33.7, 40.2, 49.7, 115.6, 115.9, 125.6, 127.0, 127.7, 128.2, 128.8, 130.9, 132.0, 142.5, 142.7, 156.6, 156.7, 172.9, 174.2
Synthesis example No. 4: 2-(1-(2-(5-Fluorothiophen-2-yl)-6,7-dihydro-5H-cyclopenta[d]pyri-midin-4-yl)indolin- 5-yl)acetic acid (compound No. 1-15) 4a) 2-(5-Fluorothiophen-2-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-ol [0123] Potassium tert-butylate (1.34 g, 12 mmol) was added to a solution of 5-fluorothiophene-2-carbonitrile (1.52 g, 12 mmol) and ethyl 2-aminocyclopent-1-enecarboxylate (1.55 g, 10 mmol) in mesitylene (50 ml) and the mixture was stirred at 150 °C for 4 h. 1 N hydrochloric acid (12 ml) was then added and the solid which had precipitated out was filtered off, washed with ethyl acetate and dried. Beige-coloured solid. Yield: 1.3 g (55 % of theory) LC-MS (method 1): Rt = 3.42 min, m/z: [M+H]+ = 237.2 1H-NMR (400 MHz, DMSO-d6, δ ppm): 1.97 (m, 2H), 2.64 (m, 2H), 2.76 (m, 2H), 6.86 (dd, J = 2.0, 4.3, 1H), 7.88 (s, 1H), 12.67 (s, 1H) 4b) 4-Chloro-2-(5-fluorothiophen-2-yl)-6,7-dihydro-5H-cyclopentafd1pyrimidine [0124] A suspension of the pyrimidinone obtained under 4a) (1.3g, 5.5 mmol) and phosphorus oxychloride (5 ml) was stirred at 95 °C (oil temperature) for 2 h. The mixture was then poured on to ice-water (50 ml) (exothermic) and the resulting emulsion was saturated with sodium chloride and extracted with methylene chloride. The combined organic phases were dried with magnesium sulfate, filtered over silica gel and concentrated in vacuo. Yellow solid. Yield: 928 mg (66 % of theory) LC-MS (method 1): Rt = 4.09 min, m/z: [M]+ = 255.1 1H-NMR (400 MHz, CDCI3, δ ppm): 2.16 (m, 2H), 2.96 (m, 2H), 3.04 (m, 2H), 6.50 (dd, J = 1.7, 4.2, 1H), 7.64 (dd (t-like), J =4.1, 1H) 13C-NMR (101 MHz, CDCI3, δ ppm): 21.3, 28.8, 34.6, 109.1 (d, JC F = 11), 126.2 (d, JC F = 3.9), 130.3 (d, Jc F = 3.6), 130.8 (d, JCF= 1.1), 156.6, 160.1 (d, JCF = 1.4), 168.5 (d, JCF =294), 176.5 4c) 2-(1-(2-(5-Fluorothiophen-2-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)indolin-5-yl)acetic acid methyl ester [0125] Reaction of 2-(indolin-5-yl)acetic acid methyl ester (191 mg, 1 mmol) and 4-chloro-2-(5-fluorothiophen-2-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidine (255 mg, 1 mmol) analogously to instructions 1d). Water was added to the reaction mixture and the mixture was extracted with ethyl acetate. The combined organic phases were dried with magnesium sulfate and concentrated. The residue was purified by column chromatography [silica gel 60; cyclohexane/ethyl acetate 2 : 1]. Colourless solid. Yield: 316 mg (77 % of theory) LC-MS (method 1): Rt = 4.07 min, m/z: [M+H]+ = 410.1 1H-NMR (400 MHz, CDCI3, δ ppm): 2.08 (m, 2H), 2.94 (m, 2H), 3.12 - 3.20 (4H), 3.60 (s, 2H), 3.70 (s, 3H), 4.31 (m, 2H), 6.50 (dd, J = 1.7, 4.1, 1H), 7.14 - 7.17 (2H), 7.58 (s (broad), 1H), 8.14 (d, J = 8.2, 1H) 13C-NMR (101 MHz, CDCI3, δ ppm): 22.1,28.5, 31.1, 34.3, 40.7, 50.4, 52.0, 108.6 (d, Jc F = 10.6), 115.0, 116.6, 124.4, 125.4, 127.7, 127.7, 128.0, 131.9, 132.4, 143.3, 157.1, 166.0 (d, JC F = 295), 172.3, 174.1 4d) 2-(1-(2-(5-Fluorothiophen-2-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)indolin-5-yl)acetic acid [0126] 1 N sodium hydroxide solution (1 ml) was added to the ester from 4c) (306 mg, 0.75 mmol) in methanol (3 ml) and the mixture was stirred at 60 °Cfor2 h. 2 N hydrochloric acid (0.5 ml) was added and the solid which had precipitated out was filtered off, washed with water and dried. Colourless solid. Yield: 246 mg (83 % of theory) LC-MS (method 1): Rt = 3.84 min, m/z: [M+H]+ = 396.2 1H-NMR (400 MHz, DMSO-d6, δ ppm): 2.00 (m, 2H), 2.83 (m, 2H), 3.12 - 3.20 (4H), 3.51 (s, 2H), 4.35 (m, 2H), 6.80 (dd, J =2.0, 4.2, 1H), 7.09-7.13 (2H), 7.53 (d (t-like), J = 4.1, 1H), 8.11 (d, J = 8.2, 1H) 13C-NMR (101 MHz, DMSO-d6, δ ppm): 21.4, 27.8, 30.3, 33.6, 40.1,49.7, 109.6 (d, JC F = 11.1), 115.3, 115.9, 124.3 (d, Jc p = 4.3), 125.6, 127.6, 128.6, 132.0, 132.4 (d, Jc F = 2.4), 142.5, 156.6, 156.9, 166.0 (d, Jc F = 290), 172.8, 174.1
Synthesis example No. 5: 2-(1-(2-(3-Chloro-4-methoxyphenyl)-6,7-dihydro-5H-cyclopenta[d]-pyrimidin-4-yl)in-dolin-5-yl)acetic acid (compound No. 1-02) 5a) 2-(3-Chloro-4-methoxyphenyl)-6,7-dihydro-3H-cyclopenta[d1pyrimidin-4(5H)-one [0127] Methyl 2-oxocyclopentanecarboxylate (2.37 g, 16.69 mmol), 3-chloro-4-methoxybenzimidamide hydrochloride (1.82 g, 8.22 mmol) and caesium carbonate (3.21 g, 9.86 mmol) were suspended in DMF and the suspension was stirred at 150 °C (oil bath temperature) for 2 h. The DMF was then distilled off and the residue was purified by chromatography [silica gel 60; diethyl ether, then THF/methanol 10 : 1], Beige solid. Yield: 438 mg (19 % of theory) LC-MS (method 1): Rt = 3.45 min, m/z: [M+H]+ = 277.2 13C-NMR (101 MHz, DMSO-d6, δ ppm): 20.7, 27.0, 34.2, 56.4, 112.6, 121.3, 127.9, 129.0, 156.8, 160.8. The signals are broad in some cases. Only clear signals are stated. 5b) 4-Chloro-2-(3-chloro-4-methoxyphenyl)-6,7-dihxdro-5H-cyclopenta[d1pyrimidine [0128] The pyrimidine from 5a) (419 mg, 1.51 mmol) was suspended in phosphorus oxychloride (4 ml) and the suspension was stirred at room temperature for 16 h. The reaction mixture was then poured on to ice-water (30 ml) and extracted with methylene chloride (3x10 ml). The combined organic phases were dried with magnesium sulfate, filtered and evaporated in vacuo. Beige solid. Yield: 365 mg (82 % of theory) LC-MS (method 1): Rt = 4.2 min, m/z: [M+H]+ = 295.1 13C-NMR (101 MHz, CDCI3, δ ppm): 21.4, 28.9, 34.8, 56.2, 111.5, 122.8, 128.1, 130.1, 130.2, 131.1, 157.0, 157.1, 162.8, 176.6 5c) 2-(1-(2-(3-Chloro-4-methoxyphenyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)indolin-5-yl)acetic acid methyl ester [0129] Preparation analogously to instructions 1d) from the chlorine compound from 5b) (350 mg, 1.20 mmol) and 2-(indolin-5-yl)acetic acid methyl ester (230 mg, 1.20 mmol). Beige solid. Yield: 205 mg (38 % of theory) LC-MS (method 1): Rt = 3.9 min, m/z: [M+H]+ = 450.2 13C-NMR (101 MHz, DMSO-d6, δ ppm): 21.5, 27.8, 30.2, 33.9, 39.7, 49.9, 51.6, 56.2,112.6,115.4,115.5,121.0,125.6, 127.5, 127.5, 128.8, 131.5, 132.1, 142.9, 155.9, 156.9, 159.6, 171.8, 174.5 5d) 2-(1-(2-(3-Chloro-4-methoxyphenyl)-6,7-dihvdro-5H-cyclopenta[d1pyrimidin-4-yl)indolin-5-yl)acetic acid
[0130] The methyl ester from 5c) (190 mg, 0.42 mmol) was reacted analogously to instructions 1e). Beige solid. Yield: 163 mg (89 % of theory) Melting point: 127 °C LC-MS (method 1): Rt = 3.7 min, m/z: [M+H]+ = 436.2 13C-NMR (101 MHz, DMSO-d6, δ ppm): 21.4,27.9,30.3, 33.7,40.2,49.9,56.3,112.6,115.4,115.6,121.0,125.7,127.4, 127.6, 128.6, 128.8, 131.1, 132.1, 142.6, 156.0, 156.9, 159.3, 172.9, 173.9
Synthesis example No. 6: 2-(1-(2-(3-Chloro-4-methoxyphenyl)-6,7-dihydro-5H-cyclopenta[d]-pyrimidin-4-yl)-1H-indazol-5-yl)acetic acid (compound No. 1-59) 6a) 5-lodo-1H-indazole [0131] Sodium nitrite (2.7 g, 39.1 mmol) in water (40 ml) was added dropwise to a solution of 1-H-indazol-5-amine (5.2 g, 39.1 mmol) in 6 N hydrochloric acid (73.7 ml) at 0 °C. The mixture obtained was in turn added dropwise to a solution of potassium iodide (26.9 g, 162 mmol) in water (60 ml) at 0 °C and the mixture was stirred at room temperature for 3 h. The reaction mixture was then extracted with ethyl acetate (4 x 30 ml) and the combined organic phases were washed with washed with 10% w/v sodium thiosulfate solution (4 x 30 ml) and brine (2 x 30 ml), dried over magnesium sulfate and concentrated. Brown solid. Yield: 8.64 g (90 % of theory) 13C-NMR (101 MHz, CDCI3, δ ppm): 84.4, 111.7, 125.6, 129.9, 133.4, 135.4, 139.0 6b) 5-lodo-1-(4-methoxybenzyl)-1H-indazole [0132] 4-Methoxybenzyl chloride (4.03 ml, 4.65 g, 29.68 mmol) was added to a solution of 5-iodo-1H-indazole (5.54 g, 24.73 mmol), sodium iodide (741 mg, 4.95 mmol) and caesium carbonate (9.67 g, 29.68 mmol) in DMF (25 ml) and the mixture was then stirred at room temperature for 16 h. Ethyl acetate (30 ml) and water (30 ml) were added to the suspension. The organic phase was separated off and washed with water (2 x 15 ml) and brine (2x15 ml), dried over magnesium sulfate, filtered and concentrated by evaporation in vacuo. The residue was purified by column chromatography [silica gel 60; cyclohexane/ethyl acetate 9 : 1], 2.82 g (31 % of theory) of the desired amine as a colourless solid and 2.16 g (24 % of theory) of the regioisomer were isolated. LC-MS (method 1): Rt = 3.95 min, m/z: [M+H]+ = 365.1. Regioisomer: LC-MS (method 1): Rt = 3.85 min, m/z: [M+H]+ = 365.1. 13C-NMR (101 MHz, CDCI3, δ ppm): 52.8, 55.2, 83.9, 111.2, 114.2, 126.9, 128.4, 128.6, 130.0, 132.1, 134.6, 138.4, 159.3. Regioisomer: 13C-NMR (101 MHz, CDCI3, δ ppm): 55.3, 57.1, 85.8, 114.4, 119.3, 121.6, 124.3, 127.2, 129.1, 129.7, 134.5, 147.2, 159.8 6c) 2-(1-(4-Methoxybenzyl)-1H-indazol-5-yl)acetic acid ethyl ester [0133] Chloroacetic acid ethyl ester (7.77 g, 6.79 ml, 63.40 mmol) and trifluoroacetic acid (341 mg, 230 μΙ, 2.99 mmol) were added to a suspension of the iodine compound obtained under 6b) (2.31 g, 6.34 mmol), manganese (3.48 g, 63.40 mmol), nickel(ll) bromide (275 mg, 1.26 mmol) and 2,2-bipyridyl (197 mg, 1.26 mmol) in DMF (23 ml) and the mixture was heated briefly with a heat gun until the reaction started (HIGHLY exothermic!). The mixture was then stirred at 60 °C (oil bath temperature) for 1 h, and thereafter ethyl acetate (30 ml) and 1 N hydrochloric acid (20 ml) were added. The manganese residues were filtered off and the aqueous phase was separated off and extracted with ethyl acetate (2 x 15 ml). The combined organic phases were dried with magnesium sulfate, filtered and concentrated by evaporation in vacuo. The residue was purified by column chromatography [silica gel 60; cyclohexane/ethyl acetate 4:1]. Yellow solid. Yield: 1.36 g (66 % of theory) LC-MS (method 1): Rt = 3.7 min, m/z: [M+H]+ = 325.3 13C-NMR (101 MHz, CDCI3, δ ppm): 14.1,41.1,52.6, 55.2, 60.8, 109.4, 114.1, 121.3, 124.6,126.5,128.0,128.6,128.8, 132.9, 138.7, 159.2, 171.8 6d) 2-(1H-lndazol-5-yl)acetic acid ethyl ester [0134] A solution of the product from 6c) (1.40 g, 4.32 mmol) in trifluoromethanesulfonic acid (10.0 g, 66.63 mmol) was stirred at room temperature overnight. The mixture was then diluted with methylene chloride (100 ml) and washed with water and saturated sodium carbonate solution (50 ml of each). The organic phase was dried with sodium sulfate and concentrated to dryness in vacuo. The residue was finally purified by column chromatography [silica gel 60; cy-clohexane/diethyl ether 2 : 1 —> 1 : 2]. Beige-coloured solid. Yield: 542 mg (61 % of theory) 13C-NMR (101 MHz, CDCI3, δ ppm): 14.2, 41.2, 60.9, 110.0, 121.1, 123.3, 127.0, 128.7, 134.2, 139.3, 172.0 6e) Ethyl 2-(1-(2-(3-chloro-4-methoxyphenyl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)-1H-indazol-5-yl)acetate [0135] 4-Chloro-2-(3-chloro-4-methoxyphenyl)-6,7-dihydro-5H-cyclopenta[d]pyrimidine (286 mg, 0,97 mmol), the product of 6d) (197 mg, 0,97 mmol), caesium carbonate (632 mg, 1,94 mmol), BINAP (36 mg, 0,06 mmol) and palladium(ll) acetate (11 mg, 0,05 mmol) in dry DMF (3 ml) were stirred under an argon atmosphere for 1 h at 120°C (oil bath temperature). Ethyl acetate (10 ml) and water (15 ml) were added to the mixture and the organic phase was separated, washed with water (2x5 ml) and dried over magnesium sulfate and evaporated. The residue was purified by column chromatography [silica gel 60; cyclohexane/ethyl acetate 4 : 1], Colorless solid. Yield: 110 mg (24% of theory) LC-MS (method 1): Rt = 4.5 min, m/z: [M+H]+ = 463.3 13C-NMR (101 MHz, CDCI3, δ ppm): 14.2, 22.1, 31.8, 34.8, 41.2, 56.3, 56.3, 61.0, 111.7, 115.8, 120.4, 121.1, 122.7, 126.2, 127.9, 129.3, 129.7, 130.2, 131.6, 137.8, 138.8, 155.6, 156.8, 161.6, 171.6, 178.0 6f) 2-(1-(2-(3-Chloro-4-methoxyphenyl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)-1H-indazol-5-yl)acetic acid [0136] Produced from the product of 6e) (102 mg, 0,22 mmol) in an analogous manner to procedure 1e). Colorless solid. Yield: 96 mg (quantitative) LC-MS (Methode 1): Rt = 4.3 min, m/z: [M+H]+ = 435.2 13C-NMR (101 MHz, DMSO-d6, δ ppm): 21.3, 31.4, 34.0, 56.3, 56.3, 66.3, 1 12.7, 114.7, 119.7, 121.3, 121.5, 125.7, 127.8, 128.8, 130.1, 130.4, 130.4, 137.7, 138.5, 154.8, 156.3, 160.3, 172.8, 177.7
Synthesis example No. 7: 1-(2-(5-Chlorothiophen-2-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)-2-oxoindo-line-5-carboxylic acid (compound No. 1-69) 7a) 3-(Carboxymethyl)-4-(2-(5-chlorothiophen-2-yl)-6,7-dihydro-5H-cyclopentafd1pyrimidin-4-ylamino)benzoic acid
[0137] Methyl 2-oxoindoline-5-carboxylate (1.14 g, 5.96 mmol) was stirred in 5 N sodium hydroxide solution (5.96 ml, 29.81 mmol) at 100 °C for 4 h. A yellow suspension was formed. After cooling, dry ice was added, and the mixture was stirred for 30 min and concentrated in vacuo. The resulting pale yellow solid (2.92 g) comprising the di-sodium salt and sodium bicarbonate was further reacted directly. For this, 4-chloro-2-(5-chlorothiophen-2-yl)-6,7-dihydro-5H-cyclopen-ta[d]-pyrimidine(694 mg, 2.56 mmol), BINAP (112 mg, 0.18 mmol), palladium(ll) acetate (40 mg, 0.18 mmol) and caesium carbonate (1.67 g, 5.12 mmol) were added to the di-sodium salt (1.61 g) in anhydrous DMSO (4 ml) and the mixture was stirred at 130 °C (oil bath temperature) for 5 h. 1 N sodium hydroxide solution (45 ml) and diethyl ether (20 ml) were then added to the reaction mixture. The aqueous phase was separated off, washed with diethyl ether (3x5 ml) and ethyl acetate (2x5 ml) and acidified (pH 4) with 1 N hydrochloric acid, after which a solid precipitated out. The mixture was extracted with THF (4x10 ml) and the combined organic phases were dried over magnesium sulfate, filtered and concentrated by evaporation in vacuo. The residue was purified by means of column chromatography [silica gel 60; ethyl acetate/methanol 1:0, 5:1,0:1, in each case with 0.5 % acetic acid]. Yellow solid. Yield: 447 mg (41 % of theory). Melting point above 260 °C LC-MS (method 1): Rt = 3.8 min, m/z: [M+H]+ = 430.2. 13C-NMR(101 MHz, DMSO-d6, δ ppm): 21.1,21.3, 27.1, 33.6, 43.5, 116.8, 118.7, 121.1, 126.7, 127.6, 128.1, 128.4, 130.7,131.8,143.1,156.0,157.3,157.7,158.0,172.0. NMR signals greatly broadened. Only signals which were clearly to be identified are stated. 7b) 1-(2-(5-Chlorothiophen-2-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)-2-oxoindoline-5-carboxylic acid [0138] Hunig’s base (0.95 ml, 5.59 mmol) and trifluoroacetic anhydride (0.80 ml, 5.67 mmol) were added to a suspension of the acid from 7a) (400 mg, 0.93 mmol) in dioxane (20 ml). After stirring at room temperature for 30 min, water (80 ml) was added to the clear solution formed. The resulting precipitate was filtered off, washed with water (3x5 ml) and dried. The crude product was purified by column chromatography [silica gel 60; ethyl acetate/acetic acid 200 : 1]. Beige-coloured solid.
Yield: 114 mg (30 % of theory) 13C-NMR(101 MHz, DMSO-d6, δ ppm): 21.9, 29.0, 34.0, 35.3, 111.1, 125.6, 125.7, 125.7, 128.0, 128.3, 128.6, 129.5, 132.3, 141.0, 145.8, 150.9, 158.0, 167.0, 173.1, 179.6
Synthesis example No. 8: 1-(2-(5-Chlorothiophen-2-yl)-6,7-dihydro-5H-cyclopenta[d]-pyrimidin-4-yl)-1H-inda-zole-5-carboxylic acid (compound No. 1-73) [0139] Caesium carbonate (652 mg, 2 mmol), BINAP (44 mg, 0.07 mmol) and palladium(ll) acetate (16 mg, 0.07 mmol) were added to 4-chloro-2-(5-chlorothiophen-2-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidine (271 mg, 1 mmol) and 1H-indazole-5-carboxylic acid (162 mg, 1 mmol) in dry DMF (2 ml) under argon and the mixture was stirred at 140 °C for 1 h. Water, saturated sodium chloride solution and ethyl acetate were added to the reaction mixture, whereby a solid precipitated out, which was filtered off and washed with water (2x5 ml). The solid was dissolved in a mixture of DMSO, water and methanol (1:1:1, 600 ml) under heating, and then precipitated out by concentration in vacuo. Pale grey solid. Yield: 40 mg (10 % of theory) LC-MS (method 1): Rt = 4.5 min, m/z: [M+H]+ = 397.2
Synthesis example No. 9: 1-(2-(5-Chlorothiophen-2-yl)-6,7-dihydro-5H-cyclopenta[d]-pyrimidin-4-yl)-1H-indole- 5-carboxylic acid (compound No. 1-70) 9a) Methyl 1-(2-(5-chlorothiophen-2-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)-1 H-indole-5-carboxylic acid [0140] Methyl 1 H-indole-5-carboxylic acid (310 mg, 1.77 mmol), copper(l) iodide (55 mg, 0.29 mmol) and caesium carbonate (720 mg, 2.21 mmol) were added to 4-chloro-2-(5-chlorothiophen-2-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimi-dine (400 mg, 1.48 mmol) in DMF (2 ml) and the mixture was stirred at 150 °C for 40 min. The solvent was then distilled off in vacuo and the residue was purified by column chromatography [silica gel 60; methylene chloride]. Beige-coloured solid.
Yield: 482 mg (80 % of theory) 13C-NMR(101 MHz, DMSO-d6, δ ppm): 22.8, 30.8, 34.6, 52.0, 107.6, 115.0, 120.2, 123.5, 124.2, 124.9, 126.7, 127.6, 128.1, 129.6, 134.3, 138.3, 141.4, 154.5, 159.0, 167.6, 178.5 9b) 1-(2-(5-Chlorothiophen-2-yl)-6,7-dihvdro-5H-cyclopenta[d1pyrimidin-4-yl)-1H-indole-5-carboxylic acid
[0141] 0.5 N lithium hydroxide solution (5.0 ml, 2.5 mmol) was added to the ester from 9a) (480 mg, 1.17 mmol) in methanol (5 ml) and THF (25 ml) and the mixture was stirred at 70 °Cfor2 h. For working up, the mixture was neutralized with 1 N hydrochloric acid (2.5 ml, 2.5 mmol) and concentrated to approx. 5 ml. The solid which had precipitated out was filtered off, washed with water and recrystallized in dioxane. White solid. Yield: 298 mg (64 % of theory). Melting point above 265 °C 13C-NMR(101 MHz, DMSO-d6, δ ppm): 22.1,29.7, 34.0, 107.2, 114.4, 121.5, 123.0, 124.4, 124.7, 127.9, 128.3, 128.6, 129.3, 132.2, 137.4, 141.2, 153.8, 157.6, 167.7, 178.6
Synthesis example No. 10:1-(2-(5-Chlorothiophen-2-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)indoline-5-carboxylic acid (compound No. 1-72) 10a) Methyl 1-(2-(5-chlorothiophen-2-yl)-6,7-dihydro-5H-cyclopenta[d1pyrimidin-4-yl)indoline-5-carboxylate [0142] The target compound was prepared analogously to instructions 1d) from 4-chloro-2-(5-chlorothiophen-2-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidine (400 mg, 1.48 mmol) and methyl indoline-5-carboxylate (314 mg, 1.77 mmol). Yellow solid. Yield: 207 mg (34 % of theory) LC-MS (method 1): Rt = 4.4 min, m/z: [M+H]+ = 412.2 10b) 1-(2-(5-Chlorothiophen-2-yl)-6,7-dihydro-5H-cyclopenta[d1pyrimidin-4-yl)indoline-5-carboxylic acid
[0143] 0.5 M lithium hydroxide solution (2 ml, 1.00 mmol) was added to the ester from 10a) (207 mg, 0.50 mmol) in THF (8 ml) and the mixture was stirred at 50 °C for 1 d. The solution was filtered over Celite®, 0.5 N hydrochloric acid (2 ml) was added and the mixture was concentrated to 4 ml in vacuo. The solid which had precipitated out was filtered off, washed with water and methanol and dried in vacuo. Yellow solid. Yield: 177 mg (89 % of theory). Melting point above 260 °C LC-MS (method 1): Rt = 4.1 min, m/z: [M+H]+ = 391.2 13C-NMR (10 MHz, THF-d8, δ ppm): 22.7, 28.4, 31.6, 34.8, 51.5, 116.0,117.0, 125.0, 126.6, 127.7, 128.1,130.3, 132.5, 132.9, 144.1, 149.0, 157.8, 158.5, 167.2, 176.3
Synthesis example No. 11: 2-(1-(2-(5-Chlorothiophen-2-yl)-6,7-dihydro-5H-cyclopenta[d]-pyrimidin-4-yl)-2-ox-oindolin-5-yl)acetic acid (compound No. 1-64) lla) 2-Oxo-2-(2-oxoindolin-5-yl)acetic acid methyl ester [0144] lndolin-2-one (2.95 g, 22.15 mmol) was added to a yellow solution of aluminium chloride (14.77 g, 110.75 mmol) and methyl 2-chloro-2-oxoacetate (3.06 ml, 4.07 g, 33.22 mmol) in 1,2-dichloroethane (38 ml) under argon and while cooling with a water bath. The reaction mixture was stirred at room temperature for 30 min, cooled and poured on to ice-water (500 ml) (evolution of gas). The solid which had precipitated out was filtered off, washed with water (3x10 ml) and dried in vacuo. Beige solid. Yield: 3.86 g (79 % of theory) LC-MS (method 1): Rt = 2.5 min, m/z: [M+H]+ = 220.2 13C-NMR (10 MHz, DMSO, δ ppm): 35.3, 52.8, 109.4, 125.0, 125.5, 126.9, 131.6, 150.7, 164.8, 176.7, 185.4 llb) 2-(2-Oxoindolin-5-yl)acetic acid methyl ester [0145] Palladium on charcoal (10 %, 4.05 g) was added to a suspension of 2-oxo-2-(2-oxoindolin-5-yl)acetic acid methyl ester (8.97 g, 40.55 mmol) and trifluoroacetic acid (10 ml, 14.80 g) under argon. The suspension was then hydrogenated at 50 °C and a hydrogen pressure of 6 bar for 4 h. The palladium was filtered off and the mother liquor was evaporated to dryness in vacuo. Colourless solid. Yield: 5.76 g (69 % of theory) LC-MS (method 1): Rt = 2.55 min, m/z: [M+H]+ = 206.2 13C-NMR (101 MHz, DMSO-d6, δ ppm): 35.7, 39.7, 51.6, 108.8, 125.3, 125.9, 127.0, 128.3, 142.5, 171.9, 176.3 llc) 2,2’-(4-Amino-1,3-phenylene)diacetic acid di-sodium salt [0146] The methyl ester from instructions 11b) (2,50 g, 12.18 mmol) was stirred in 5 N aqueous sodium hydroxide solution (12.18 ml, 60.91 mmol) at 100 °C for 4 h. The orange-coloured solution was cooled, dry ice was added and the mixture was stirred for 30 min. The residue was concentrated by evaporation in vacuo. 6.15 g of a yellow solid, which comprises the di-sodium salt of the target compound and sodium bicarbonate, were obtained. LC-MS (method 1): Rt = 0.35 min, m/z: [M+H]+ = 210.2 13C-NMR (101 MHz, DMSO-d6, δ ppm): 44.0, 44.9, 114.3, 123.7, 126.5, 127.2, 131.0, 144.6, 175.2, 175.8 11 d) 2,2’-(4-(2-(5-Chlorothiophen-2-yl)-6,7-dihydro-5H-cycopenta[d]pyrimidin-4-ylamino)-1,3-phenylene)diacetic acid [0147] 4-Chloro-2-(5-chlorothiophen-2-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidine (437 mg, 1.61 mmol), the amine from 11c) (1.22 g), BINAP (70 mg, 0.11 mmol), palladium(ll) acetate (25 mg, 0.11 mmol) and caesium carbonate (1.05 g, 3.22 mmol) in anhydrous DMSO (4.5 ml) were stirred at 130 °C (oil bath temperature) under argon for 1.5 h. 1 N sodium hydroxide solution (30 ml) and diethyl ether (15 ml) were then added to the reaction mixture. The aqueous phase was separated off, washed with diethyl ether (3x5 ml) and ethyl acetate (2x5 ml) and acidified (pH 4) with 1 N hydrochloric acid, after which a solid precipitate out. The aqueous phase was extracted with THF (4x10 ml) and the combined THF extracts were dried with magnesium sulfate, filtered and concentrated. The residue was purified by column chromatography [silica gel 60; THF/cyclohexane 1 : 2, then 1:1, with in each case 0.5 % acetic acid]. Yellow solid. Yield: 178 mg (25 % of theory) LC-MS (method 1): Rt = 3.6 min m/z: [M+H]+ = 444.2 11 e) 2-(1-(2-(5-Chlorothiophen-2-yl)-6,7-dihydro-5H-cyclopenta[d1pyrimidin-4-yl)-2-oxoindolin-5yl)acetic acid
[0148] Pyridine (324 μΙ, 317 mg, 4.01 mmol) and methanesulfonic acid chloride (142 μΙ, 211 mg, 1,84 mmol) were added to the product from 11 d) (178 mg, 0.40 mmol) in 1,2-dichloroethane (3 ml) and the mixture was stirred at 0 °Cfor 1 h. The solid which had precipitated out was filtered off and 1 N hydrochloric acid (10 ml) and diethyl ether (10 ml) were added to the filtrate. The aqueous phase of the filtrate was separated off and extracted with diethyl ether (3x5 ml). The organic phases were then combined, washed with 1 N hydrochloric acid (3x5 ml), dried with magnesium sulfate and concentrated. The residue was purified by means of column chromatography [silica gel 60; methylene chloride, then diethyl ether, with in each case 0.5 % acetic acid]. Pale yellow solid. Yield: 48 mg (28 % of theory), Melting range: 223-226 °C LC-MS (method 1): Rt = 4.0 min, m/z: [M+H]+ = 426.2 13C-NMR(101 MHz, DMSO, δ ppm): 21.8, 29.0, 34.0, 36.4, 40.2,111.1,125.2, 125.6, 127.7, 128.2, 128.3, 128.6, 130.2, 132.1, 140.7, 141.1, 151.2, 157.8, 172.7, 172.9, 179.2
Synthesis example No. 12: 2-(1-(2-(5-Fluorothiophen-2-yl)-6,7-dihydro-5H-cyclopenta[d]-pyrimidin-4-yl)-2-ox-oindolin-5-yl)acetic acid (compound No. 1-65) 12a) 2,2’-(4-(2-(5-Fluorothiophen-2-yl)-6,7-dihydro-5H-cyclopenta[dlpyrimidin-4-ylamino)-1,3-phenylene)diacetic acid [0149] Reaction of 2,2’-(4-amino-1,3-phenylene)diacetic acid di-sodium salt from 11c) (1.52 g) and 4-chloro-2-(5-fluorothiophen-2-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidine (510 mg, 2 mmol) analogously to instructions 11d). The reaction was worked up by the addition of water (50 ml) to the reaction mixture and the mixture was adjusted to pH 4 with 2 N hydrochloric acid and extracted with THF (4 x 20 ml). The combined organic phases were dried with magnesium sulfate and concentrated. The residue was purified by column chromatography [silica gel 60; methylene chloride/methanol 15:1, with 1 % acetic acid]. Beige-coloured solid. Yield: 400 mg (47 % of theory) LC-MS (method 1): Rt = 3.33 min, m/z: [M+H]+ = 428.2 1H-NMR (400 MHz, DMSO-d6, δ ppm): 2.05 (m, 2H), 2.70 (m, 2H), 2.82 (m, 2H), 3.56 (s, 2H), 3.63 (s, 3H), 6.71 (dd, J = 1.9, 4.2, 1H), 7.20-7.22 (2H), 7.35 (t, J = 4.1, 1H), 7.56 (d, J = 8.7, 1H), 8.62 (s, 1H), 12.17 (s (broad), 2H) 13C-NMR (101 MHz, DMSO-d6, δ ppm): 21.1,27.0, 33.5, 35.6, 37.8,109.4 (d, JC F = 10.6), 115.1, 123.9 (d, Jc F = 4.4), 125.2, 127.9, 129.5, 131.3, 131.5, 132.7 (d, JC F = 2.4), 135.9, 156.7, 157.6, 165.9 (d, JC F = 290.0), 172.6, 172.9, 173.0 12b) 2-(1-(2-(5-Fluorothiophen-2-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)-2-oxoindolin-5-yl)acetic acid [0150] Reaction of the phenyldiacetic acid from 12a) (350 mg, 0.82 mmol) analogously to instructions 11 e). 1 N hydrochloric acid (20 ml) was added to the reaction mixture. The aqueous phase was then separated off and extracted with ethyl acetate (3 x 20 ml). The organic phases were combined, dried with magnesium sulfate and concentrated. The residue was purified by means of column chromatography [silica gel 60; methylene chloride/methanol 100 : 1, with 0.5 % acetic acid]. Colourless solid. Melting range 240-242 °C; Yield: 244 mg (73 % of theory) LC-MS (method 1): Rt= 3.91 min, m/z: [M+H]+ = 410.20 1H-NMR (400 MHz, DMSO-d6, δ ppm): 2.07 (m, 2H), 2.86 (m, 2H), 3.05 (m, 2H), 3.57 (s, 2H), 3.85 (s, 2H), 6.84 (dd, J = 1.9, 4.2, 1H), 7.15 (dd, J = 1.7, 8.2,1H), 7.22 (d, J = 8.2, 1H), 7.28 (d, J = 1.7, 1H), 7.61 (dd (t-like), J = 4.1, 1H), 12.29 (s, 1H) 13C-NMR (101 MHz, DMSO-d6, δ ppm): 21.8, 28.9, 33.9, 35.3,40.1, 110.1 (d, Jc F = 10.9), 111.0, 125.2, 125.6, 125.7, 127.3, 128.2, 130.1, 131.0 (d, JC F = 3.0), 140.7, 151.1, 158.2, 166.8 (d, Jc F = 291.4), 172.7, 172.9, 179.1
Synthesis example No. 13: 2-(1-(2-(3-Chloro-4-methoxyphenyl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)-2-oxoindolin-5-yl)acetic acid (compound No. 1-66) 13a) 2,2’-(4-(2-(3-Chloro-4-methoxyphenyl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-ylamino)-1,3-phenylene)diacetic acid [0151] Preparation analogously to instructions 11 d) from 4-chloro-2-(3-chloro-4-methoxyphenyl)-6,7-dihydro-5H-cy-clopenta[d]pyrimidine (500 mg, 1.70 mmol) and the di-sodium salt from 11c) (1.29 g). The final purification of the crude product was carried out by means of column chromatography [silica gel 60; ethyl acetate/methanol 95 : 5, with 0.5 % acetic acid]. Yellow solid. Yield: 258 mg (32 % of theory) LC-MS (method 1): Rt = 3.25 min, m/z: [M+H]+ = 468.2 13C-NMR (101 MHz, DMSO, δ ppm): 21.2, 27.1,33.7, 37.8, 40.4, 56.2, 112.4, 115.0, 120.8,125.4,127.4, 127.9, 128.7, 129.6, 131.3, 131.5, 131.6, 136.2, 155.8, 157.1, 160.1, 172.2, 172.6, 173.0 13b) 2-(1-(2-(3-Chloro-4-methoxyphenyl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)-2-oxoindolin-5-yl)acetic acid
[0152] Reaction of the product from 13a) (243 mg, 0.52 mmol) analogously to instructions 11e). In deviation, the crude product was not purified by column chromatography but suspended in methanol (3 ml). The solid was then filtered off, washed with methanol (2x2 ml) and diethyl ether (1x2 ml) and dried in vacuo. White solid. Yield: 122 mg (52 % of theory). Melting range 206-207 °C LC-MS (method 1): Rt = 3.95 min, m/z: [M+H]+ = 450.2 13C-NMR (101 MHz, DMSO, δ ppm): 21.8, 28.9, 34.1,35.4, 40.2, 56.3, 110.9, 112.9, 121.4,125.3,125.7, 127.4, 127.9, 128.3, 128.9, 130.1, 130.2, 140.9, 151.4, 156.5, 160.8, 172.8, 173.0, 179.1
Synthesis example No. 14: 2-(3-(2-(5-Chlorothiophen-2-yl)-6,7-dihydro-5H-cyclopenta[d]-pyrimidin-4-yl)-2-oxo- 2,3-dihydrobenzo[d]oxazol-6-yl)acetic acid (compound No. 1-67) 14a) 2-(4-Amino-3-hydroxyphenyl)acetic acid methyl ester acetate [0153] Zinc (3.28 g, 50 mmol) and then, dropwise, acetic acid (5.72 ml, 100 mmol) were added to a solution of 2-(3-hydroxy-4-nitrophenyl)acetic acid methyl ester (2.11 g, 10 mmol) in ethanol (50 ml) and the mixture was then stirred at room temperature for 15 min. Methyl tert-butyl ether (100 ml) was added and the mixture was filtered over silica gel, the silica gel then being eluted with ethyl acetate (200 ml). The solvents were distilled off on a rotary evaporator. Grey solid. Yield: 2.1 g (88 % of theory) 1H-NMR (400 MHz, DMSO-d6, δ ppm): 1.91 (s, 3H, CH3COOH), 3.39 (s, 2H), 3.57 (s, 3H), 6.42 (dd, J = 1.9, 7.9, 1H), 6.51 (d, J =7.9, 1H), 6.55 (d, J = 1.9, 1H), 8.97 (s (broad), 1H) 13C-NMR(101 MHz, DMSO-d6, δ ppm): 20.9 (CH3COOH), 39.7, 51.3, 114.2, 115.2, 120.1, 122.0, 135.0, 143.9, 171.9 (CH3COOH), 172.1 LC-MS (method 1): Rt= 0.31 min, m/z: [M+H]+ = 182.20 14b) 2-(4-(2-(5-Chlorothiophen-2-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-ylamino)-3-hydroxyphenyl)acetic acid methyl ester [0154] The amino compound from 14 a) (965 mg, 4 mmol), 4-chloro-2-(5-chlorothiophen-2-yl)-6,7-dihydro-5H-cy-clopenta[d]pyrimidine (542 mg, 2 mmol), caesium carbonate (3.25 g, 10 mmol), BINAP (75 mg, 120 μπιοΙ) and palládiumul) acetate (23 mg, 100 μπιοΙ) in dioxane (40 ml) were stirred at 100 °C under argon for 3 h. Water (25 ml) was added to the reaction mixture and the aqueous phase was separated off and extracted with ethyl acetate (3 x 25 ml). The combined organic phases were then dried with magnesium sulfate and concentrated. The residue was purified by column chromatography [silica gel 60; cyclohexane/ethyl acetate 2:1, then methanol and THF]. Colourless solid. Yield: 730 mg (88 % of theory) LC-MS (method 1): Rt = 3.88 min, m/z: [M+H]+ = 416.20 1H-NMR (400 MHz, CDCI3, δ ppm): 2.07 (m, 2H), 2.78 (m, 2H), 2.84 (m, 2H), 3.60 (s, 2H), 3.62 (s, 3H), 6.77 (d, J = 8.1, 1 H), 6.85 (d, J = 1.4, 1H), 7.14 (d, J = 3.9, 1H), 7.57 (d, J = 3.9, 1H), 7.86 (dd, J = 8.1, 1 H), 7.86 (s, 1H), 9.87 (s, 1H) 14c) 2-(4-(2-(5-Chlorothiophen-2-yl)-6,7-dihydro-5H-cyclopenta[dlpyrimidin-4-ylamino)-3-hydroxyphenyl)acetic acid [0155] 2 N sodium hydroxide solution (1 ml) was added to the product from 14b) (140 mg, 0.34 mmol) in methanol (4 ml) and the mixture was stirred at room temperature for 16 h. 2 N hydrochloric acid (1 ml) and methyl tert-butyl ether (10 ml) were added and the mixture was then stirred for 20 min. The precipitate was then filtered off, washed with methyl tert-butyl ether and dried. Colourless solid. Yield: 125 mg (92 % of theory) LC-MS (method 1): Rt = 3.72 min, m/z: [M+H]+ = 403.20 1H-NMR (400 MHz, DMSO-d6, δ ppm): 2.05 (m, 2H), 2.78-2.85 (4H), 3.47 (s, 2H), 6.75 (dd, J = 1.6, 8.2, 1H), 6.90 (d, J = 1.6, 1H), 7.14 (d, J =4.0, 1H), 7.56 (d, J =4.0, 1H), 7.86 (d, J = 8.2, 1H), 7.96 (s, 1H), 10.03 (s, 1H) 13C-NMR (101 MHz, DMSO-d6, δ ppm): 21.0, 26.8, 33.5,40.4, 115.7, 116.5, 119.7, 122.5, 125.4, 126.7, 128.0, 130.6, 130.8, 142.9, 148.3, 156.3, 157.3, 171.6, 172.6 14d) 2-(3-(2-(5-Chlorothiophen-2-yl)-6,7-dihydro-5H-cyclogenta[d1pyrimidin-4-yl)-2-oxo-2,3-dihydrobenzo[d1oxazol-6-yl)acetic acid [0156] The carboxylic acid from 14c) (330 mg, 0.82 mmol) in THF (5 ml) was cooled to 0 °C and a solution of CDI (266 mg, 1.64 mmol) in THF (5 ml) was slowly added. The reaction mixture was heated at 70 °C for 1 h and then cooled to room temperature, water (5 ml) and trifluoroacetic acid (0.2 ml) were added and the mixture was stirred for 3 h. Brine (20 ml) was added and the aqueous phase was separated off and extracted with THF (3 x 20 ml). The combined organic phases were dried with magnesium sulfate and concentrated. The residue was purified by column chromatography [silica gel 60; methylene chloride/methanol 15:1 - 10:1], Colourless solid. Yield: 84 mg (24 % of theory) 1H-NMR (400 MHz, DMSO-d6, δ ppm): 2.09 (m, 2H), 3.03 (m, 2H), 3.06 (m, 2H), 3.51 (s, 2H), 7.17 (dd, J = 1.3, 8.2, 1H), 7.22 (d, J =4.0, 1H), 7.39 (d, J = 1.3, 1H), 7.47 (d, J = 8.2, 1H), 7.75 (d, J=4.0, 1H) 13C-NMR(101 MHz, DMSO-d6, δ ppm): 21.9, 29.0, 34.0, 42.5, 111.1, 111.7, 125.1, 126.0, 126.9, 128.5, 128.5, 128.6, 128.6, 132.4, 140.7, 142.5, 150.0, 150.2, 157.7, 180.1 LC-MS (method 1): Rt = 3.70 min, m/z: [M+H]+ = 429.20
Synthesis example No. 15: 2-(1-(2-(5-Chlorothiophen-2-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)-1H-ben-zo[d]imidazol-5-yl)acetic acid (compound No. 1-62) 15a) 2-(4-(2-(5-Chlorothiophen-2-yl)-6,7-dihydro-5H-cvclopentafd1pyrimidin-4-ylamino)-3-nitrophenyl)acetic acid ethyl ester [0157] 4-Chloro-2-(5-chlorothiophen-2-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidine (407 mg, 1.5 mmol), 2-(4-amino-3-nitrophenyl)acetic acid ethyl ester (336 mg, 1.5 mmol), caesium carbonate (978 mg, 3 mmol), BINAP (93 mg, 150 μηιοΙ) and palladium(ll) acetate (34 mg, 150 μίτιοΙ) in dioxane (7.5 ml) were stirred at 100 °Cfor2 h. Water (50 ml) was added to the reaction mixture and the aqueous phase was separated off and extracted with methylene chloride (3 x 20 ml). The combined organic phases were dried with magnesium sulfate and concentrated. The residue was purified by column chromatography [silica gel 60; cyclohexane/ethyl acetate 3 : 1], Colourless solid. Yield: 520 mg (76 % of theory) LC-MS (method 1): Rt = 4.44 min, m/z: [M+H]+ = 460.20 1H-NMR (400 MHz, CDCI3, δ ppm): 1.29 (t, J = 7.1, 3H), 2.23 (m, 2H), 2.93 (m, 2H), 3.03 (m, 2H), 3.67 (s, 2H), 4.20 (q, J = 7.1,2H), 6.94 (d, J =4.0, 1H), 6.68 (dd, J =2.2, 9.0, 1H), 7.70 (d, J = 4.0, 1H), 7.20 (d, J = 2.2,1H), 9.19 (d, J = 9.0, 1H), 10.19 (s, 1H) 15b)2-(3-Amino-4-(2-(5-chlorothiophen-2-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-ylamino)phenyl)aceticacid ethyl ester [0158] Zinc (459 mg, 7 mmol) and iron(lll) chloride (252 mg, 1.55 mmol) were added to a solution of the ester from 15a) (357 mg, 0.78 mmol) in DMF (10 ml) and water (2 ml) and the mixture was stirred at 150 °C for 30 min. Saturated sodium carbonate solution (10 ml) and thereafter water (50 ml) were then added and the aqueous phase was extracted with ethyl acetate (4 x 20 ml). The combined organic phases were dried with magnesium sulfate and concentrated. The residue was purified by column chromatography [silica gel 60; cyclohexane/ethyl acetate 2 : 1], The product mixture isolated in this way was further purified by means of HPLC. Colourless solid. Yield: 176 mg (53 % of theory) LC-MS (method 1): Rt = 3.68 min, m/z: [M+H]+ = 430.20 1H-NMR (400 MHz, CDCI3, δ ppm): 1.26 (t, J = 7.1,3H), 2.06 (m, 2H), 2.56 (m, 2H), 2.91 (m, 2H), 3.55 (s, 2H), 4.17 (q, J = 7.1,2H), 6.15 (s, 1H), 6.73 (dd, J = 1.8, 8.0, 1H), 6.77 (d, J = 1.8, 1H), 6.88 (d, J = 4.0, 1H), 7.27 (d, J = 8.0, 1H), 7.63 (d, J =4.0, 1 H), 8.01 (s, 1H) 15c) 2-(1-(2-(5-Chlorothiophen-2-yl)-6,7-dihydro-5H-cyclopentafdlpvrimidin-4-yl)-1H-benzofdlimidazol-5-yl)acetic acid ethyl ester [0159] Ethyl acetate (10 ml) was added to the suspension from the product of 15b) (159 mg, 0.37 mmol) and triethyl orthoformate (5 ml). The solvent was then removed on a rotary evaporator and the residue was heated at 200 °C in an oil bath for 30 min. The reaction mixture was cooled and dissolved in methylene chloride to remove the excess ortho ester, and the solution was then concentrated. Colourless solid. Yield: 157 mg (96 % of theory) 1H-NMR (400 MHz, CDCI3, δ ppm): 1.27 (t, J = 7.2, 3H), 2.87 (m, 2H), 3.15 (m, 2H), 3.22 (m, 2H), 3.79 (s, 2H), 7.00 (d, J = 3.9, 1H), 7.43 (dd, J = 1.6, 8.6, 1H), 7.80 (d, J = 1.6, 1H), 7.85 (d, J = 3.9, 1H), 8.37 (d, J = 8.6, 1H), 8.49 (s, 1H) 15d) 2-(1-(2-(5-Chlorothiophen-2-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)-1H-benzo[d]imidazol-5-yl)acetic acid [0160] 2 N sodium hydroxide solution (0.5 ml) was added to the product from 15c) (159 mg, 0.37 mmol) in THF (6 ml) and the mixture was stirred at room temperature for 64 h. 2 N hydrochloric acid solution (0.5 ml) was then added and the THF was largely distilled off. The suspension was diluted with methanol (5 ml) and the solid was filtered off. Colourless solid. Melting range: 268-270 °C. Yield: 86 mg (58 % of theory) LC-MS (method 1): Rt = 4.01 min, m/z: [M+H]+ = 412.10 1H-NMR (400 MHz, DMSO-d6, δ ppm): 2.15 (m, 2H), 3.05 (m, 2H), 3.23 (m, 2H), 3.73 (s, 2H), 7.24 (d, J = 4.0,1H), 7.35 (d, J = 8.4, 1H), 7.69 (s, 1H), 7.83 (d, J = 4.0, 1H), 8.24 (d, J = 8.4, 1 H), 8.74 (s, 1H), 12.33 (s, 1H) 13C-NMR (100 MHz, DMSO-d6, δ ppm): 21.9, 29.5, 34.0, 40.4, 114.3, 120.5, 121.5, 125.9, 128.4, 128.6, 130.7, 130.8, 132.3, 140.9, 142.4, 143.5, 152.0, 157.8, 172.8, 178.9
Synthesis example No. 16: 2-(1-(2-(5-Chlorothiophen-2-yl)-6,7-dihydro-5H-cyclopenta[d]-pyrimidin-4-yl)-1H-in-dazol-5-yl)acetic acid (compound No. 1-61) 16a) 2-(1-(2-(5-Chlorothiophen-2-yl)-6,7-dihydro-5H-cyclopenta[d1pyrimidin-4-yl)-1H-indazol-5-yl)acetic acid ethyl ester [0161] Potassium tert-butylate (217.7 mg, 1.94 mmol) and toluene (4 ml) were added to 4-chloro-2-(5-chlorothiophen-2-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidine (350 mg, 1.29 mmol), 2-(1H-indazol-5-yl)acetic acid ethyl ester (264 mg, 1.29 mmol), tBuXPhos (109.8 mg, 0.26 mmol) and Pd2(dba)3 (59.2 mg, 0.06 mmol) under argon and the mixture was stirred at 80 °Cfor 90 min. The reaction mixture was filtered over Celite® and the volatile constituents of the filtrate were removed in vacuo. The residue was purified by means of column chromatography [silica gel; cyclohexane/ethyl acetate 5:1], Colourless solid. Yield 94 mg (17 % of theory) 13C-NMR (101 MHz, CDCI3, δ ppm): 14.2, 22.0, 32.0, 34.7, 41.2, 61.0, 116.1, 120.4,121.0, 126.2, 127.5, 129.4, 129.9, 133.5, 138.1, 138.8, 142.0, 155.3, 158.3, 171.6, 177.9 16b) 2-(1-(2-(5-Chlorothiophen-2-yl)-6,7-dihydro-5H-cvclopenta[d1pyrimidin-4-yl)-1 H-indazol-5-yl)acetic acid [0162] Preparation from the ester obtained under 16a) (91 mg, 0.21 mmol) analogously to instructions 1e). Colourless solid. Yield: 62 mg (72 % of theory) 13C-NMR (101 MHz, DMSO-d6, δ ppm): 21.3, 31.6, 33.9, 40.3, 115.0, 119.8, 121.5, 125.7, 128.0, 128.4, 130.4, 130.5, 131.8, 137.7, 138.9, 141.4, 154.5, 157.2, 172.7, 177.7
Synthesis example No. 17: 2-(1-(2-(3-Fluoro-4-methoxyphenyl)-6,7-dihydro-5H-cyclopenta-[d]pyrimidin-4-yl)-1H-indazol-5-yl)acetic acid (compound No. 1-60) 17a) 2-(1-(2-(3-Fluoro-4-methoxyphenyl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)-1H-indazol-5-yl)acetic acid ethyl ester [0163] The target compound was prepared from 4-chloro-2-(3-fluoro-4-methoxyphenyl)-6,7-dihydro-5H-cyclopen-ta[d]pyrimidine (423 mg, 1.52 mmol) and 2-(1H-indazol-5-yl)acetic acid ethyl ester (310 mg, 1.52 mmol) analogously to instructions 16a). Colourless solid. Yield: 130 mg (19 % of theory) 13C-NMR (101 MHz, CDCI3, δ ppm): 14.2, 22.1, 31.8, 34.8, 41.2, 56.3, 61.0, 112.9, 112.9, 115.7, 115.8, 116.0, 120.4, 121.1, 124.4, 124.4, 126.1, 129.3, 129.7, 131.3, 131.4, 137.8, 138.8, 149.6, 149.7, 151.2, 153.6, 155.6, 161.7, 161.7, 172.6, 178.0 17b) 2-(1-(2-(3-Fluoro-4-methoxyphenyl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)-1H-indazol-5-yl)acetic acid
[0164] Saponification of the esterobtained under 17a) (125 mg, 0.28 mmol) analogously to instructions 1e). Colourless solid. Yield: 101 mg (86 % of theory). Melting range: 236-238 °C 13C-NMR (101 MHz, DMSO-d6, δ ppm): 21.3, 31.4, 34.0, 40.3, 56.1, 113.7, 113.7, 114.5, 114.7, 114.7, 119.7, 121.5, 124.3, 124.4, 125.7, 130.1, 130.2, 130.3, 137.7, 138.5, 149.1, 149.2, 150.1, 152.5, 154.8, 160.5, 160.6, 172.8, 177.7
Synthesis example No. 18: 2-(1-(2-(5-Chlorothiophen-2-yl)-5,6,7,8-tetrahydroquinazolin-4-yl)indolin-5-yl)acetic acid (compound No. 1-50) 18a) 2-(1-(2-(5-Chlorothiophen-2-yl)-5,6,7,8-tetrahydroquinazolin-4-yl)indolin-5-yl)acetic acid methyl ester [0165] Preparation from 4-chloro-2-(5-chlorothiophen-2-yl)-5,6,7,8-tetrahydroquinazoline (301 mg, 1.06 mmol) and 2-(indolin-5-yl)acetic acid methyl ester (203 mg, 1.06 mmol) analogously to instructions 1d). Yellow solid. Yield: 339 mg (73 % of theory) 13C-NMR (101 MHz, CDCI3, δ ppm): 22.3, 22.7, 26.1,28.9, 32.4, 40.7, 52.0, 52.4, 114.2, 116.9, 125.6, 126.7, 126.8, 127.2, 127.5, 132.4, 132.9, 142.6, 144.4, 156.5, 160.7, 166.8, 172.4 18b) 2-(1-(2-(5-Chlorothiophen-2-yl)-5,6,7,8-tetrahydroquinazolin-4-yl)indolin-5-yl)acetic acid
[0166] Saponification of the ester obtained under 18a) (339 mg, 0.77 mmol) analogously to instructions 1e). Pale yellow solid. Yield: 286 mg (87 % of theory). Melting range: 120-122 °C 13C-NMR (101 MHz, DMSO-d6, δ ppm): 21.6,22.2,25.5,28.5,31.9,40.2,52.0,114.7,116.4,125.6,126.9,127.2,128.1, 130.9, 132.1, 142.4, 143.4, 155.0, 160.4, 166.2, 168.4, 173.0
Synthesis example No. 19: 2-(1-(2-(3-Chloro-4-methoxyphenyl)-5,6,7,8-tetrahydroquinazolin-4-yl)indolin-5-yl)acetic acid (compound No. 1-39) 19a) 2-(1-(2-(3-Chloro-4-methoxyphenyl)-5,6,7,8-tetrahydroquinazolin-4-yl)indolin-5-yl)acetic acid methyl ester [0167] The target compound was prepared analogously to instructions 1d) from 4-chloro-2-(3-chloro-4-methoxyphe-nyl)-5,6,7,8-tetrahydroquinazoline (483 mg, 1.56 mmol) and 2-(indolin-5-yl)acetic acid methyl ester (299 mg, 1.56 mmol). Beige solid. Yield: 164 mg (34 % of theory) LC-MS (method 1): Rt = 3.5 min, m/z: [M+H]+ = 416.3 13C-NMR (101 MHz, CDCI3, δ ppm): 22.4, 22.7, 26.0, 28.9, 32.6, 40.7, 52.0, 52.5, 56.2, 111.5, 113.7, 117.1, 122.4, 125.7, 126.4, 127.4, 127.6, 129.9, 131.9, 132.4, 144.8, 156.4, 159.2, 161.0, 166.8, 172.5 19b) 2-(1-(2-(3-Chloro-4-methoxyphenyl)-5,6,7,8-tetrahydroquinazolin-4-yl)indolin-5-yl)acetic acid
[0168] 1 N sodium hydroxide solution (0.66 ml, 0.66 mmol) was added to the methyl ester from 19a) (152 mg, 0.33 mmol) in methanol (1.5 ml) and 1,4-dioxane (1.5 ml) and the mixture was stirred at room temperature for 1 h. Water (10 ml) and 1 N hydrochloric acid (0.66 ml) were then added to the reaction mixture. The solid which had precipitated out was filtered off, washed with water (3x2 ml) and cyclohexane (2x2 ml) and dried in vacuo. Pale yellow solid. Yield: 99 mg (67 % of theory). Melting range 121-125 °C 13C-NMR (101 MHz, DMSO-d6, δ ppm): 21.7, 22.2, 25.3, 28.5, 32.1,40.2, 52.0, 56.2, 112.6, 114.1, 116.5, 121.0, 125.7, 127.1, 127.4, 127.7, 128.6, 131.1, 132.2, 143.8, 156.0, 157.6, 160.7, 166.2, 173.0
Synthesis example No. 20: 2-(1-(2-(3-Chloro-4-methoxyphenyl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)in-dolin-4-yloxy)acetic acid (compound No.1-76) 20a) Ethyl 2-(1-(2-chloro-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)indolin-4-yloxy)acetate [0169] 2,4-Dichloro-6,7-dihydro-5H-cyclopenta[d]pyrimidine (5.00 g, 26,45 mmol), ethyl 2-(indolin-4-yloxy)acetate (6.15 g, 27.78 mmol) and Hünig base (9.0 ml) in NMP (50 ml) were stirred overnight at 80°C. The reaction mixture was cooled to ambient temperature, ethyl acetate (200 ml) was added and the phases were separated. The organic layer was washed with water (3 x 50 ml), dried over magnesium sulfate and evaporated. The residue was triturated with methanol and hexane. The precipitating solid was filtered off, washed with hexane and dried in vacuo. Beige solid. Yield: 7.1g (72% of theory) LC-MS (method 2): Rt = 0.83 min, m/z: [M+H]+ = 374.1 20b) Ethyl 2-(1-(2-(3-chloro-4-methoxyphenyl)-6,7-dihydro-5H-cyclopenta[d1pyrimidin-4-yl)indolin-4-yloxy)acetate [0170] Four glas tubes were loaded under a nitrogen atmosphere each with the product of 20a) (349 mg, 0.94 mmol), 3-chloro-4-methoxyphenylboronic acid (261 mg, 1.40 mmol), 2 N sodium carbonate solution (2.3 ml) and tetrakis(triphe-nylphosphine)-palladium(O) (33 mg, 29 μΐηοΙ) in 1,2-dimethoxymethane (16 ml). The tubes were sealed and then irradiated with microwaves for 2 h at 120°C. Water (120 ml) was added and the mixture was filtered through a Celite® pad and extracted with dichloromethane (3x 90 ml). The combined organic layers were dried over magnesium sulfate, filtered and evaporated. The residue was chromatographed [silica gel 60; dichloromethane/diethylether 25:1], Yield: 500 mg (28% of theory) LC-MS (method 2): Rt = 0.87 min, m/z: [M+H]+ = 480.1 20c) 2-(1-(2-(3-Chloro-4-methoxyphenyl)-6,7-dihydro-5H-cyclopenta[d1pyrimidin-4-yl)indolin-4-yloxy)acetic acid [0171] Lithium hydroxide (48 mg, 2.08 mmol) was added to a suspension of the product of 20b) (500 mg, 1.04 mmol) in THF (8 ml) and water (1 ml) and the mixture was stirred for 24 h at room temperature. Water (30 ml) was added and the pH value was adjusted to 1-2 with 1N hydrochloride solution. The mixture was extracted with dichloromethane/THF (4:1) and the combined organic layers were washed with brine, dried over magnesium sulfate and evaporated. The residue was triturated with diethyl ether and ethanol, filtered, washed with ether and dried in vacuo. Colorless solid. Yield: 500 mg (76% of theory) LC-MS (method 2): Rt = 0.69 min, m/z: [M+H]+ = 452.1
Synthesis example No. 21: 2-(1-(2-(5-Chlorothiophen-2-yl)-5,7-dihydrothieno[3,4-d]pyrimidin-4-yl)indolin-5-yljacetic acid (compound No. 1-20) 21a) 2-(5-Chlorothiophen-2-yl)-5,7-dihydrothieno[3,4-d1pyrimidin-4-ol [0172] Hünig base (0,515 ml, 392 mg, 3,03 mmol) and 5-chlorothiophene-2-carboximidamide (500 mg, 2,53 mmol) were added to methyl 4-oxotetrahydrothiophene-3-carboxylate (810 mg, 5,06 mmol) in n-propanol (2 ml) and the mixture was irradiated with microwaves in a sealed tube at 90°C for 16 h. The reaction mixture was cooled, diluted with ethyl acetate (10 ml) and stirred for 30 min under cooling with an ice bath. The precipitate was filtered off and washed with ethyl acetate (3 ml) and diethyl ether (3 ml). Beige solid. Yield: 50% of theory 13C-NMR (101 MHz, DMSO-d6, δ ppm): 3,9 (2H, d, J = 2,8), 4,1 (2H, d, J = 3,2), 7,2 (1H, d, J = 4,4), 8,0 (1H, d, J = 3,6) 21b) 4-Chloro-2-(5-chlorothiophen-2-yl)-5,7-dihydrothieno[3,4-d1pyrimidine [0173] A mixture consisting of the thioetherfrom 21a) (321 mg, 1,18 mmol) and phosphorus oxychloride (2,2 ml, 3,69 g, 23,7 mmol) was heated for 2 h at 95°C. The reaction mixture was cooled with an ice bath and then slowly quenched with water (15 ml). Dichloromethane was added (20 ml) and the mixture was stirred for 10 min. The phases were separated and the aqueous phase was extracted with dichloromethane (2 x 20 ml). The organic layers were combined, dried over sodium sulfate, and evaporated. Orange solid.
Yield: 312 mg (92% of theory). Melting range: 150-152°C 13C-NMR (101 MHz, CDCI3, δ ppm): 33.5, 38.8, 127.6, 127.7, 129.4, 135.5, 139.5, 157.7, 160.1, 172.0 21c) Methyl 2-(1-(2-(5-chlorothiophen-2-yl)-5,7-dihydrothieno[3,4-d]pyrimidin-4-yl)indolin-5-yl)acetate [0174] Methyl 2-(indolin-5-yl)acetate (192 mg, 1,0 mmol), 4-chloro-2-(5-chlorothiophen-2-yl)-5,7-dihydrothieno[3,4-
d]pyrimidine (289 mg, 1,0 mmol), palladium (ll)acetate (13 mg, 0,059 mmol), caesium carbonate (391 mg, 1,2 mmol) and BINAP (45,5 mg, 0,073 mmol) in dry dioxane (3 ml) were heated for 1,5 h at 110°C. The mixture was diluted with dichloromethane (1 ml) and chromatographed [silica gel 60; ethyl acetate/cyclohexane 1 : 3], Yellow solid. Yield: 260 mg (59% of theory). Melting range: 167-160°C 13C-NMR (101 MHz, CDCI3, δ ppm): 28.6, 34.8, 38.1,40.6, 50.7, 52.0, 112.4,116.6,125.6, 127.3,127.6,128.0, 128.3, 132.0, 133.6, 141.8, 142.9, 157.6, 158.4, 171.2, 172.2 21 d) 2-(1-(2-(5-chlorothiophen-2-yl)-5,7-dihydrothieno[3,4-d1pyrimidin-4-yl)indolin-5-yl)acetic acid [0175] 1 N Sodium hydroxide solution (1,69 ml, 1,69 mmol) was added to the product of 21c) (150 mg, 0,338 mmol) in THF (10 ml) and the mixture was stirred for 16 h at room temperature. Water (2 ml) and 1N hydrochloric acid (1,7 ml) were then added and stirring was continued for 1,5 h. The precipitate was filtered off and washed with water (2x2 ml) and dichloromethane (2x2 ml). Yellow solid. Yield: 89 mg (61% of theory). Melting point: 143-145°C 13C-NMR (101 MHz, DMSO-d6, δ ppm): 27.9, 33.8, 37.2, 38.8, 40.1, 49.9, 112.6, 116.3, 125.9, 127.6, 127.7, 128.3, 129.2, 131.5, 132.2, 141.7, 142.2, 156.9, 157.0, 170.4, 172.8
Synthesis example No. 22: 2-(1-(2-(5-Chlor-thiophen-2-yl)-6-oxo-5,7-dihydro-thieno[3,4-d]pyrimidin-4-yl)-2,3-di-hydro-1H-indol-5-yl)acetic acid (compound No. 1-21)
[0176] Peracetic acid (39% in acetic acid; 0,93 mmol, 157,7 μΙ) was added to 2-(1-(2-(5-chlorothiophen-2-yl)-5,7-dihydrothieno[3,4-d]pyrimidin-4-yl)indolin-5-yl)acetic acid (200 mg, 0,47 mmol) dissolved in sulfolane (6 ml) at ambient temperature and the mixture was stirred for 1,5 h. Water (40 ml) was poured into the mixture and the precipitating solid was filtered off, washed with water (4x5 ml) and dried in vacuo. Orange solid. Yield: 160 mg (77% of theory). Melting range: 180-185°C 13C-NMR (101 MHz, DMSO-d6, δ ppm): 28.0, 40.1, 50.4, 56.8, 59.3, 108.8, 116.3, 125.8, 127.7, 128.0, 128.5, 129.5, 131.9, 132.5, 141.6, 142.0, 157.8, 158.2, 167.9, 172.8
Synthesis example No. 23: 2-(1-(2-(5-Chlor-thiophen-2-yl)-6,6-dioxo-5,7-dihydro-thieno[3,4-d]pyrimidin-4-yl)- 2.3- dihydro-1H-indol-5-yl)acetic acid (compound No. 1-22) [0177] m-Chloroperoxybenzoic acid (77 %, 323,2 mg, 1,44 mmol) was added at room temperature to the product from 21d) (200 mg, 0,47 mmol) in sulfolane (6 ml) and the mixture was stirred for 18 h at ambient temperature. Water (10 ml) was poured into the reaction mixture and the resulting precipitate was filtered off, washed with water (4x5 ml) and dried. Trituration of the raw product in methanol (5 ml) provided the target compound as a yellow solid. Yield: 113 mg (53% of theory) 13C-NMR (101 MHz, DMSO-d6, δ ppm): 28.0, 40.1, 50.2, 55.2, 56.2, 108.0, 116.6, 125.8, 127.7, 128.4, 128.5, 129.9, 132.3, 132.6, 141.3, 141.7, 156.0, 157.3, 161.4, 172.8
Synthesis example No. 24: 2-(1-(2-(5-Fluoro-thiophen-2-yl)-6,6-dioxo-5,7-dihydro-thieno[3,4-d]pyrimidin-4-yl)- 2.3- dihydro-1H-indol-5-yl)acetic acid (compound No. 1-25) 24a) Methyl 2-(1-(2-(5-fluorothiophen-2-yl)-5,7-dihvdrothienor3,4-d1pyrimidin-4-yl)indolin-5-yl)acetate [0178] Synthesized from 4-chloro-2-(5-fluorothiophen-2-yl)-5,7-dihydrothieno[3,4-d]pyrimidine (712 mg, 2,61 mmol) and methyl 2-(indolin-5-yl)acetate (500 mg, 2,61 mmol) in an analogous manner to procedure 21 c). Light yellow solid. Yield: 550 mg (49% of theory) LC-MS (Method 1): Rt = 4.2 min, m/z: [M+H]+ = 428.2 13C-NMR(101 MHz, CDCI3, δ ppm): 28.6, 34.8, 38.2,40.6, 50.8, 52.0, 108.8, 108.9, 112.2, 116.7,125.4,125.6, 128.0, 128.3, 131.5, 132.0, 143.0, 157.6, 158.8, 166.7, 169.6, 171.2, 172.2 24b) 2-(1-(2-(5-fluorothiophen-2-yl)-5,7-dihydrothieno[3,4-d]pyrimidin-4-yl)indolin-5-yl)acetic acid [0179] 1 N Sodium hydroxide solution (6,26 ml, 6,26 mmol) was added to the methyl ester from 24a) (535 mg, 1,25 mmol) in THF (3 ml) and the mixture was stirred for 30 min at70°C(oil bath temperature). Water (5 ml) and 1 N hydrochloric acid (6,26 ml) were added and the precipitating solid was filtered off, washed with water (3X2 ml) and dried in vacuo. Light yellow solid. Yield: 467 mg (90% of theory) LC-MS (Method 1): Rt = 4.05 min, m/z: [M+H]+ = 414.1 13C-NMR (101 MHz, DMSO-d6, δ ppm): 28.0, 33.8, 37.2, 40.2, 49.9, 109.8, 109.9, 112.4, 116.4, 125.2, 125.2, 125.7, 127.6, 129.2, 131.6, 131.6, 132.2, 142.3, 157.0, 157.3, 165.0, 167.9, 170.4, 172.8 24c) 2-(1-(2-(5-Fluoro-thiophen-2-yl)-6,6-dioxo-5,7-dihydrothieno[3,4-d]pyrimidin-4-yl)-2,3-dihydro-1H-indol-5-yl)acetic acid [0180] The product from 24b) (449,2 mg, 1,08 mmol) was reacted with m-chloroperoxybenzoic acid (77 %, 323,2 mg, 1,44 mmol) in analogous manner as described for synthesis example No. 23 with the difference that the raw product was purified by chromatography [silica gel 60; THF/acetic acid 1000 : 1], Yellow solid. Yield: 57 mg (12% of theory) 13C-NMR (101 MHz, DMSO-d6, δ ppm): 28.0, 40.3, 50.2, 55.2, 56.2, 107.8, 110.1, 110.2, 116.6, 125.8, 126.0, 126.1, 127.7, 130.0, 131.2, 131.2, 132.6, 141.7, 156.0, 157.6, 161.3, 165.4, 168.3, 172.9
Synthesis example No. 25: 2-(1-(2-(3-Fluoro-4-methoxy-phenyl)-6,6-dioxo-5,7-dihydro-thieno[3,4-d]pyrimidin-4-yl)-2,3-dihydro-1H-indol-5-yl)acetic acid (compound No. 1-10) 25a) Methyl 2-(1-(2-(3-fluoro-4-methoxyphenvl)-5,7-dihydrothienof3,4-d1pyrimidin-4-yl)indolin-5-yl)acetate [0181] Beige solid. LC-MS (Method 1): Rt = 4.15 min, m/z: [M+H]+ = 452.2 13C-NMR (101 MHz, CDCI3, δ ppm): 28.7, 34.7, 38.4, 40.6, 51.0, 52.0, 56.2, 112.6, 112.7, 112.7, 115.8, 116.0, 116.0, 124.5, 125.7, 127.9, 131.0, 132.1, 143.2, 149.6, 149.7, 151.0, 153.4, 157.9, 161.7, 161.7, 171.5, 172.3 25b) 2-(1-(2-(3-Fluoro-4-methoxyphenyl)-5,7-dihydrothieno[3,4-d1pyrimidin-4-yl)indolin-5-yl)acetic acid [0182] Yellow solid. LC-MS (Method 1): Rt = 4.00 min, m/z: [M+H]+ = 438.2 13C-NMR (101 MHz, DMSO-d6, δ ppm): 28.1, 33.7, 37.4, 40.1, 50.1, 56.1, 112.6, 113.6, 114.6, 114.8, 115.8, 124.3, 125.8, 127.5, 129.0, 130.3, 130.4, 132.2, 142.5, 149.0, 149.2, 150.1, 152.5, 157.4; 160.1, 160.2, 170.9, 172.9 25c) 2-(1-(2-(3-Fluoro-4-methoxv-phenyl)-6,6-dioxo-5,7-dihydro-thieno[3,4-d1pyrimidin-4-vl)-2,3-dihydro-1H-indol-5-yl)acetic acid [0183] Yellow solid. Melting range: 192-195°C LC-MS (Method 1): Rt = 3.65 min, m/z: [M+H]+ = 470.2 13C-NMR (101 MHz, DMSO-d6, δ ppm): 28.1,40.1,50.4, 54.8,55.2, 56.1,56.5,108.0,113.7,114.6,114.8,116.1,124.5, 124.5, 125.9, 127.6, 129.6, 129.9, 130.0, 132.6, 141.9, 149.4, 149.5, 150.1, 152.5., 156.4, 160.4, 160.5, 161.6, 172.8
Synthesis example No. 26:2-(1-(2-(3-Chloro-4-methoxy-phenyl)-6,6-dioxo-5,7-dihydro-thieno[3,4-d]pyrimidin-4-yl)-2,3-dihydro-1H-indol-5-yl)acetic acid (compound No. 1-11) 26a) Methyl 2-(1-(2-(3-chloro-4-methoxyphenyl)-5,7-dihydrothieno[3,4-d1pyrimidin-4-yl)indolin-5-yl)acetate [0184] Colorless solid. LC-MS (Method 1): Rt = 4.25 min, m/z: [M+H]+ = 468.2 13C-NMR (101 MHz, DMSO-d6, δ ppm): 28.0, 33.7, 37.4, 39.6,50.1,51.6,56.3,112.5,112.6,115.9,121.1,125.7,127.4, 127.8, 128.2, 128.9, 130.6, 132.4, 142.7, 156.3, 157.4, 159.9, 170.8, 171.8 26b) 2-(1-(2-(3-Chloro-4-methoxyphenyl)-5,7-dihydrothieno[3,4-d1pyrimidin-4-yl)indolin-5-yl)acetic acid [0185] Yellow solid. LC-MS (Method 1): Rt = 4.15 min, m/z: [M+H]+ = 454.2 13C-NMR (101 MHz, DMSO-d6, δ ppm): 28.1, 33.8, 37.4, 40.1, 50.1, 56.3, 112.5, 112.6, 115.9, 121.1, 125.7, 127.4, 127.7, 128.9, 129.0, 130.6, 132.2, 142.5, 156.2, 157.4, 159.9, 170.8, 172.9 26c) 2-(1-(2-(3-Chloro-4-methoxy-phenyl)-6,6-dioxo-5,7-dihydro-thieno[3,4-d1pyrimidin-4-yl)-2,3-dihydro-1H-indol-5-yQacetic acid [0186] Yellow solid. Melting range: 245-247°C. LC-MS (Method 1): Rt = 3.75 min, m/z: [M+H]+ = 486.1 13C-NMR (101 MHz, DMSO-d6, δ ppm): 28.1, 40.1, 50.4, 55.2, 56.3, 56.5, 108.0, 112.8, 116.2, 121.2, 125.9, 127.5, 127.9, 129.0, 129.6, 130.3, 132.6, 141.9, 156.4, 156.6, 160.3, 161.6, 172.8
Synthesis example No. 27: 2-(1-(2-(4-Methoxyphenyl)-6,6-dioxo-5,7-dihydro-thieno[3,4-d]pyrimidin-4-yl)-2,3-di-hydro-1H-indol-5-yl)acetic acid (compound No. 1-12) 27a) Methyl 2-(1-(2-(4-methoxyphenyl)-5,7-dihydrothieno[3,4-d]pyrimidin-4-yl)indolin-5-yl)acetate [0187] Colorless solid. LC-MS (Method 1): Rt = 4.05 min, m/z: [M+H]+ = 434.2 13C-NMR (101 MHz, DMSO-d6, δ ppm): 28.1,33.8, 37.5, 39.6, 50.1,51.6, 55.2, 112.1,113.9, 115.9, 125.7,127.7, 128.0, 129.3, 129.8, 132.3, 142.8, 157.4, 161.2, 170.8, 171.8 27b) 2-(1-(2-(4-Methoxyphenyl)-5,7-dihydrothieno[3,4-d]pyrimidin-4-yl)indolin-5-yl)acetic acid [0188] Yellow solid. LC-MS (Method 1): Rt = 3.9 min, m/z: [M+H]+ = 420.2 13C-NMR (101 MHz, DMSO-d6, δ ppm): 28.1, 33.8, 37.5, 40.2, 50.1, 55.2, 112.0, 113.9, 115.8, 125.7, 127.5, 128.8, 129.3, 129.8, 132.1, 142.6, 157.4, 161.2, 170.8, 172.9 27c) 2-(1 -(2-(4-Methoxyphenvl)-6,6-dioxo-5,7-dihydro-thieno[3,4-d1pyrimidin-4-yl)-2,3-dihydro-1H-indol-5-yl)acetic acid [0189] Yellow solid. Melting range: 239-243°C. LC-MS (Method 1): Rt = 3.65 min, m/z: [M+H]+ = 452.2 13C-NMR (101 MHz, DMSO-d6, δ ppm): 28.1, 40.2, 50.3, 55.2, 55.3, 56.5, 107.5, 114.0, 116.1, 125.9, 127.7, 129.4, 129.4, 129.4, 132.5, 142.0, 156.4, 161.5, 161.5, 161.6, 172.8
Synthesis example No. 28: 2-((1-(2-(5-Fluoro-thiophen-2-yl)-6,6-dioxo-5,7-dihydro-thieno[3,4-d]pyrimidin-4-yl)- 2,3-dihydro-1H-indol-4-yl)oxy)-N,N-dimethyl-acetamide (compound No. 2-17) 28a) 2-(1-(2-(5-Fluorothiophen-2-yl)-5,7-dihydrothieno[3,4-d1pyrimidin-4-yl)indolin-4-yloxy)-N,N-dimethylacetamide
[0190] The product was obtained from 2-(indolin-4-yloxy)-N,N-dimethylacetamide (200 mg, 0,908 mmol) and 4-chloro-2-(5-fluorothiophen-2-yl)-5,7-dihydrothieno[3,4-d]pyrimidine (248 mg, 0,908 mmol) in an analogous manner to procedure 21c). Beige solid. Yield: 241 mg (58% of theory). Melting range: 189-196°C 13C-NMR(101 MHz, CDCI3, δ ppm): 25.8, 34.3, 35.4, 36.0, 37.7, 50.6, 66.4, 107.1, 110.3, 110.4, 110.5, 113.1, 119.6, 125.6, 125.7, 128.3, 132.0, 145.4, 155.0, 157.6, 157.8, 165.5, 167.6, 168.4, 171.0 28b) 2-((1-(2-(5-Fluoro-thiophen-2-yl)-6,6-dioxo-5,7-dihydro-thieno[3,4-d1pyrimidin-4-yl)-2,3-dihydro-1H-indol-4-yl)oxy)-N,N-dimethyl-acetamide
[0191] m-Chloroperoxybenzoic acid (77 %, 362 mg, 1,62 mmol) in dichloromethane (15 ml) was added under cooling with an ice bath within 15 min to a solution of the product of 28a) (233 mg, 0,51 mmol) in dichloromethane (20 ml) and the mixture was stirred for 17 h at ambient temperature. Further m-chloroperoxybenzoic acid (77 %, 114 mg, 0,51 mmol) in dichloromethane (10 ml) was added and stirring was continued for 4 h. The mixture was quenched with saturated sodium hydrogen carbonate solution (50 ml) and stirred for 30 min. The organic phase was separated, washed with saturated sodium hydrogen carbonate solution (30 ml), dried over sodium sulfate and evaporated. The residue was purified by column chromatography [silica gel 60; ethyl acetate]. Yellow solid. Yield: 95 mg (38% of theory). Melting range: 241-244X 13C-NMR (101 MHz, DMSO-d6, δ ppm): 25.3, 34.9,35.5, 50.4,55.2, 56.2,65.9,107.1,107.9,110.0,110.2,119.5,126.0, 127.9, 131.1, 131.2, 144.3, 154.5, 156.1, 157.6, 161.4, 165.4, 167.0, 168.3
Compound No. 2-08: 2-((1 -(2-(3-Chloro-4-methoxy-phenyl)-6,6-dioxo-5,7-dihydro-thieno[3,4-d]pyrimidin-4-yl)-2,3-di-hydro-1 H-indol-4-yl)oxy)-N,N-dimethyl-acetamide (synthesis example No. 29) [0192] Prepared in an analogous manner to synthesis example No. 28 as yellow solid. Yield: 105 mg (46 % of theory).
Melting range: 260-262°C 13C-NMR (101 MHz, DMSO-d6, δ ppm): 25.4, 34.9, 35.5, 50.6, 55.1,56.3, 56.4, 65.9,106.9,108.2,109.7,112.7,119.5, 121.2, 127.7, 127.8, 129.0, 130.2, 144.5, 154.7, 156.5, 156.6, 160.2, 161.7, 167.0
Synthesis example No. 30: 2-((1-(2-(3-Fluoro-4-methoxy-phenyl)-6,6-dioxo-5,7-dihydro-thieno[3,4-d]pyrimidin- 4-yl)-2,3-dihydro-1H-indol-4-yl)oxy)-N,N-dimethyl-acetamide (compound No. 2-10) 30a) 2-(1-(2-(3-Fluoro-4-methoxyphenyl)-5,7-dihydrothieno[3,4-d]pyrimidin-4-yl)indolin-4-yloxy)-N,N-dimethylaceta-mide
[0193] Beige solid. Yield: 307 mg (70% of theory). Melting range: 98-105°C 13C-NMR (101 MHz, CDCI3, δ ppm): 25.8, 34.6, 35.6, 36.5, 38.3, 51.3, 56.2, 67.4, 105.8, 109.9, 110.0, 112.7, 112.9, 115.8, 116.0, 119.2, 124.4, 124.5, 128.3, 131.0, 145.7, 149.5, 149.6, 151.0, 153.4, 154.5, 158.0, 1671.7, 167.7, 171.6 30b) 2-((1-(2-(3-Fluoro-4-methoxy-phenyl)-6,6-dioxo-5,7-dihydro-thieno[3,4-d]pyrimidin-4-yl)-2,3-dihydro-1H-indol-4-yl)oxy)-N,N-dimethyl-acetamide
[0194] Yellow solid. Yield: 108 mg (36% of theory). Melting range: 231-233°C 13C-NMR (101 MHz, DMSO-d6, δ ppm): 25.4, 34.9, 35.5, 50.6, 55.1,56.1,56.4, 65.9, 106.9, 108.2, 109.7,113.7,114.6, 114.8, 119.5, 124.5, 127.8, 129.9, 144.5, 149.4, 149.5, 150.0, 152.4, 154.6, 156.5, 160.4, 161.6, 167.0
Synthesis example No. 31:2-((1-(2-(4-Methoxyphenyl)-6,6-dioxo-5,7-dihydro-thieno[3,4-d]pyrimidin-4-yl)-2,3-di-hydro-1 H-indol-4-yl)oxy)-N,N-dimethyl-acetamide (compound No. 2-02) 31a) 2-(1-(2-(4-Methoxyphenvl)-5,7-dihvdrothieno[3,4-dlpvrimidin-4-yl)indolin-4-yloxy)-N,N-dimethylacetamide
[0195] Orange solid. Yield: 286 mg (58% of theory). Melting range: 195-200°C 13C-NMR(101 MHz, DMSO-d6, δ ppm): 25.3, 33.7,34.9, 35.5,37.4, 50.3,65.9,106.2,109.5,112.2,113.8,118.9,127.7, 129.2, 129.7, 145.3, 154.6, 157.5, 161.2, 167.1, 170.9 31b) 2-((1-(2-(4-Methoxyphenvl)-6,6-dioxo-5,7-dihydro-thieno[3,4-d1pyrimidin-4-yl)-2,3-dihydro-1H-indol-4-v)oxv)-N,N-dimethyl-acetamide
[0196] Yellow solid. Yield: 153 mg (40% of theory). Melting range: 225-232°C 13C-NMR(101 MHz, DMSO-d6, δ ppm): 25.3, 34.9, 35.5, 50.5, 55.1,55.2, 56.5, 65.9, 106.8, 107.7, 109.7, 113.9, 119.3, 127.8, 129.3, 129.4, 144.7, 154.6, 156.5, 161.4, 161.5, 161.6, 167.0
Synthesis example No. 32: 2-((1-(2-(3-Chlorophenyl)-6,6-dioxo-5,7-dihydro-thieno[3,4-d]pyrimidin-4-vl)-2,3-di-hydro-1H-indol-4-yl)oxy)-N,N-dimethyl-acetamide (compound No. 2-06) 32a) 2-(1-(2-(3-Chlorophenvl)-5,7-dihydrothieno[3,4-d1pyrimidin-4-yl)indolin-4-yloxy)-N,N-dimethylacetamide
[0197] Yellow solid. Yield: 369 mg (70% of theory). Melting range: 183-194°C 13C-NMR (101 MHz, DMSO-d6, δ ppm): 25.4, 33.7, 34.9, 35.5, 37.4, 50.4, 65.9,106.5,109.5,113.8,119.2,126.1,127.2, 127.7, 130.1, 130.5, 133.4, 139.3, 145.1, 154.6, 157.6, 159.8, 167.1, 171.1 32b) 2-((1-(2-(3-Chlorophenyl)-6,6-dioxo-5,7-dihydro-thieno[3,4-d1pvrimidin-4-yl)-2,3-dihydro-1H-indol-4-yl)oxy1-N,N-dimethyl-acetamide
[0198] Yellow solid. Yield: 153 mg (40% of theory). Melting range: 222-226°C 13C-NMR (101 MHz, DMSO-d6, δ ppm): 25.4, 34.9, 35.5, 50.6, 55.1,56.4, 65.9,107.0,109.1,109.8,119.6,126.1,127.3, 127.8, 130.5, 130.6, 133.4, 139.0, 144.4, 154.7, 156.6, 160.1, 161.7, 167.0
Synthesis example No. 33: 2-((1-(2-(3,4-Difluoro-phenyl)-6,6-dioxo-5,7-dihydro-thieno[3,4-d]pyrimidin-4-yl)-2,3-dihydro-1H-indol-4-yl)oxy)-N,N-dimethyl-acetamide(compound No. 2-12) 33a) 2-(1-(2-(3,4-Difluorophenyl)-5,7-dihydrothieno[3,4-d]pyrimidin-4-yl)indolin-4-yloxy)-N,N-dimethylacetamide
[0199] Beige solid. Yield: 381 mg (72% of theory). Melting range: 198-200°C 13C-NMR(101 MHz, DMSO-d6, δ ppm): 25.4, 33.6, 34.9,35.5,37.3,50.4,65.9,106.5,109.5,113.6,116.1,116.3,117.6, 117.8, 119.2, 124.6, 127.8, 134.9, 145.0, 148.2, 149.6, 149.8, 150.7, 152.1, 152.2, 154.6, 157.6, 159.2, 167.1, 171.0 33b) 2-((1-(2-(3,4-Difluoro-phenyl)-6,6-dioxo-5,7-dihydro-thieno[3,4-d]pyrimidin-4-yl)-2,3-dihydro-1H-indol-4-yl)oxy)-N,N-dimethyl-acetamide
[0200] Yellow solid. Yield: 206 mg (53% of theory). Melting range: 212-217°C 13C-NMR(101 MHz, DMSO-d6, δ ppm): 25.4, 34.9,35.5, 50.7,55.1,56.4,65.9,107.0,109.0,109.7,116.2,116.4,117.8, 117.9, 119.6, 124.7, 127.9, 134.5, 134.6, 144.4, 148.2, 148.3, 149.9, 150.0, 150.6, 150.7, 152.4, 152.5, 154.7, 156.6, 159.5, 161.7, 167.1
Synthesis example No. 34:2-((1-(2-(3-Fluorophenyl)-6,6-dioxo-5,7-dihydro-thieno[3,4-d]pyrimidin-4-yl)-2,3-dihy-dro-1H-indol-4-yl)oxy)-N,N-dimethyl-acetamide (compound No. 2-04) 34a) 2-(1-(2-(3-Fluorophenyl)-5,7-dihydrothieno[3,4-d]pyrimidin-4-yl)indolin-4-yloxy)-N,N-dimethylacetamide
[0201] Yellow solid. Yield: 321 mg (63% of theory). Melting range: 168-175°C 13C-NMR(101 MHz, DMSO-d6, δ ppm): 25.4, 33.7, 34.9, 35.5, 37.4, 50.3, 65.9,106.5,109.5,113.7,113.8,114.0,117.1, 117.3, 119.1, 123.6, 127.7, 130.5, 130.6, 139.8, 139.9, 145.1, 154.6, 157.6, 160.0, 163.5, 167.1, 171.0 34b) 2-((1-(2-(3-Fluorophenyl)-6,6-dioxo-5,7-dihydro-thieno[3,4-d]pyrimidin-4-yl)-2,3-dihydro-1H-indol-4-yl)oxy)-N,N-dimethyl-acetamide
[0202] Yellow solid. Yield: 149 mg (52% of theory). Melting range: 237-245X 13C-NMR(101 MHz, DMSO-d6, δ ppm): 25.4, 34.9, 35.5, 50.6, 55.1,56.4, 65.9,107.0,109.1,109.7,113.9,114.1,117.5, 117.8, 119.5, 123.6, 127.8, 130.7, 139.5, 144.4, 154.6, 156.6, 160.3, 161.1, 161.7, 163.5, 167.0
Synthesis example No. 35:2-((1-(2-(5-Chlorothiophen-2-yl)-6-oxido-5,7-dihydrothieno[3,4-d1pyrimidin-4-yl)indo-lin-6-yl)oxy)-1-(pyrrolidin1-yl)ethanone (compound No. 2-116) [0203] TBTU (0.125 g, 0.39 mmol) and N-methylmorpholine (0.07 mL, 0.64 mmol) were added at 0°C to a solution of 2-((1-(2-(5-chlorothiophen-2-yl)-6-oxido-5,7-dihydrothieno[3,4-d]pyrimidin-4-yl)indolin-6-yl)oxy)acetic acid (0.15 g, 0.325 mmol) in DMF (2 mL). After stirring for 15 min, pyrrolidine (0.08 mL, 0.97 mmol) was introduced and the resulting mixture was stirred at room temperature for 16 h. The mixture was then poured onto cold water and extracted with dichloromethane (3 x 30 mL). The combined organic layers were washed with brine (1 x 50 mL), dried over sodium sulfate and evaporated to dryness. The residue was purified by flash column chromatography [methanol/dichloromethane = 1: 30], Yellow solid. Yield: 0.04 g (24% of theory) 1H NMR (400 MHz, DMSO-d6, δ ppm): 7.75 (d, 1H, J = 3.92 Hz), 7.65 (s, 1H), 7.23 (d, 1H, J = 4.04 Hz), 7.16 (d, 1H, J = 8.04 Hz), 6.58 (d, 1H, J = 8.12 Hz), 4.72-4.68 (m, 3H), 4.5-4.46 (m, 2H), 4.36 (d, 1H, J = 16.7 Hz), 4.29-4.28 (m, 1H), 3.98 (d, 1 H, J = 14.48 Hz), 3.44 (t, 2H, J = 6.56 Hz), 3.28 (2H, obscured by H20 peak), 3.17-3.06 (m, 2H), 1.86-1.83 (m, 2H), 1.76-1.71 (m, 2H).
[0204] The following compounds were prepared in an analogous manner:
Compound No. 2-117: 2-((1 -(2-(5-Chlorothiophen-2-yl)-6-oxido-5,7-dihydrothieno[3,4-d]pyrimidin-4-yl)indolin-6-yl)oxy)-1-(4-methylpiperazin-1-yl)ethanone (synthesis example No. 36).
[0205] Yellow solid. Yield: 53 mg (22% of theory) 1H NMR (400 MHz, DMSO-d6, δ ppm): 7.74 (d, 1H, J = 3.96 Hz), 7.64 (s, 1H), 7.24 (d, 1H, J = 3.96 Hz), 7.16 (d, 1H, J = 8.0 Hz), 6.58 (d, 1H, J = 6.48 Hz), 4.81 (s, 2H), 4.70 (d, 1H, J = 16.12 Hz), 4.35-4.5 (m, 4H), 3.98 (d, 1H, J = 16.88 Hz), 3.42 (bs, 4H), 3.2-3.08 (m, 2H), 2.26 (bs, 2H), 2.21 (bs, 2H), 2.13 (s, 3H).
Compound No. 2-118: 2-((1 -(2-(5-Chlorothiophen-2-vl)-6-oxido-5,7-dihydrothienof3,4-d1pyrimidin-4-yl)indolin-6-yl)oxy)-1-morpholinoethanone (synthesis example No. 37) [0206] Yellow solid. Yield: 55 mg (24% of theory) 1H NMR (400 MHz, DMSO-d6, δ ppm): 7.74 (d, 1H, J = 3.96 Hz), 7.66 (d, 1H, J = 1.92 Hz), 7.24 (d, 1H, J = 3.96 Hz), 7.17 (d, 1 H, J = 8.16 Hz), 6.6 (dd, 1H, J = 2.2 and 8.28 Hz), 4.83 (s, 2H), 4.71 (d, 1H, J = 16.4 Hz), 4.5-4.28 (m, 4H), 3.98 (d, 1 H, J = 16.96 Hz), 3.53 (bs, 4H), 3.44 (bs, 4H), 3.12-3.06 (m, 2H).
Compound No. 2-119: 38: 2-((1-(2-(3-Fluoro-4-methoxyphenyl)-6-oxido-5,7-dihydrothieno[3,4-d]pyrimidin-4-yl)indolin- 6-yl)oxy)-1-(pyrrolidin-1-yl)ethanone (synthesis example No. 38) [0207] White solid. Yield: 0.12 g (34% of theory) 1H NMR (400 MHz, DMSO-d6, δ ppm): 8.18 (d, 1H, J = 8.68 Hz), 8.06 (d, 1H, J = 12.8 Hz), 7.61 (d, 1H, J = 1.76 Hz), 7.32 (t, 1H, J = 8.76 Hz), 7.16 (d, 1H, J = 8.36 Hz), 6.57 (dd, 1H, J = 2.08 and 8.16 Hz), 4.72-4.68 (m, 3H), 4.52-4.44 (m, 2H), 4.36-4.2 (m, 2H), 4.01 (d, 1 H, J = 16.88 Hz), 3.92 (s, 3H), 3.38 (t, 2H, J = 6.6 Hz), 3.27 (t, 2H, J = 6.88 Hz), 3.15-3.07 (m, 2H), 1.82-1.77 (m, 2H), 1.74-1.69(m, 2H).
Compound No. 2-120: 2-((1 -(2-(5-Fluorothiophen-2-yl)-6-oxido-5,7-dihydrothieno[3,4-d]pyrimidin-4-yl)indolin-6-yl)oxy)-1-(pyrrolidin-1-yl)ethanone (synthesis example No. 39) [0208] Yellow solid. Yield: 75 mg (33% of theory) 1H NMR (400 MHz, DMSO-d6, δ ppm): 7.65-7.61 (m, 2H), 7.16 (d, 1H, J = 8.24 Hz), 6.86 (d, 1H, J = 3.96 Hz), 6.58 (dd, 1H, J = 1.92 and 8.08 Hz), 4.72-4.68 (m, 3H), 4.49-4.37 (m, 2H), 4.34-4.25 (m, 2H), 3.97 (d, 1H, J = 16.88 Hz), 3.44 (t, 2H, J = 6.72 Hz), 3.17-3.06 (m, 2H), 1.86-1.83 (m, 2H), 1.76-1.72 (m, 2H).
Compound No. 2-121: 2-((1-(2-(4-Methoxyphenyl)-6-oxido-5,7-dihydrothieno[3,4-d]pyrimidin-4-yl)indolin-6-yl)oxy)-1-(pyrrolidin-1-yl)ethanone (synthesis example No. 40) [0209] White solid. Yield: 0.15 g (56% of theory) 1H NMR (400 MHz, DMSO-d6, δ ppm): 8.32 (d, 2H, J = 8.76 Hz), 7.64 (d, 1 H, J = 1.88 Hz), 7.16 (d, 1H, J = 8.12 Hz), 7.07 (d, 2H, J = 8.76 Hz), 6.56 (dd, 1H, J = 2.12 and 8.12 Hz), 4.72-4.68 (m, 3H), 4.51-4.43 (m, 2H), 4.35-4.27 (m, 2H), 4.0 (d, 1 H, J = 16.76 Hz), 3.83 (s, 3H), 3.38-3.34 (m, 2H), 3.27 (t, 2H, J = 6.88 Hz), 3.15-3.07 (m, 2H), 1.8-1.75 (m,2H), 1.73-1.68 (m, 2H).
Compound No. 2-122: 1-(Azetidin-1-yl)-2-((1-(2-(5-chlorothiophen-2-yl)-6-oxido-5,7-dihydrothieno[3,4-d]pyrimidin-4-yl)indolin-6-yl)oxy)ethanone (synthesis example No. 41) [0210] EDCI (0.198 g, 1.03 mmol), HOBT (0.14 g, 1.03) and diisopropylethylamine (0.46 ml, 2.6 mmol) were added to a solution of 2-((1 -(2-(5-chlorothiophen-2-yl)-6-oxido-5,7-dihydrothieno[3,4-d]pyrimidin-4-yl)indolin-6-yl)oxy)acetic acid (0.4 g, 0.865 mmol) in DMF (5 mL) and azetidine (0.054 g, 0.95 mmol). The resulting mixture was stirred at room temperature for 16 h, then diluted with dichloromethane (30 mL) and washed with saturated sodium hydrogen carbonate solution (10 ml) and water (2x10 mL). The organic layer was separated, dried over sodium sulfate and concentrated. The residue was purified by flash chromatography [dichloromethane with 0-3% methanol]. White solid. Yield: 165 mg (38% of theory) 1H NMR (400 MHz, DMSO-d6, δ ppm): 7.73 (d, 1H, J =4.0 Hz), 7.66 (d, 1H, J = 2.16 Hz), 7.24-7.23 (m, 1H), 7.18 (d, 1 H, J = 8.2 Hz), 6.56 (dd, 1 H, J = 2.28 and 8.12 Hz), 4.71 (d, 1H, J = 16.4 Hz), 4.59 (s, 2H), 4.53-4.4 (m, 2H), 4.37 (d, 1 H, J = 16.4 Hz), 4.19-4.25 (m, 3H), 3.98 (d, 1 H, J = 13.28 Hz), 3.89 (t, 2H, J = 7.72 Hz), 3.14-3.07 (m, 2H), 2.22 (m, 2H, J = 7.6 Hz).
Synthesis example No. 42: 2-((1-(2-(5-Chlorothiophen-2-yl)-6,6-dioxido-5,7-dihydrothieno[3,4-d]pyrimidin-4-yl)indolin-6-yl)oxy)-N-ethylacetamide (compound No. 2-55) 42a) Ethyl 2-((1 -(2-(5-chlorothiophen-2-yl)-5,7-dihydrothieno[3,4-d1pyrimidin-4-yl)indolin-6-yl)oxy)acetate [0211] Prepared from 4-chloro-2-(5-chlorothiophen-2-yl)-5,7-dihydrothieno[3,4-d]pyrimidine (8.0 g, 27.77 mmol) and ethyl 2-(indolin-6-yloxy)acetate (6.13 g, 27.77 mmol) in an analogous manner to procedure 21 c). Light yellow solid. Yield: 9.5 g (72% of theory) 42b) 2-((1-(2-(5-Chlorothiophen-2-yl)-5,7-dihydrothieno[3,4-d1pyrimidin-4-yl)indolin-6-yl)oxy)acetic acid [0212] The ethyl ester 42a) (9.2 g, 19.45 mmol) was reacted with 1 N sodium hydroxide solution (58.3 mL) for 1 h at 95°C in a blend of 1,4-dioxane and ethanol (1:1,300 mL). Dark brown solid (9.0 g) that was used in the next step without further purification. 42c) 2-((1-(2-(5-chlorothiophen-2-yl)-6,6-dioxido-5,7-dihydrothieno[3,4-d]pyrimidin-4-yl)indolin-6-yl)oxy)acetic acid [0213] m-Chloroperoxybenzoic acid (1.73 g, 7.75 mmol) in anhydrous THF was added portion wise at 0°C to a solution of 42b) (1.5 g, 3.37 mmol) in dry THF (600 mL). The mixture was stirred at room temperature for 16 h and then poured onto a saturated sodium sulphite solution (300 mL). After stirring for 30 min, the organic layer was separated, dried over sodium sulfate and concentrated. The residue was purified by flash column chromatography [dichloromethane/methanol = 50:1 with 0.5% acetic acid]. Light yellow solid. Yield: 3.2 g (66 % of theory) 42d) 2-((1-(2-(5-Chlorothiophen-2-yl)-6,6-dioxido-5,7-dihydrothieno[3,4-d]pyrimidin-4-yl)indolin-6-yl)oxy)-N-ethylaceta-mide [0214] Prepared from 42c) (0.20 g, 0.42 mmol) and ethyl amine (0.09 g, 0.84 mmol) in analogy to the procedure for synthesis example No. 35. Yellow solid. Yield: 0.04 g (19% of theory) 1H NMR (400 MHz, DMSO-d6, δ ppm): 8.02 (bt, 1H, J = 8.0 Hz), 7.74-7.72 (m, 2H), 7.23-7.18 m, 2H), 6.65 (dd, 1H, J = 2.2 and 8.2 Hz), 4.87 (s, 2H), 4.59 (s, 2H), 4.47 (s, 2H), 4.34 (t, 2H, J = 8.16 Hz), 3.17-3.06 (m, 4H), 1.02 (t, 3H, J = 7.2 Hz).
[0215] The following compounds were prepared in an analogous manner:
Compound No. 2-123: 2-((1-(2-(5-Chlorothiophen-2-yl)-6,6-dioxido-5,7-dihydrothieno[3,4-d]pyrimidin-4-yl)indolin-6-yl)oxy)-1-(4-methylpiperazin-1-yl)ethanone (synthesis example No. 43) [0216] Light yellow solid. Yield: 85 mg (37% of theory) 1H NMR (400 MHz, DMSO-d6, δ ppm): 7.72 (d, 1H, J = 3.96 Hz), 7.62 (d, 1H, J = 2.0 Hz), 7.24 (d, 1H, J = 3.96 Hz), 7.17 (d, 1 H, J = 8.24 Hz), 6.6 (dd, 1 H, J = 2.16 and 8.28 Hz), 4.86 (s, 2H), 4.81 (s, 2H), 4.59 (s, 2H), 4.33 (t, 2H, J = 7.88 Hz), 3.41-3.4 (m, 4H), 3.07 (t, 2H, J = 8.4 Hz), 2.25-2.20 (m, 4H), 2.13 (s, 3H).
Compound No. 2-54: 2-((1-(2-(5-Chlorothiophen-2-yl)-6,6-dioxido-5,7-dihydrothieno[3,4-d]pyrimidin-4-yl)indolin-6-yl)oxy)-N-isopropylacetamide (synthesis example No. 44) [0217] Yellow solid. Yield: 0.11 g (50% of theory) 1H NMR (400 MHz, DMSO-d6, δ ppm): 7.79-7.73 (m, 3H), 7.23-7.18 (m, 2H), 6.65 (dd, 1H, J = 2.08 and 8.2 Hz), 4.87 (s, 2H), 4.59 (s, 2H), 4.45 (s, 2H), 4.35 (t, 2H, J = 8.12 Hz), 3.96-3.91 (m, 1H), 3.08 (t, 2H, J = 8.16 Hz), 1.08 (d, 6H, J = 6.56 Hz).
Compound No. 2-56: 2-((1-(2-(5-Chlorothiophen-2-yl)-6,6-dioxido-5,7-dihydrothieno[3,4-d]pyri-midin-4-yl)indolin-6-yl)oxy)-N-cyclopropyl-N-methylacetamide (synthesis example No. 45) [0218] White solid. Yield: 85 mg (38% of theory) 1H NMR (400 MHz, DMSO-d6, δ ppm): 7.71 (d, 1H, J = 3.96 Hz), 7.6 (s, 1H), 7.23 (d, 1 H, J = 3.88 Hz), 7.16 (d, 1H, J = 8.24 Hz), 6.58 (dd, 1H, J = 1.96 and 8.16 Hz), 4.93 (s, 2H), 4.86 (s, 2H), 4.59 (s, 2H), 4.33 (t, 2H, 8.08 Hz), 3.07 (t, 2H, J = 8.28 Hz), 2.78-2.7 (m, 4H), 0.74-0.68 (m, 4H).
Compound No. 2-57: 2-((1-(2-(5-Chlorothiophen-2-yl)-6,6-dioxido-5,7-dihydrothieno[3,4-d]pyrimidin-4-yl)indolin-6-yl)oxy)-N-(cyclopropylmethyl)-N-methylacetamide (synthesis example No. 46) [0219] Light yellow solid. Yield: 65 mg (28% of theory) 1H NMR (400 MHz, DMSO-d6 at 100°C, δ ppm): 7.75 (d, 1 H, J = 4.0 Hz), 7.66 (d, 1 H, J = 4.0 Hz), 7.18-7.16 (m, 2H), 6.64 (dd, 1 H, J = 4.0 and 8.0 Hz), 4.77 (s, 4H), 4.5 (s, 2H), 4.34 (t, 2H, J = 8.0 Hz), 3.22 (d, 2H, J = 8.0 Hz), 3.11 (t, 2H, J = 8.0 Hz), 3.0 (s, 3H), 0.96 (bs, 1H), 0.44 (d, 2H, J = 4.0 Hz), 0.2 (d, 2H, J = 4.0 Hz).
Compound No. 2-124: 1-(Azetidin-1-yl)-2-((1-(2-(5-chlorothiophen-2-yl)-6,6-dioxido-5,7-dihydrothieno[3,4-d]pyrimidin- 4-yl)indolin-6-yl)oxy)ethanone (synthesis example No. 47) [0220] Light yellow solid. Yield: 95 mg (44% of theory) 1H NMR (400 MHz, DMSO-d6, δ ppm): 7.71 (d, 1H, J = 3.92 Hz), 7.65 (s, 1H), 7.23 (d, 1H, J = 3.92 Hz), 7.17 (d, 1H, J = 8.2 Hz), 6.58 (d, 1 H, J = 8.0 Hz), 4.87 (s, 2H), 4.59 (s, 4H), 4.34 (t, 2H, J = 8.08 Hz), 4.27 (t, 2H, J = 7.6 Hz), 3.89 (t, 2H, J = 7.56 Hz), 3.08 (t, 2H, J = 8.08 Hz), 2.22 (m, 2H).
Compound No. 2-58: 2-((1-(2-(5-Chlorothiophen-2-yl)-6,6-dioxido-5,7-dihydrothieno[3,4-d]pyrimidin-4-yl)indolin-6-yl)oxy)-N-methylacetamide (synthesis example No. 48) [0221] Yellow solid. Yield: 85 mg (41% of theory) 1H NMR (400 MHz, DMSO-d6, δ ppm ): 7.97 (d, 1H, 4.0 Hz), 7.73-7.71 (m, 2H), 7.23 (d, 1 H, J = 3.96 Hz), 7.19 (d, 1H, J = 8.16 Hz), 6.65 (dd, 1H, J = 1.96 and 8.16 Hz), 4.87 (s, 2H), 4.59 (s, 2H), 4.49 (s, 2H), 4.34 (t, 2H, J = 8.16 Hz), 3.08 (t, 2H, J = 8.16 Hz), 2.64 (d, 3H, J = 4.64 Hz).
Compound No. 2-59: 2-((1-(2-(5-Chlorothiophen-2-yl)-6,6-dioxido-5,7-dihydrothieno[3,4-d]pyrimidin-4-yl)indolin-6-yl)oxy)acetamide (synthesis example No. 49) [0222] Light yellow solid. Yield: 55 mg (27% of theory) 1 H NMR (400 MHz, DMSO-d6, δ ppm): 7.73 (d, 1H, J = 3.96 Hz), 7.69 (s, 1H), 7.47 (bs, 1H), 7.37 (bs, 1H), 7.24 (d, 1 H, J =3.96 Hz), 7.19 (d, 1H, J =8.08 Hz), 6.63 (dd, 1H, J =2.08 and 8.28 Hz), 4.87 (s, 2H), 4.59 (s, 2H), 4.45 (s, 2H), 4.34 (t, 2H, J = 8.08 Hz), 3.08 (t, 2H, J = 8.0 Hz).
Compound No. 2-60: 2-((1-(2-(5-Chlorothiophen-2-yl)-6,6-dioxido-5,7-dihydrothieno[3,4-d]pyrimidin-4-yl)indolin-6-yl)oxy)-N-(oxetan-3-yl)acetamide (synthesis example No. 50) [0223] Yellow solid. Yield: 90 mg (40% of theory) 1H NMR (400 MHz, DMSO-d6, δ ppm): 8.8 (d, 1H, J = 6.52 Hz), 7.73 (d, 2H, J = 3.76 Hz), 7.23-7.18 (m, 2H), 6.66 (1H, J = 8.08 Hz), 4.90-4.85 (m, 3H), 4.68 (t, 2H, J = 6.52 Hz), 4.59 (s, 2H), 4.52-4.48 (m, 4H), 4.35 (t, 2H, J = 8.08 Hz), 3.08 (t, 2H, J =8.08 Hz).
Compound No. 2-61: 2-((1-(2-(5-Chlorothiophen-2-yl)-6,6-dioxido-5,7-dihydrothieno[3,4-d]pyrimidin-4-yl)indolin-6-yl)oxy)-N-cyclopropylacetamide (synthesis example No. 51) [0224] Light yellow solid. Yield: 0.07 g (37% of theory) 1H NMR (400 MHz, DMSO-d6, δ ppm): 8.06 (d, 1H, J = 4.0 Hz), 7.72 (d, 1H, J = 3.92 Hz), 7.7 (s, 1H), 7.23 (d, 1H, J = 3.96 Hz), 7.18 (d, 1H, J = 8.28 Hz), 6.61 (dd, 1H, J = 2.08 and 8.16 Hz), 4.87 (s, 2H), 4.59 (s, 2H), 4.46 (s, 2H), 4.34 (t, 2H, J = 8.16 Hz), 3.08 (t, 2H, J = 8.36 Hz), 2.69-2.66 (m, 1H), 0.62-0.59 (m, 2H), 0.48-0.46 (m, 2H).
Compound No. 2-125: 2-((1-(2-(5-Chlorothiophen-2-vl)-6,6-dioxido-5,7-dihydrothieno[3,4-d]pyrimidin-4-yl)indolin-6-yl)oxy)-1-morpholinoethanone (synthesis example No. 52) [0225] White solid. Yield: 0.06 g (35% of theory) 1H NMR (400 MHz, DMSO-d6, δ ppm): 7.72 (d, 1H, J = 3.8 Hz), 7.65 (s, 1H), 7.24 (d, 1H, J = 3.88 Hz), 7.17 (d, 1H, J = 8.12 Hz), 6.62 (d, 1H, J = 8.32 Hz), 4.86 (s, 2H), 4.83 (s, 2H), 4.59 (s, 2H), 4.34 (t, 2H, J = 8.12 Hz), 3.53 (bs, 4H), 3.44 (bs, 4H), 3.07 (t, 2H, J = 7.88 Hz).
Compound No. 2-126: 2-((1-(2-(5-Chlorothiophen-2-vl)-6,6-dioxido-5,7-dihydrothieno[3,4-d]pyrimidin-4-yl)indolin-6-yl)oxy)-1-(pyrrolidin-1-yl)ethanone (synthesis example No. 53) [0226] White solid. Yield: 0.12 g (52% of theory) 1H NMR (400 MHz, DMSO-d6, δ ppm): 7.73 (s, 1H), 7.64 (s, 1H), 7.24 (s, 1H), 7.17 (d, 1H, J = 7.36 Hz), 6.6 (d, 1H, J = 6.8 Hz), 4.86 (s, 2H), 4.72 (s, 2H), 4.59 (s, 2H), 4.33 (t, 2H, J = 7.3 Hz), 3.44 (t, 2H, J = 7.16 Hz), 3.31 (2H, obscured by H20 peak), 3.07 (t, 2H, J = 7.38), 1.86-1.83 (m, 2H), 1.74-1.7 (m, 2H).
Compound No. 1-77: Example 54: Methyl 2-((1-(2-(5-chlorothiophen-2-yl)-6,6-dioxido-5,7-dihydrothieno[3,4-d]pyrimi-din-4-yl)indolin-6-yl)oxy)acetate (synthesis example No. 54) [0227] Refluxing of the carboxylic acid 42c) (0.20 g, 0.42 mmol) in methanol (8.0 mL) for 24 h and in the presence of concentrated sulphuric acid (0.2 mL) yielded the target compound. Light green solid. Yield: 80 mg (39% of theory) 1H NMR (400 MHz, DMSO-d6, δ ppm): 7.71 (d, 1H, J = 3.92 Hz), 7.68 (d, 1H, J = 1.6 Hz), 7.24 (d, 1H, J = 3.88 Hz), 7.18 (d, 1H, J = 8.08 Hz), 6.61 (dd, 1H, J = 1.64 and 8.32 Hz), 4.87 (s, 2H), 4.83 (s, 2H), 4.59 (s, 2H), 4.34 (t, 2H, J = 8.04 Hz), 3.66 (s, 3H), 3.08 (t, 2H, J = 7.88 Hz).
Compound No. 2-52: 2-((1-(2-(5-Chlorothiophen-2-yl)-6,6-dioxido-5,7-dihydrothieno[3,4-d]pyrimidin-4-yl)indolin-6-yl)oxy)-N-(2-hydroxyethyl)acetamide (synthesis example No. 55) [0228] HATU (0.19g, 0.50 mmol), diisopropylethylamine (0.3 mL, 1.67 mmol) and 2-amino ethanol (0.04 g, 0.67 mmol) were added to the carboxylic acid 42c) (0.20 g, 0.42 mmol) in DMF (2 mL). The resulting mixture was stirred at room temperature for 16 h, then poured onto ice-water (10 mL) and stirred for further 15 min. A precipitate was filtered off, the filtrate was evaporated, and the residue purified by flash column chromatography [dichloromethane/methanol = 1:50]. Light yellow solid. Yield: 0.09 g (40% of theory) 1H NMR (400 MHz, DMSO-d6, δ ppm): 7.95 (bs, 1H), 7.73 (d, 2H, J =2.6 Hz), 7.24-7.18 (m, 2H), 6.65 (d, 1H, J = 6.28 Hz), 4.87 (s, 2H), 4.70 (t, 1H, J = 5.36 Hz), 4.59 (s, 2H), 4.5 (s, 2H), 4.35 (t, 2H, J = 7.96 Hz), 3.45-3.4 (m, 2H, 3.23-3.19 (m, 2H), 3.1-3.06 (m, 2H).
[0229] The following examples were obtained from 4-chloro-2-(5-chlorothiophen-2-yl)-5,7-dihydrothieno[3,4-d]pyrimi-dine in two chemical steps, comprising a Buchwald reaction with the appropriate indoline and an oxidation with m-chloroperoxybenzoic acid in analogy to the procedures 21c) and 42c), respectively.
Compound No. 3-1: 2-((1-(2-(5-Chlorothiophen-2-yl)-6,6-dioxido-5,7-dihydrothieno[3,4-d]pyrimidin-4-yl)indolin-6-yl)oxy)acetonitrile (synthesis example No. 56) [0230] Yellow solid. Yield: 0.10 g 1H NMR (400 MHz, DMSO-d6, δ ppm): 7.75 (d, 1H, J = 1.8 Hz), 7.72 (d, 1H, J = 4.0 Hz), 7.28-7.23 (m, 2H), 6.77 (dd, 1 H, J = 2.0 and 8.2 Hz), 5.18 (s, 2H), 4.87 (s, 2H), 4.6 (s, 2H), 4.36 (t, 2H, J = 8.24 Hz), 3.1 (t, 2H, J = 8.12 Hz).
Compound No. 3-2: 2-(5-Chlorothiophen-2-yl)-4-(6-(2-methoxyethoxy)indolin-1-yl)-5,7-dihydrothieno[3,4-d]pyrimidine 6,6-dioxide (synthesis example No. 57) [0231] White solid. Yield: 0.12 g 1H NMR (400 MHz, DMSO-d6, δ ppm): 7.71-7.7 (m, 2H), 7.23 (d, 1H, J = 3.96 Hz), 7.17 (d, 1H, J = 8.2 Hz), 6.61 (dd, 1 H, J = 2.04 and 8.24 Hz), 4.87 (s, 2H), 4.59 (s, 2H), 4.34 (t, 2H, J = 8.12 Hz), 4.13 (t, 2H, J = 4.52 Hz), 3.67 (t, 2H, J = 4.52 Hz), 3.35 (s, 3H), 3.07 (t, 2H, J = 8.12 Hz).
Compound No. 3-3: 2-(5-Chlorothiophen-2-yl)-4-(6-(2-(dimethylamino)ethoxy)indolin-1-yl)-5,7-dihydrothieno[3,4-d]py-rimidine 6,6-dioxide (synthesis example No. 58) [0232] Light yellow solid. Yield: 0.08 g 1H NMR (400 MHz, DMSO-d6, δ ppm): 7.72-7.71 (m, 2H), 7.22 (d, 1H, J = 3.92 Hz), 7.17 (d, 1H, J = 8.24 Hz), 6.62 (dd, 1 H, J = 2.0 and 8.2 Hz), 4.87 (s, 2H), 4.59 (s, 2H), 4.34 (t, 2H, J = 8.2 Hz), 4.1 (t, 2H, J = 5.56 Hz), 3.07 (t, 2H, J = 8.12 Hz), 2.67 (bs, 2H), 2.26 (s, 6H).
Compound No. 2-45: 2-((1-(2-(5-Chlorothiophen-2-yl)-6,6-dioxido-5,7-dihydrothieno[3,4-d]pyrimidin-4-yl)indolin-6-yl)oxy)-N,N-dimethylacetamide (synthesis example No. 59) [0233] Synthesized from 42b) in two chemical steps comprising an amide coupling with TBTU as coupling reagent followed by an oxidation with m-chloroperoxybenzoic acid. Light yellow solid. Yield: 35 mg 1H NMR (400 MHz DMSO-d6, δ ppm): 7.72 (d, 1H, J = 3.84 Hz), 7.64 (s, 1H), 7.24 (d, 1H, J =3.84 Hz), 7.16 (d, 1H, J = 8.08 Hz), 6.59 (d, 1 H, J = 7.92 Hz), 4.86 (s, 2 H), 4.8 (s, 2H), 4.59 (s, 2H), 4.33 (t, 2H, J = 8.16 Hz), 3.07 (t, 2H, J = 8.24 Hz), 2.99 (s, 3H), 2.82 (s, 3H).
Compound No. 2-33: 2-((1-(2-(3-Chloro-4-methoxyphenyl)-6,6-dioxido-5,7-dihydrothieno[3,4-d]pyrimidin-4-yl)indolin- 6-yl)oxy)-N,N-dimethylacetamide (synthesis example No. 60) [0234] Obtained in an analogous manner as synthesis example No. 59. White solid. Yield: 35 mg 1H NMR (400 MHz, DMSO-d6, δ ppm): 8.32 (d, 1H, J = 1.48 Hz), 8.28 (d, 1H, J = 8.68 Hz), 7.64 (s, 1H), 7.30 (d, 1H, J = 8.76 Hz), 7.17 (d, 1H, J = 8.2 Hz), 6.60 (d, 1H, J = 8.08 Hz), 4.85 (s, 2H), 4.78 (s, 2H), 4.61 (s, 2H), 4.34 (t, 2H, J = 7.92 Hz), 3.94 (s, 3H), 3.08 (t, 2H, J = 8.16 Hz), 2.92 (s, 3H), 2.79 (s, 3H).
Synthesis example No. 61: 2-((1-(2-(5-Fluorothiophen-2-yl)-6,6-dioxido-5,7-dihydrothieno[3,4-d]pyrimidin-4-yl)indolin-6-yl)oxy)-N,N-dimethylacetamide (compound No. 2-49) 61a) Ethyl 2-((1 -(2-(5-fluorothiophen-2-yl)-5,7-dihydrothieno[3,4-d1pyrimidin-4-yl)indolin-6-yl)oxy)acetate [0235] Synthesized from 4-chloro-2-(5-fluorothiophen-2-yl)-5,7-dihydrothieno[3,4-d]pyrimidine (0.35 g, 1.28 mmol) and ethyl 2-(indolin-6-yloxy)acetate (0.28 g, 1.28 mmol) following the instructions of procedure 21c). White solid. Yield: 0.40 g (66% of theory) 61b) Ethyl 2-((1-(2-(5-fluorothiophen-2-yl)-6,6-dioxido-5,7-dihydrothieno[3,4-d]pyrimidin-4-yl)indolin-6-yl)oxy)acetate [0236] Oxidation of 61a) (0.50 g, 1.05 mmol) with m-chloroperbenzoic acid (0.61 g, 1.69 mmol) in analogy to procedure 28b). Light yellow solid. Yield: 0.30 g (58% of theory) 61c) 2-((1-(2-(5-Fluorothiophen-2-yl)-6,6-dioxido-5,7-dihydrothieno[3,4-d]pyrimidin-4-yl)indolin-6-yl)oxy)-N,N-dimethyl-acetamide [0237] Trimethylaluminium (2 M in toluene, 0.245 mL, 0.49 mmol) was added to a solution of dimethylamine (2M in THF, 0.245 mL, 0.49 mmol) in dichloromethane (3 mL) at 0°C and the resulting mixture was stirred for 30 min. Compound 61b) (0.06 g, 0.122 mmol) in dichloromethane (10 mL) was added and the mixture was heated at 70°C for 2 min and then stirred for further 16 h at room temperature. The reaction mixture was quenched with saturated ammonium chloride solution (10 mL) and extracted with dichloromethane (3 x 20 mL). The combined organic layers were washed with water (30 mL) and brine (30 mL), dried over sodium sulphate and evaporated. The residue was purified first by flash column chromatography [methanol/dichloromethane = 1:200] and then by preparative HPLC. White solid. Yield: 0.04 g (16% of theory) 1H NMR (400 MHz, DMSO-d6, δ ppm): 7.63-7.59 (m, 2H), 7.16 (d, 1H, J = 8.0 Hz), 6.87 (d, 1H, J = 3.68 Hz), 6.6 (d, 1 H, J = 8.12 Hz), 4.85 (s, 2H), 4.81 (s, 2H), 4.57 (s, 2H), 4.32 (t, 2H, J = 8.0 Hz), 3.06 (t, 2H, J = 7.92 Hz), 2.98 (s, 3H), 2.81 (s, 3H).
Compound No. 2-37: 2-((1-(2-(3-Fluoro-4-methoxyphenyl)-6,6-dioxido-5,7-dihydrothieno[3,4-d]pyrimidin-4-yl)indolin- 6-yl)oxy)-N,N-dimethylacetamide (synthesis example No. 62) [0238] The target compound was synthesized in an analogous manner as synthesis example No. 61. Yellow solid. Yield: 35 mg 1H NMR (400 MHz, DMSO-d6, δ ppm): 8.15 (d, 1H, J = 8.52 Hz), 8.03 (d, 1H, J = 12.48 Hz), 7.62 (s, 1H), 7.32 (t, 1H, J = 8.76 Hz), 7.17 (d, 1 H, J = 8.24 Hz), 6.60 (d, 1H, J = 8.0 Hz), 4.85 (s, 2H), 4.77 (s, 2H), 4.61 (s, 2H), 4.34 (t, 2H, J = 8.2 Hz), 3.92 (s, 3H), 3.08 (t, 2H, J = 8.04 Hz), 2.93 (s, 3H), 2.80 (s, 3H).
Synthesis example No. 63: 2-((1-(6,6-Dioxido-2-(pyridin-4-yl)-5,7-dihydrothieno[3,4-d]pyrimidin-4-yl)indolin-6-yl)oxy)-1-(pyrrolidin-1-yl)ethanone (Compound No. 2-130) 63a) 2-(Pyridin-4-yl)-5,7-dihydrothieno[3,4-d]pyrimidin-4-ol [0239] A mixture of isonicotinamidine (3.0 g, 19.03 mmol), 4-oxo-tetrahydro-thiophene-3-carboxylic acid methyl ester (4.6 g, 28.55 mmol) and diisoproylethylamine (16.36 mL, 95.15 mmol) in n-butanol (60 mL) was stirred at 120°C for 16 h. After cooling to ambient temperature, a precipitate was filtered off and washed with ethyl acetate (2 x 50 mL) yielding the product as white solid. Yield: 2.0 g (45% of theory) 63b) 4-Chloro-2-(pyridin-4-yl)-5,7-dihydrothieno[3,4-d1pyrimidine [0240] A mixture of 2-(pyridin-4-yl)-5,7-dihydrothieno[3,4-d]pyrimidin-4-ol (2.1 g, 9.09 mmol) and phosphoroxychloride (17.7 mL, 189.07 mmol) was heated at 100°C for 3 h. The reaction mixture was cooled to room temperature and excess phosphoroxychloride was removed under vacuum. The remnant was poured onto a mixture of ice water (75 mL) and saturated sodium hydrogen carbonate solution (100 mL), and was extracted with dichloromethane (3 x 100 mL). The combined organic layers were washed with brine (50 mL), dried over sodium sulphate and concentrated. The residue was purified by column chromatography [ethyl acetate/hexane = 1:4]. White solid. Yield: 1.6 g (80% of theory) 63c) Ethyl 2-((1 -(2-(pyridin-4-yl)-5,7-dihydrothieno[3,4-d]pyrimidin-4-yl)indolin-6-yl)oxy)acetate [0241] The target compound was synthesized from the pyrimidine chloride 63b) (1.5 g, 6.0 mmol) and ethyl 2-(indolin- 6-yloxy)acetate (1.24 g, 6.0 mmol) in analogy to the procedure 21c). Light yellow solid. Yield: 1.5 g (57% of theory) 63d) 2-((1-(2-(Pyridin-4-yl)-5,7-dihydrothieno[3,4-d]pyrimidin-4-yl)indolin-6-yl)oxy)acetic acid [0242] The methyl ester 63c) (2.5 g, 5.95 mmol) was dissolved in ethanol (46 mL) and dioxane (46 mL), 1N sodium hydroxide solution (17.8 ml, 17.8 mmol) was added and the mixture was refluxed at 100°C for 3 h. Light yellow solid. Yield: 0.7 g (29% of theory) 63e) 2-((1-(2-(Pyridin-4-yl)-5,7-dihydrothieno[3,4-d]pyrimidin-4-yl)indolin-6-yl)oxy)-1-(pyrrolidin-1-yl)ethanone [0243] HATU (0.95 g, 2.5 mmol), diisopropylethylamine (1.09 mL, 6.27 mmol) and pyrrolidine (0.21 mL, 2.51 mmol) were added to a solution of 63d) (0.85 g, 2.09 mmol) in DMF (8 mL). The resulting mixture was stirred at room temperature for 2 h, then diluted with water (30 mL) and extracted with dichloromethane (3 x 40 mL). The organic layers were dried over sodium sulphate and evaporated to dryness. The residue was purified by flash column chromatography [methanol/dichloromethane = 1:50], White solid. Yield: 0.6 g (62% of theory) 63f) 2-((1-(2-(3-Fluoro-4-methoxyphenyl)-6,6-dioxido-5,7-dihydrothieno[3,4-d]pyrimidin-4-yl)indolin-6-yl)oxy)-N,N-dimethylacetamide [0244] The thioether 63e) (0.3 g, 0.65 mmol) and MMPP (1.29 g, 2.61 mmol) in THF (700 mL) were stirred at room temperature for 4 h. The solvent was removed under vacuum, water (50 mL) was added to the remnant and the resulting mixture was extracted with dichloromethane (3 x 30 mL). The combined organic layers were washed with saturated sodium hydrogen carbonate solution, dried over sodium sulphate and concentrated. The residue was purified first by flash column chromatography [dichloromethane with 1-2.5% methanol] and finally by successive washing with methanol, diethyl ether, and pentane. Light yellow solid. Yield: 85 mg (27% of theory) 1H NMR (400 MHz, DMSO-d6, δ ppm): 8.76 (d, 2H, J = 5.36 Hz), 8.17 (d, 2H, J = 5.44 Hz), 7.67 (s, 1H), 7.19 (d, 1H, J = 8.2 Hz), 6.63 (d, 1H, J = 7.76 Hz), 4.91 (s, 2H), 4.7 (s, 2H), 4.67 (s, 2H), 4.37 (t, 2H, J = 7.88 Hz), 3.35 (t, 2H, J = 6.56 Hz), 3.26 (t, 2H, J = 6.64 Hz), 3.09 (t, 2H, J = 7.88 Hz), 1.81-1.68 (m, 4H).
[0245] The following compounds were obtained in an analogous manner
Compound No. 2-131: 1-(Azetidin-1-yl)-2-((1-(6,6-dioxido-2-(pyridin-4-yl)-5,7-dihydrothieno[3,4-d]pyrimidin-4-yl)indo-lin-6-yl)oxy)ethanone (synthesis example No. 64) [0246] Light yellow solid. Yield: 0.09 g 1H NMR (400 MHz, DMSO-d6, δ ppm): 8.75 (d, 2H, J = 5.84 Hz), 8.18 (d, 2H, J = 5.88 Hz), 7.7 (d, 1H, J = 2.16 Hz), 7.2 (d, 1 H, J = 8.24 Hz), 6.6 (dd, 1H, J = 8.28 and 2.32 Hz), 4.93 (s, 2H), 4.68 (s, 2H), 4.59 (s, 2H), 4.38 (t, 2H, J = 8.2 Hz), 4.21 (t, 2H, J = 7.64 Hz), 3.86 (t, 2H, J = 7.64 Hz), 3.1 (t, 2H, J = 8.12 Hz), 2.21-2.17 (m, 2H).
Compound No. 2-132: 2-((1-(6,6-Dioxido-2-(pyridin-4-yl)-5,7-dihydrothieno[3,4-d]pyrimidin-4-yl)indolin-6-yl)oxy)-N,N-dimethylacetamide (synthesis example No. 65) [0247] White solid. Yield: 0.09 g 1H NMR (400 MHz, DMSO-d6, δ ppm): 8.76 (d, 2H, J = 5.28 Hz), 8.17 (d, 2H, J = 5.72 Hz), 7.67 (d, 1H, J = 2.0 Hz), 7.18 (d, 1H, J = 8.16 Hz), 6.62 (dd, 1H, J = 8.16 and 2.16 Hz), 4.91 (s, 2H), 4.78 (s, 2H), 4.67 (s, 2H), 4.37 (t, 2H, J = 8.12 Hz), 3.09 (t, 2H, J = 8.04 Hz), 2.91 (s, 3H), 2.79 (s, 3H).
Compound No. 2-133: 2-((1-(6-Oxido-2-(pyridin-4-yl)-5,7-dihydrothieno[3,4-d]pyrimidin-4-yl)indolin-6-yl)oxy)-1-(pyrro-lidin-1-yl)ethanone (synthesis example No. 66) [0248] The thioether 63e) (0.15 g, 0.33 mmol) and m-chloroperoxybenzoic acid (77%, 58 mg, 0.26 mmol) in THF (300 mL) were stirred at room temperature for 1 h. The reaction mixture was diluted with brine (100 mL), and the aqueous phase was separated and extracted with THF (3 x 30 mL). The combined organic layers were washed with saturated sodium hydrogen carbonate solution, dried over sodium sulfate and evaporated to dryness. The residue was purified by flash column chromatography [methanol/dichloromethane = 1: 20]. White solid. Yield: 80 mg (51 % of theory) 1H NMR (400 MHz, DMSO-d6, δ ppm): 8.76 (d, 2H, J = 5.52 Hz), 8.21 (d, 2H, J = 5.64 Hz), 7.66 (d, 1H, J = 1.76 Hz), 7.18 (d, 1H, J = 8.2 Hz), 6.59 (dd, 1H, J = 8.16 and 2.04 Hz), 4.77-4.70 (m, 3H), 4.57-4.50 (m, 2H), 4.42-4.31 (m, 2H), 4.07 (d, 1 H, J = 16.92 Hz), 3.4-3.35 (m, 2H), 3.26 (t, 2H, J = 6.8 Hz), 3.11-3.04 (m, 2H), 1.81-1.77 (m, 2H), 1.7-1.66 (m, 2H).
[0249] The following compounds were obtained in an analogous manner
Compound No. 2-134: 1-(Azetidin-1-yl)-2-((1-(6-oxido-2-(pyridin-4-yl)-5,7-dihydrothieno[3,4-d]pyrimidin-4-yl)indolin-6-yl)oxy)ethanone (synthesis example No. 67) [0250] White solid. Yield: 68 mg (60% of theory) 1H NMR (400 MHz, DMSO-d6, δ ppm): 8.75 (d, 2H, J = 5.84 Hz), 8.21 (d, 2H, J = 5.88 Hz), 7.7 (d, 1H, J = 2.12 Hz), 7.2 (d, 1H, J = 8.16 Hz), 6.59 (dd, 1H, J = 8.16 and 2.28 Hz), 4.77 (d, 1 H, J = 16.44 Hz), 4.59 (s, 2H), 4.56-4.49 (m, 2H), 4.41 (d, 1H, J = 16.48 Hz), 4.37-4.31 (m, 1H), 4.22 (t, 2H, J = 7.72 Hz), 4.07 (d, 1 H, J = 16.9 Hz), 3.87 (t, 2H, J = 7.76 Hz), 3.19-3.09 (m, 2H), 2.2 (p, 2H, J = 7.52 Hz).
Compound No. 2-135: N,N-Dimethyl-2-((1-(6-oxido-2-(pyridin-4-yl)-5,7-dihydrothieno[3,4-d]pyrimidin-4-yl)indolin-6-yl)oxy)acetamide (synthesis example No. 68) [0251] Light yellow solid. Yield: 80 mg 1H NMR (400 MHz, DMSO-d6, δ ppm): 8.76 (d, 2H, J = 5.12 Hz), 8.22 (d, 2H, J = 5.0 Hz), 7.66 (s, 1H), 7.18 (d, 1H, J = 8.4 Hz), 6.6 (d, 1 H, J = 8.0 Hz), 4.73-4.8 (m, 3H), 4.58-4.47 (m, 2H), 4.39 (d, 1H, J = 16.52 Hz), 4.34-4.29 (m, 1 H), 4.07 (d, 1 H, J = 16.92 Hz), 3.2-3.05 (m, 2H), 2.92 (s, 3H), 2.79 (s, 3H).
Compound No. 2-136: 2-((1-(6,6-Dioxido-2-(pyridin-3-yl)-5,7-dihydrothieno[3,4-d]pyrimidin-4-yl)indolin-6-yl)oxy)-N,N-dimethylacetamide (synthesis example No. 69) [0252] Synthesized from 4-chloro-2-(pyridin-3-yl)-5,7-dihydrothieno[3,4-d]pyrimidine and 2-(indolin-6-yloxy)-N,N-dimethylacetamide in two chemical steps, namley a Buchwald-Hartwig reaction and an oxidation using MMPP as reagent. White solid. Yield: 0.08 g 1H NMR (400 MHz, DMSO-d6, δ ppm): 9.45 (s, 1H), 8.72 (d, 1H, J = 6.2 Hz), 8.59 (d, 1H, J = 8.0 Hz), 7.68 (s, 1H), 7.56 (dd, 1H, J = 8.0 and 4.84 Hz), 7.18 (d, 1 H, J = 8.24 Hz), 6.6 (dd, 1H, J = 8.2 and 2.0 Hz), 4.9 (s, 2H), 4.78 (s, 2H), 4.65 (s, 2H), 4.37 (t, 2H, J = 8.08 Hz), 3.09 (t, 2H, J = 7.96 Hz), 2.93 (s, 3H), 2.79 (s, 3H).
Compound No. 2-137: N,N-Dimethyl-2-((1-(6-oxido-2-(pyridin-3-yl)-5,7-dihydrothieno[3,4-d]pyrimidin-4-yl)indolin-6-yl)oxy)acetamide (synthesis example No. 70) [0253] Tetrakis(triphenylphosphine)palladium(0) (20 mg, 0.017 mmol), 2M sodium carbonate solution (0.73 mL), 3-pyridylboronic acid (0.15 g, 0.92 mmol) and ethanol (6.5 mL) were added under an argon atmosphere to a solution of 2-((1 -(2-chloro-6-oxido-5,7-dihydrothieno[3,4-d]pyrimidin-4-yl)indolin-6-yl)oxy)-N,N-dimethylacetamide (0.3 g, 0.74 mmol) in DME (6.5 mL). The resulting mixture was stirred at 95°C for 4 h and then cooled to ambinet temperature. The solid material was filtered off, the filtrate was evaporated and the resiude purified by column chromatography [neutral alumina; dichloromethane with 0.3 % methanol]. Yellow solid. Yield: 0.08 g (24% of theory) 1H NMR (400 MHz, DMSO-d6, δ ppm): 9.49 (s, 1H), 8.71 (d, 1H, J = 3.44 Hz), 8.64 (d, 1H, J = 7.68 Hz), 7.67 (d, 1H, J = 1.64 Hz), 7.56 (dd, 1H, J = 7.7 and 4.8 Hz), 7.18 (d, 1H, J = 8.12 Hz), 6.6-6.58 (m, 1H), 4.78-4.73 (m, 3H), 4.56-4.49 (m, 2H), 4.41-4.32 (m, 2H), 4.05 (d, 1 H, J = 16.96 Hz), 3.14-3.08 (m, 2H), 2.93 (s, 3H), 2.79 (s, 3H).
Compound No. 1-78: Methyl 2-(1-(2-(5-chlorothiophen-2-yl)-6,6-dioxido-5,7-dihydrothieno[3,4-d]pyrimidin-4-yl)indolin- 5-yl)acetate (synthesis example No. 71) [0254] Obtained from compound 21c) (0.3 g, 0.68 mmol) via oxidation with m-chloroperbenzoic acid (0.397 g, 1.78 mmol) following the instructions of procedure 28b). Yellow solid. Yield: 0.2 g (62% of theory) 1H NMR (400 MHz, DMSO-d6, δ ppm): 8.01 (d, 1H, J = 8.16 Hz), 7.7 (d, 1H, J = 4.0 Hz), 7.23 (d, 1H, J = 3.96 Hz), 7.19-7.16 (m, 2H), 4.88 (s, 2H), 4.58 (s, 2H), 4.33 (t, 2H, J = 8.2 Hz), 3.69 (s, 2H), 3.62 (s, 3H), 3.14 (t, 2H, J = 8.16 Hz).
Compound No. 3-4: 2-(1-(2-(5-Chlorothiophen-2-yl)-6,6-dioxido-5,7-dihydrothieno[3,4-d]pyrimidin-4-yl)indolin-5-yl)-N-ethylacetamide (synthesis example No. 72) [0255] Prepared from synthesis example No. 23 in an analogous manner as described in procedure 35). Light yellow solid. Yield: 45 mg (22% of theory) 1H NMR (400 MHz, DMSO-d6, δ ppm): 7.98 (d, 2H, 7.52), 7.7 (d, 1H, J = 4.0 Hz), 7.23 (d, 1H, J = 4.0 Hz), 7.17-7.14 (m, 2H), 4.87 (s, 2H), 4.57 (s, 2H), 4.35 (t, 2H, J = 8.24 Hz), 3.36 (s, 2H), 3.16-3.05 (m, 4H), 1.02 (t, 3H, J = 8.0 Hz).
Compound No. 3-8: 2-(1-(2-(5-Chlorothiophen-2-yl)-6,6-dioxido-5,7-dihydrothieno[3,4-d]pyrimidin-4-yl)indolin-5-yl)-N,N-dimethylacetamide (synthesis example No. 73) [0256] Yellow solid. Yield: 0.05 g 1H NMR (400 MHz, DMSO-d6, δ ppm): 7.99 (d, 1H, J = 8.4 Hz), 7.71 (d, 1H, J = 4.0 Hz), 7.23 (d, 1H, J = 4.0 Hz), 7.14-7.12 (m, 2H), 4.88 (s, 2H), 4.57 (s, 2H), 4.34 (t, 2H, J = 8.0 Hz), 3.66 (s, 2H), 3.14 (t, 2H, J = 8.0 Hz), 3.02 (s, 3H), 2.84 (s, 3H).
Compound No. 3-5: 2-(1-(2-(5-Chlorothiophen-2-yl)-6,6-dioxido-5,7-dihydrothieno[3,4-d]pyrimidin-4-yl)indolin-5-yl)-N-methylacetamide (synthesis example No. 74) [0257] Light yellow solid. Yield: 35 mg 1H NMR (400 MHz, DMSO-d6, δ ppm): 7.98 (d, 1H, J = 8.4 Hz), 7.92 (bs, 1H), 7.70 (d, 1H, J = 4.0 Hz), 7.23 (d, 1H, J = 4.0 Hz), 7.17-7.14 (m, 2H), 4.88 (s, 2H), 4.57 (s, 2H), 4.33 (t, 2H, J = 8.16 Hz), 3.36 (s, 2H), 3.14 (t, 2H, J = 12 Hz), 2.57 (d, 3H, 4.11 Hz).
Compound No. 3-6: 2-(1-(2-(5-Chlorothiophen-2-yl)-6,6-dioxido-5,7-dihydrothieno[3,4-d]pyrimidin-4-yl)indolin-5-yl)acetamide (synthesis example No. 75) [0258] Prepared from example No. 23 (0.10 g, 0.216 mmol) in analogy to the procedure 41). Yellow solid. Yield: 0.05 g (50% of theory) 1H NMR (400 MHz, DMSO-d6, δ ppm): 7.98 (d, 1H, J = 8.2 Hz), 7.71 (d, 1H, J = 3.96 Hz), 7.43 (s, 1H), 7.23 (d, 1H, J = 3.96), 7.18-7.15 (m, 2H), 6.86 (s, 1H), 4.88 (s, 2H), 4.57 (s, 2H), 4.32 (t, 2H, J = 8.12 Hz), 3.35 (s, 2H), 3.14 (t, 2H, J = 7.92 Hz).
Synthesis example No. 76: 1-(Azetidin-1-yl)-2-((1-(2-(5-chlorothiophen-2-yl)-6,7-dihydro-5H-cyclopenta[d]pyri-midin-4-yl)indolin-6-yl)oxy)ethanone (compound No. 2-127) 76a) Ethyl 2-((1 -(2-(5-chlorothiophen-2-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)indolin-6-yl)oxy)acetate [0259] Synthesis from 4-chloro-2-(5-chlorothiophen-2-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidine (3.66 g, 13.57 mmol) and ethyl 2-(indolin-6-yloxy)acetate (3.0 g, 13.57 mmol) in an analogous manner as described in procedure 21c). Dark yellow solid. Yield: 4.5 g (73% of theory) 76b) 2-((1-(2-(5-Chlorothiophen-2-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)indolin-6-yl)oxy)acetic acid [0260] The ethyl ester 76a) (1.4 g, 3.08 mmol) was stirred for 1 h at 95°C in a mixture of 1,4-dioxane (22 mL), ethanol (22 mL) and 1N sodium hydroxide solution (9.2 mL). Brown solid. Yield: 0.92 g (70% of theory) 76c) 1-(Azetidin-1-yl)-2-((1-(2-(5-chlorothiophen-2-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)indolin-6-yl)oxy)eth-anone [0261] The product of 76b) (0.15 g, 0.35 mmol) and azetidine (0.051 g, 0.88 mmol) were reacted in analogy to the procedure of synthesis example No. 35). White solid. Yield: 0.08 g (49% of theory) 1H NMR (400 MHz, DMSO-d6, δ ppm): 7.78 (d, 1H,J = 2.21 Hz),7.67 (d, 1H, J = 4.0 Hz), 7.19 (d, 1H, J=4.0 Hz), 7.14 (d, 1H, J = 8.16 Hz), 6.5 (dd, 1H, J =8.16 Hz and 2.2 Hz), 4.58 (s, 2H), 4.38 (t, 2H, J = 8.34 Hz), 4.28 (t, 2H, J = 7.64 Hz), 3.89 (t, 2H, J = 7.64 Hz), 3.19 (t, 2H, J = 7.16 Hz), 3.08 (t, 2H, J = 8.36 Hz), 2.85 (t, 2H, J = 7.8 Hz), 2.22 (m, 2H), 2.03 (m, 2H).
[0262] The following compounds were obtained in an analogous manner
Compound No. 2-42: 2-((1-(2-(5-Chlorothiophen-2-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)indolin-6-yl)oxy)-N,N-dimethylacetamide (synthesis example No. 77) [0263] White solid. Yield: 55 mg 1H NMR (400 MHz, DMSO-d6, δ ppm): 7.77 (d, 1H, J = 2.24 Hz), 7.67 (d, 1H, J = 3.92 Hz), 7.2 (d, 1H, J = 3.92 Hz), 7.12 (d, 1H, J = 8 Hz), 6.52 (dd, 1H, J = 8 Hz and 2.28 Hz), 4.79 (s, 2H), 4.37 (t, 2H, J = 8.44 Hz), 3.19 (t, 2H, J = 8.0 Hz), 3.07 (t, 2H, J = 8.0 Hz), 2.96 (s, 3H), 2.87-2.82 (m, 5H), 2.01 (p, 2H, J = 7.44 Hz).
Compound No. 2-128:2-((1-(2-(5-Chlorothiophen-2-yl)-6,7-dihydro-5H-cyclopenta[dlpyrimidin-4-yl)indolin-6-yl)oxy)-1-morpholinoethanone (synthesis example No. 78) [0264] Yellow solid. Yield: 75 mg (40% of theory) 1H NMR (400 MHz, DMSO-d6, δ ppm): 7.77 (d, 1H, J = 2.21 Hz), 7.68 (d, 1H, J = 3.92 Hz), 7.20 (d, 1H, J = 3.88 Hz), 7.13 (d, 1H, J = 8.24 Hz), 6.51 (dd, 1H, J = 8.2 Hz and 2.2 Hz), 4.81 (s, 2H), 4.37 (t, 2H, J = 8.32 Hz), 3.54-3.3 (m, 8H), 3.19 (t, 2H, J = 7.32 Hz), 3.07 (t, 2H, J = 8.16 Hz), 2.85 (t, 3H, J = 7.8 Hz), 2.01 (m, 2H).
Compound No. 2-129: 2-((1 -(2-(5-Chlorothiophen-2-yl)-6,7-dihydro-5H-cyclopenta[dlpyrimidin-4-yl)indolin-6-yl)oxy)-1-(4-methylpiperazin-1-yl)ethanone (synthesis example No. 79) [0265] Yellow solid. Yield: 0.06 g (39% of theory) 1H NMR (400 MHz, DMSO-d6, δ ppm): 7.75 (d, 1H, J = 2.04 Hz), 7.68 (d, 1H, J = 3.92 Hz), 7.20 (d, 1H, J = 3.92 Hz), 7.11 (d, 1 H, J = 8.2 Hz), 6.52 (d, 1H, J = 8.2 Hz and 2.2 Hz), 4.79 (s, 2H), 4.37 (t, 2H, J = 8.36 Hz), 3.42 (bs, 4H), 3.19 (t, 2H, J = 7.36 Hz), 3.07 (t, 2H, J = 8.2 Hz), 2.85 (t, 2H, J = 7.8 Hz), 2.26-2.20 (m, 4H), 2.13 (s, 3H), 2.01 (m, 2H).
Compound No. 2-64: 2-((1-(2-(5-Chlorothiophen-2-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)indolin-6-yl)oxy)-N-cyclopropyl-N-methylacetamide (synthesis example No. 80) [0266] White solid. Yield: 0.06 g (18% of theory) 1H NMR (400 MHz, DMSO-d6, δ ppm): 7.74 (s, 1H), 7.67 (d, 1H, J = 3.76 Hz), 7.18 (d, 1H, J = 3.52 Hz), 7.12 (d, 1H, J = 8.08 Hz), 6.50 (d, 1H, J = 7.88 Hz), 4.91 (s, 2H), 4.36 (t, 2H, J = 8.12 Hz), 3.19 (t, 2H, J = 7.0 Hz), 3.08 (t, 2H, J = 8.08 Hz), 2.86 (t, 2H, J = 7.74 Hz), 2.79 (bs, 4H), 2.01 (p, 2H, J = 7.16 Hz), 0.75-0.65 (m, 4H).
Compound No. 2-65: 2-((1-(2-(5-Chlorothiophen-2-yl)-6,7-dihydro-5H-cvclopenta[dlpyrimidin-4-yl)indolin-6-yl)oxy)-N-(oxetan-3-yl)acetamide (synthesis example No. 81) [0267] Yellowish solid. Yield: 75 mg (33% of theory) 1 H NMR (400 MHz, DMSO-d6, δ ppm): 8.78 (d, 1 H, J = 4.52 Hz), 7.87 (s, 1 H), 7.69 (d, 1H, J = 3.6 Hz), 7.19-7.14 (m, 2H), 6.58 (d, 1H, J = 8.2 Hz), 4.86 (m, 1H), 4.68 (t, 2H, J = 7.12 Hz), 4.52-4.49 (m, 4H), 4.39 (t, 2H, J = 8.08 Hz), 3.20 (t, 2H, J = 7.32 Hz), 3.09 (t, 2H, J = 8.36 Hz), 2.86 (t, 2H, J = 7.76 Hz), 2.01 (m, 2H).
Compound No. 2-66: 2-((1-(2-(5-Chlorothiophen-2-yl)-6,7-dihvdro-5H-cvclopenta[d1pyrimidin-4-yl)indolin-6-yl)oxy)-N-isopropylacetamide (synthesis example No. 82) [0268] White solid. Yield: 0.07 g (21 % of theory) 1H NMR (400 MHz, DMSO-d6, δ ppm): 7.86 (d, 1H, J = 1.84 Hz), 7.77 (d, 1H, J = 8.04 Hz), 7.68 (d, 1H, J = 3.92 Hz), 7.17 (d, 1H, J = 3.88 Hz), 7.14 (d, 1H, J = 8.2 Hz), 6.56 (dd, 1H, J = 8.12 Hz and 2.12 Hz), 4.44 (s, 2H), 4.39 (t, 2H, J = 8.44 Hz), 4.0-3.9 (m, 1H), 3.20 (t, 2H, J = 7.16 Hz), 3.08 (t, 2H, J = 8.44 Hz), 2.86 (t, 2H, J = 7.76 Hz), 2.01 (m, 2H), 1.07 (d, 6H, J = 6.6 Hz).
Compound No. 2-67: 2-((1 -(2-(5-Chlorothiophen-2-yl)-6,7-dihvdro-5H-cvclopentafd1pyrimidin-4-yl)indolin-6-yl)oxy)-N-(cyclopropylmethyl)-N-methylacetamide (synthesis example No. 83) [0269] White solid. Yield: 0.05 g (29% of theory) 1H NMR (400 MHz, DMSO-d6, 100°C, δ ppm): 7.78 (s, 1H), 7.69 (d, 1H, J = 4.0 Hz), 7.15-7.11 (m, 2H), 6.56 (d, 1H, J = 4.0 Hz), 4.76 (s, 2H), 4.37 (t, 2H, J = 8.0 Hz), 3.24-3.09 (m, 7 H), 3.01 (s, 2H), 2.88 (t, 2H, J = 8.0 Hz), 2.06 (m, 2H). 1.0-0.85 (m, 1 H), 0.46-0.39 (m, 2H), 0.3-0.2 (m, 2H).
Compound No. 2-68: 2-((1 -(2-(5-Chlorothiophen-2-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)indolin-6-yl)oxy)-N- ethylacetamide (synthesis example No. 84) [0270] Synthesized in an analogous manner as described for synthesis example No. 41. Light greenish solid. Yield: 0.06 g (43% of theory) 1H NMR (400 MHz, DMSO-d6, δ ppm): 8.01 (t, 1H, J = 4.0 Hz), 7.84 (d, 1H, J = 2.16 Hz), 7.68 (d, 1H, J = 3.92 Hz), 7.17 (d, 1 H, J = 3.96 Hz), 7.14 (d, 1 H, J = 8.12 Hz), 6.57 (dd, 1H, J = 8.16 and 2.32 Hz), 4.46 (s, 2H), 4.38 (t, 2H, J = 8.32 Hz), 3.21-3.06 (m, 6H), 2.85 (t, 2H, J = 7.8 Hz), 2.01 (m, 2H), 1.03 (t, 3H, J = 7.2 Hz).
Compound No. 2-69: 2-((1 -(2-(5-Chlorothiophen-2-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)indolin-6- yl)oxy)-N-(2-hydroxyethyl)acetamide (synthesis example No. 85) [0271] The target compound was prepared in analogy to the procedure of synthesis example No. 55. White solid. Yield: 45 mg (27% of theory) 1H NMR (400 MHz, DMSO-d6, δ ppm): 7.92 (t, 1H, J = 4.1 Hz), 7.86 (d, 1H, J = 1.89 Hz), 7.68 (d, 1H, J = 3.88 Hz), 7.18 (d, 1 H, J = 3.92 Hz), 7.14 (d, 1H, J = 8.08 Hz), 6.58 (dd, 1H, J = 8.0 Hz, and 1.88 Hz), 4.70 (t, 1H, J = 5.48 Hz), 4.49 (s, 2H), 4.38 (t, 2H, J = 8.44 Hz), 3.45-3.40 (m, 2H), 3.23-3.18 (m, 4H), 3.08 (t, 2 H, J = 8.1 Hz), 2.86 (t, 2H, J = 7.76 Hz), 1.99 (m, 2H).
Compound No. 2-70: 2-((1-(2-(5-Chlorothiophen-2-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)indolin-6-yl)oxy)-N- methylacetamide (synthesis example No. 86) [0272] Oxalyl chloride (0.06 mL, 0.7 mmol) and a catalytic amount of DMF (0.03 mL) were added drop wise at 0°C to a solution of the acetic acid 76b) (0.15 g, 0.35 mmol) in dichloromethane (5.0 mL). The resulting mixture was stirred at room temperature for 3 h. The solvent was then evaporated, the residue was re-dissolved in dichloromethane (5.0 mL) and dimethyl amine (2M in THF, 0.52 mL, 1.05 mmol) was added at 0°C. After stirring for 16 h at room temperature, the mixture was concentrated and the remnant purified first by flash column chromatography [dichloromethane/methanol = 50:1] and then by preparative TLC. Yellow solid. Yield: 0.05 g (32% of theory) 1H NMR (400 MHz, DMSO-d6, δ ppm): 7.95 (bs, 1H), 7.83 (d, 1H, J = 1.8 Hz), 7.68 (d, 1H, J = 3.88 Hz), 7.18 (d, 1H, J = 3.96 Hz), 7.14 (d, 1H, J =8.2 Hz), 6.57 (dd, 1H, J = 7.96 Hz and 2.04 Hz), 4.48 (s, 2H), 4.38 (t, 2H, J = 8.28 Hz), 3.20 (t, 2H, J = 7.28 Hz), 3.08 (t, 2H, J = 8.16 Hz), 2.86 (t, 2H, J = 7.8 Hz), 2.65 (d, 3H, J = 4.6 Hz), 2.01 (m, 2H).
Compound No. 2-71: 2-((1-(2-(5-Chlorothiophen-2-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)indolin-6-yl)oxy)acetamide (synthesis example No. 87) [0273] Amide couling with acetic acid 76b) as substrate and EDCI and ammonium 1H-1,2,3-benzotriazol-1-olate (HOBTNH3) as coupling reagents in analogy to the procedure of synthesis example No. 41. White solid. Yield: 0.09 g 1H NMR (400 MHz, DMSO-d6, δ ppm): 7.81 (d, 1H, J = 1.84 Hz), 7.68 (d, 1H, J = 3.92 Hz), 7.44 (s, 1H), 7.38 (s, 1H), 7.19 (d, 1H, J = 3.92 Hz), 7.14 (d, 1H, J = 8.24 Hz), 6.55 (dd, J = 8.12 and 2.0 Hz), 4.44 (s, 2H), 4.38 (t, 2H, J = 8.24 Hz), 3.19 (t, 2H, J = 7.4 Hz), 3.08 (t, 2H, J = 8.28 Hz), 2.85 (t, 2H, J = 7.68 Hz), 2.01 (m, 2H).
Compound No. 1-79: Methyl 2-((1 -(2-(5-chlorothiophen-2-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)indolin-6-yl)oxy)acetate (synthesis example No. 88) [0274] Synthesized from the acetic acid 76b) (0.15 g, 0.35 mmol) in analogy to the procedure of synthesis example No. 54. White solid. Yield: 0.06 g (24% of theory) 1H NMR (400 MHz, DMSO-d6, δ ppm): 7.82 (d, 1H, J = 2.08 Hz), 7.66 (d, 1H, J = 3.92 Hz), 7.19 (d, 1H, J = 3.92 Hz), 7.13 (d, 1H, J = 8.16 Hz), 6.52 (dd, 1H, J = 8.12 and 2.2 Hz), 4.82 (s, 2H), 4.38 (t, 2H, J = 8.44 Hz), 3.66 (s, 3H), 3.20 (t, 2H, J = 7.32 Hz), 3.08 (t, 2H, J = 8.4 Hz), 2.85 (t, 2H, J = 7.84 Hz), 2.01 (m, 2H).
Synthesis example No. 89: 2-((1-(2-(5-Chlorothiophen-2-yl)-6-oxido-5,7-dihydrothieno[3,4-d]pyrimidin-4-yl)-1H-indazol-6-yl)oxy)-N,N-dimethylacetamide (compound No. 2-72) 89a) 2-((1-(2-(5-Chlorothiophen-2-yl)-5,7-dihydrothieno[3,4-d1pyrimidin-4-yl)-1H-indazol-6-yl)oxy)-N,N-dimethylaceta-mide [0275] Prepared from 4-chloro-2-(5-chlorothiophen-2-yl)-5,7-dihydrothieno[3,4-d]pyrimidine (0.25 g, 0.86 mmol) and 2-((1 H-indazol-6-yl)oxy)-N,N-dimethylacetamide (0.2 g, 0.86 mmol; synthesized from 1 H-indazol-6-ol and 2-chloro-N,N-dimethylacetamide) in an analogous manner as described in procedure 21c). Yellow solid. Yield: 0.15 g (37% of theory) 89b) 2-((1-(2-(5-Chlorothiophen-2-yl)-6-oxido-5,7-dihydrothieno[3,4-d]pyrimidin-4-yl)-1H-indazol-6-yl)oxy)-N,N-dimeth-ylacetamide [0276] m-Chloroperoxybenzoic acid (77%, 50 mg, 0.225 mmol) in THF (5 mL) was added under cooling with an ice bath to a solution of 89a) (140 mg, 0.3 mmol) in THF. The resulting mixture was stirred for 20 min at room temperature and then diluted with brine (10 mL). The aqueous phase was extracted with THF (3x10 mL) and the combined organic layers were dried over sodium sulfate and evaporated. The residue was purified by column chromatography [dichloromethane/methanol = 50:1], Yellow solid. Yield: 67 mg (44% of theory) 1H NMR (400 MHz, DMSO-d6, δ ppm): 8.53 (s, 1H), 8.2 (s, 1H), 7.95 (s, 1H), 7.84 (d, 1H, J = 8.4 Hz), 7.32 (d, 1H, J = 3.3 Hz), 7.1 (d, 1H, J = 8.8 Hz), 5.07 (s, 2H), 4.83 (d, 1 H, J = 17.6 Hz), 4.63 (d, 2H, J = 14 Hz), 4.17 (d, 1H, J = 17.2 Hz), 3.06 (s, 3H), 2.86 (s, 3H).
Compound No. 2-73: 2-((1-(2-(5-Chlorothiophen-2-yl)-6-oxido-5,7-dihydrothieno[3,4-d]pyrimidin-4-yl)-1 H-indol-6-yl)oxy)-N,N-dimethylacetamide (synthesis example No. 90) [0277] The target compound was synthesized from 4-chloro-2-(5-chlorothiophen-2-yl)-5,7-dihydrothieno[3,4-d]pyrimi-dine and 2-((1 H-indol-6-yl)oxy)-N,N-dimethylacetamide in an analogous manner as described for synthesis example No. 89. Yellow solid. Yield: 145 mg (44% of theory) 1H NMR (400 MHz, DMSO-d6, δ ppm): 7.92 (d, 1H, J =3.9 Hz), 7.82 (d, 1H, J = 1.7 Hz), 7.69 (d, 1H, J = 3.5 Hz), 7.58 (d, 1 H, J = 8.6 Hz), 7.31 (d, 1 H, J = 3.9 Hz), 6.94 (dd, 1 H, J = 2.1 and 8.6 Hz), 6.81 (d, 1H, d, J = 3.4 Hz), 4.89-4.86 (m, 3H), 4.71 (d, 1H, J = 16 Hz), 4.22-4.16 (m, 2H), 2.96 (s, 3H), 2.81 (s, 3H).
Compound No. 2-74: 2-((1-(2-(5-Chlorothiophen-2-yl)-6-oxido-5,7-dihydrothieno[3,4-d]pyrimidin-4-yl)-1H-benzo[d]im-idazol-6-yl)oxy)-N,N-dimethylacetamide (synthesis example No. 91)
Compound No. 2-75: 2-((1-(2-(5-Chlorothiophen-2-yl)-6-oxido-5,7-dihydrothieno[3,4-d]pyramid-din-4-yl)-1 H-ben-zo[d]imidazol-5-yl)oxy)-N,N-dimethylacetamide (synthesis example No. 92) [0278] Compounds 2-74 and 2-75 were synthesized from 4-chloro-2-(5-chlorothiophen-2-yl)-5,7-dihydrothieno[3,4- d]pyrimidine (1.4 g, 5.0 mmol) and 2-((1 H-benzo[d]imidazol-6-yl)oxy)-N,N-dimethylacetamide (1.27 g, 5.0 mmol) in the two chemical steps as described for synthesis example No. 76). The two obtained regioisomers were separated after the last step by means of SFC (supercritical fluid chromatography) and the structures were assigned based on their activity in the primary assays.
Compound 2-74: (peak 1): White solid. Yield: 127 mg (18% of theory) [0279] 1H NMR (400 MHz, DMSO-d6, δ ppm): 8.68 (s, 1H), 7.95 (d, 1H, J = 4 Hz), 7.73-7.7 (m, 2H), 7.32 (d, 1H, J = 4 Hz), 7.05 (dd, 1 H, J = 2.1 and 8.9 Hz), 4.91-4.83 (m, 3H), 4.78 (d, 1H, J = 17.1 Hz), 4.37 (d, 1 H, J = 16.8 Hz), 4.27 (d, 1H, J = 17.1 Hz), 2.98 (s, 3H), 2.83 (s, 3H).
Compound No. 2-75: (peak 2): White solid. Yield: 95 mg (14% of theory) [0280] 1H NMR (400 MHz, DMSO-d6, δ ppm): 8.77 (s, 1H), 8.15 (d, 1H, J = 8.9 Hz), 7.93 (d, 1H, J = 3.7 Hz), 7.35-7.33 (m, 2H), 7.15 (d, 1 H, J = 8.8 Hz), 4.95-4.9 (m, 3H), 4.77 (d, 1H, J = 17.16 Hz), 4.42 (d, 1H, J = 16.7 Hz), 4.26 (d, 1H, J = 17.2 Hz), 3.04 (s, 3H), 2.87 (s, 3H).
Compound 2-76: 2-((3-(2-(5-Chlorothiophen-2-yl)-6-oxido-5,7-dihydrothieno[3,4-d]pyrimidin-4-yl)-2-oxo-2,3-dihyd-robenzo[d]oxazol-5-yl)oxy)-N,N-dimethylacetamide (synthesis example No. 93) [0281] Synthesized in an analogous manner to synthesis example Nos. 14 and 95. White solid. Yield: 40 mg 1H NMR (400 MHz, DMSO-d6, δ ppm): 7.89 (s, 1H), 7.41 (d, 1H, J = 8.6 Hz), 7.32 (s,2H), 6.87 (d, 1H, J = 7.6 Hz), 4.86 (s, 2H), 4.77 (d, 1H, J = 16.5 Hz), 4.5 (q, 2H, J = 17.3 Hz), 4.22 (d, 1H, J = 17.7 Hz), 2.93 (s, 3H), 2.81 (s, 3H).
Compound No.1-71: 2-(1-(2-(5-Chlorothiophen-2-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)-IH-indol-5-yl)acetic acid (synthesis example No. 94) [0282] Synthesized in two steps from 4-chloro-2-(5-chlorothiophen-2-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidine and methyl 2-(1 H-indol-5-yl)acetate. White solid. Yield: 165 mg 1H NMR (400 MHz, DMSO-d6, δ ppm): 12.4 (bs, 1H), 8.32 (d, 1H, J = 8.52 Hz), 7.85 (d, 1H, J = 3.48 Hz), 7.81 (d, 1H, J = 3.92 Hz), 7.55 (s, 1H), 7.25-7.23 (m, 2H), 6.8 (d, 1H, J = 3.4 Hz), 3.65 (s, 2H), 3.19 (t, 2H, J = 7.2 Hz), 3.03 (t, 2H, J = 7.64 Hz), 2.14 (m,2H).
Compound No.1-68: 3-(2-(5-Chlorothiophen-2-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)-2-oxo-2,3-dihydroben-zo[d]oxazole-6-carboxylic acid (synthesis example No. 95) [0283] Synthesized from 4-chloro-2-(5-chlorothiophen-2-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidine and methyl 4-amino-3-methoxybenzoate analogously to synthesis example No. 14 in three steps comprising a Buchwald-Hartwig reaction, a déméthylation with BBr3 in dichloromethane and a cyclisation with CDI. White solid. Yield: 45 mg 1H NMR (400 MHz, DMSO-d6, δ ppm): 7.94-7.90 (m, 2H), 7.8 (d, 1H, J = 3.96 Hz), 7.64 (d, 1H, J = 8.28 Hz), 7.25 (d, 1H, J = 3.92 Hz), 3.11-3.05 (m, 4H), 2.1 (m, 2H).
Compound No. 1-74: 1-(2-(5-Chlorothiophen-2-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)-1H-benzo[d]imidazole- 6-carboxylic acid (synthesis example No. 96)
Compound No. 1-63: 1-(2-(5-Chlorothiophen-2-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)-1H-benzo[d]imidazole- 5-carboxylic acid (synthesis example No. 97) [0284] Prepared from 4-chloro-2-(5-chlorothiophen-2-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidine and methyl 1 H-ben-zo[d]imidazole-5-carboxylate in two steps, namely a Buchwald-Hartwig reaction and an ester saponification with lithium hydroxide in THF/water. The two regioisomers obtained were separated after the last step by means of HPLC. The structures were assigned based on the compounds activity in the primary assays.
Example 96 (peak 1): White solid. Yield: 28 mg [0285] 1H NMR (400 MHz, DMSO-d6, δ ppm): 13.0 (bs, 1H), 9.08 (s, 1H), 8.96 (s, 1H), 8.01-7.99 (m, 1H), 7.89-7.86 (m, 2H), 7.29 (d, 1H, J = 3.36 Hz), 3.3-3.28 (m, 2H, obscured by water peak), 3.1 (t, 2H, J = 7.84 Hz), 2.18 (m, 2H).
Example 97 (peak 2): White solid. Yield: 0.05 g [0286] 1H NMR (400 MHz, DMSO-d6, δ ppm): 13.0 (bs, 1H), 8.92 (s, 1 H), 8.38-8.35 (m, 2H), 8.07 (d, 1 H, J = 8.12 Hz), 7.88 (d, 1H, J = 3.84 Hz), 7.28 (d, 1 H, J = 3.8 Hz), 3.27-3.26 (m, 2H, obscured by water peak), 3.1 (t, 2H, J = 7.24 Hz), 2.1 (m, 2H).
[0287] The following compounds were obtained applying analogues synthesis routes as described for synthesis example Nos. 21-23:
Compound No. 1-5:2-(1-(2-(3-Chloro-4-methoxyphenyl)-5,7-dihydrothieno[3,4-d]pyrimidin-4-yl)indolin-5-yl)aceticacid (synthesis example No. 98) [0288] Yield: 0.09 g. Light yellow solid. 1H NMR (400 MHz, DMSO-d6, δ ppm): 12.32 (bs, 1 H), 8.29 (d, 1H, J = 1.28 Hz), 8.23 (d, 1H, J = 8.68 Hz), 7.97 (d, 1H, J = 8.24 Hz), 7.28 (d, 1H, J = 8.72 Hz), 7.17 (s, 1H), 7.08 (d, 1H, J = 8.16 Hz), 4.49 (s, 2H), 4.37 (t, 2H, J = 8.24 Hz), 4.2 (s, 2H), 3.92 (s, 3H), 3.53 (s, 2H), 3.15 (2H, J = 8.16 Hz).
Compound No. 1-8: 2-(1-(2-(3-Chloro-4-methoxyphenyl)-6-oxido-5,7-dihydrothieno[3,4-d]pyrimidin-4-yl)indolin-5-yl)acetic acid (synthesis example No. 99) [0289] Yellow solid. Yield: 60 mg (19% of theory) 1 H NMR (400 MHz, DMSO-d6, δ ppm): 12.3 (bs, 1H), 8.34 (d, 1H, J = 1.64 Hz), 8.28 (d, 1H, J = 1.72 Hz), 7.98 (d, 1H, J = 8.24 Hz), 7.32 (d, 1H, J = 8.72 Hz), 7.2 (s, 1H), 7.12 (d, 1H, J = 8.32 Hz), 4.74 (d, 1H, J = 16.32 Hz), 4.52-4.43 (m, 2H), 4.38-4.27 (m, 2H), 4.02 (d, 1H, J = 16.84 Hz), 3.94 (s, 3H), 3.55 (s, 2H), 3.24-3.11 (m, 2H).
Compound No. 1-23: 2-(1-(2-(5-Fluorothiophen-2-yl)-5,7-dihydrothieno[3,4-d]pyrimidin-4-yl)indolin-5-yl)acetic acid (synthesis example No. 100) [0290] Yellow solid. Yield: 1.7 g 1H NMR (400 MHz, DMSO-d6, δ ppm): 8.01 (d, 1H, J = 8.32 Hz), 7.56 (t, 1H, J = 3.52 Hz), 7.16-7.11 (m, 2H), 6.83 (d, 1H, J = 3.08 Hz), 4.51 (s, 2H), 4.39 (t, 2H, J = 8.16 Hz), 4.16 (s, 2H), 3.53 (s, 2H), 3.15 (t, 2H, J = 7.88 Hz).
Compound No. 1-24:2-(1-(2-(5-Fluorothiophen-2-yl)-6-oxido-5,7-dihydrothieno[3,4-d]pyrimidin-4-yl)indolin-5-yl)acetic acid (synthesis example No. 101) [0291] Yellow solid. Yield: 52 mg 1H NMR (400 MHz, DMSO-d6, δ ppm): 12.29 (s, 1H), 8.01 (d, 1H, J = 8.24 Hz), 7.61 (t, 1H, J = 3.8 Hz), 7.18-7.14 (m, 2H), 6.85 (d, 1H, J = 2.84 Hz), 4.72 (d, 1H, J = 16.28 Hz), 4.48-4.27 (m, 4H), 3.96 (d, 1H, J = 16.88 Hz), 3.54 (s, 2H), 3.25-3.1 (m,2H).
Compound No. 1-80:2-(1 -(2-(Benzo[b]thiophen-2-yl)-6-oxido-5,7-dihydrothieno[3,4-d]pyrimidin-4-yl)indolin-5-yl)acetic acid (synthesis example No. 102) [0292] Light yellow solid. Yield: 77 mg (15% of theory) 1H NMR (400 MHz, DMSO-d6, δ ppm): 8.26 (s, 1H), 8.2 (d, 1H, J = 8.48 Hz), 8.0 (d, 1H, J = 6.25 Hz), 8.05-7.98 (m, 2H), 7.44-7.42 (m, 2H), 7.22-7.2 (m, 2H), 4.76 (d, 1H, J = 16.44 Hz), 4.54-4.44 (m, 3H), 4.34-4.3 (m, 1H), 4.02 (d, 1H, J = 16.76 Hz), 3.56 (s, 2H), 3.15-3.16 (m, 2H).
Compound No. 1-81: 2-(1-(2-(Benzofuran-5-yl)-6-oxido-5,7-dihydrothieno[3,4-d]pyrimidin-4-yl)indolin-5-yl)acetic acid (synthesis example No. 103) [0293] White solid. Yield: 51 mg (19% of theory) 1H NMR (400 MHz, DMSO-d6, δ ppm): 12.26 (s, 1H), 8.68 (s, 1H), 8.36 (d, 1H, J = 8.68 Hz), 8.07-8.05 (m, 2H), 7.73 (d, 1H, J =8.64 Hz), 7.2-7.16 (m, 2H), 7.11 (d, 1 H, J = 1.28 Hz), 4.75 (d, 1 H, J = 16.28 Hz), 4.54-4.46 (m, 2H), 4.39-4.29 (m, 2H), 4.03 (d, 1H, J = 16.68 Hz), 3.56 (s, 2H), 3.26-3.13 (m, 2H).
Compound No. 1-18:2-(1-(2-(4-Chlorothiophen-2-yl)-6,7-dihydro-5H-cyclopentafd1pyrimidin-4-yl)indolin-5-yl)aceticac-id (synthesis example No. 104) [0294] The synthesis route described for synthesis example No. 5 was applied in the preparation of the target compound. Yellow solid. Yield: 0.09 g 1H NMR (400 MHz, DMSO-d6, δ ppm): 12.23 (bs, 1H), 8.14 (d, 1H, J = 8.24 Hz), 7.7-7.67 (m, 2H), 7.14-7.1 (m, 2H), 4.38 (t, 2H, J = 8.36 Hz), 3.52 (s, 2H), 3.21 (t, 2H, J = 7.12 Hz), 3.15 (t, 2H, J = 8.24 Hz), 2.85 (t, 2H, J = 7.64 Hz), 2.05-2.0 (m,2H).
Compound No. 1-19:2-(1-(2-(5-Chlorothiophen-3-yl)-6,7-dihydro-5H-cyclopenta[d1pyrimidin-4-yl)indolin-5-yl)aceticac-id (synthesis example No. 105) [0295] Synthesized in analogy to synthesis example No. 5. White solid. Yield: 0.12 g 1H NMR (400 MHz, DMSO-d6, δ ppm): 12.24 (bs, 1H), 8.12-8.08 (m, 2H), 7.62 (s, 1H), 7.14-7.1 (m, 2H), 4.36 (t, 2H, J = 7.52 Hz), 3.51 (s, 2H), 3.21-3.12 (m, 4H), 2.85 (t, 2H, J = 7.6 Hz), 2.03-1.99 (m, 2H).
Compound No. 1-16:2-(1-(2-(5-Cyanothiophen-2-yl)-6,7-dihydro-5H-cyclopenta[d1pyrimidin-4-yl)indolin-5-yl)aceticac-id (synthesis example No. 106) [0296] Prepared in three steps from 2,4-dichloro-6,7-dihydro-5H-cyclopenta[d]pyrimidine and methyl 2-(indolin-5-yl)ac-etate in analogy to example No. 20. Yellow solid. Yield: 0.12 g 1H NMR (400 MHz, DMSO-d6, δ ppm): 12.26 (bs, 1 H), 8.11 (d, 1H, J = 8.64 Hz), 7.99 (d, 1H, J = 3.76 Hz), 7.86 (d, 1H, J = 3.8 Hz), 7.16-7.14 (m, 2H), 4.0 (t, 2H, J = 8.4 Hz), 3.52 (s, 2H), 3.25 (t, 2H, J = 7.36 Hz), 3.16 (t, 2H, J = 8.28 Hz), 2.88 (t, 2H, J = 7.56 Hz), 2.05-2.01 (m, 2H)
Compound No. 1-75: 2-(1-(2-(5-Carbamoylthiophen-2-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)indolin-5-yl)ace-tic acid (synthesis example No. 107) [0297] Sodium hydroxide (0.086 g, 2.16 mmol) in water (5 mL) was added to a cooled solution of synthesis example No. 105 (0.18 g, 0.43 mmol) in THF (5 mL) and the mixture was stirred at room temperature for 4 h. The solvent was evaporated and the residue was diluted with water (15 mL) and washed with ethyl acetate (2x15 mL). The aqueous phase was then acidified with sodium hydrogen sulphate, and brine (30 mL) and THF (20 mL) were added. The organic layer was separated, dried over sodium sulfate and concentrated. The remnant was finally washed with methanol/dichlo-romethane = 1:100 (3 x 20 mL). Yellow solid. Yield: 95 mg (52% of theory) 1H NMR (400 MHz, DMSO-d6, δ ppm): 12.28 (bs, 1H), 8.18 (d, 1H, J = 8.12 Hz), 8.1 (bs, 1H), 7.8-7.74 (m, 2H), 7.5 (bs, 1H), 7.14-7.11 (m,2H), 4.37 (t,2H,J = 8.32 Hz), 3.53 (s,2H), 3.23-3.13 (m,4H), 2.86 (t,2H,J= 7.76 Hz), 2.03-1.99(m,2H).
Synthesis example No. 108:2-(1-(2-(Thiazol-5-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)indolin-5-yl)acetic acid (compound No. 1-17) 108a) Methyl 2-(1-(2-(thiazol-5-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)indolin-5-yl)acetate [0298] Bis(triphenylphosphine)palladium(ll) dichloride (18.38 mg, 0.026 mmol) was added to a solution of methyl 2-(1-(2-chloro-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)indolin-5-yl)acetate (0.18 g, 0.52 mmol) and 5-tributylstanna-nyl-thiazole (0.235 g, 0.629 mmol) in DMF (2 mL) and the resulting mixture was stirred at 120°C for 16 h. The mixture was diluted with saturated potassium fluoride solution (10 mL), stirred for 10 min and then extracted with ethyl acetate (3 x 20 mL). The combined organic layers were dried over sodium sulfate and evaporated. The residue was purified by flash column chromatography [silica containing 10% potassium fluoride; ethyl acetate/ hexane = 3:10], White solid. Yield: 0.08 g (39% of theory) 108b) 2-(1-(2-(Thiazol-5-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)indolin-5-yl)acetic acid [0299] Ester hydrolysis of 107a) via stirring with sodium hydroxide in methanol at 75°C. Light yellow solid. Yield: 0.05 g 1H NMR (400 MHz, DMSO-d6, δ ppm): 12.24 (bs, 1H), 9.16 (s, 1H), 8.51 (s, 1H), 8.15 (d, 1H, J = 8.24 Hz), 7.15-7.11 (m, 2H), 4.38 (t, 2H, J = 8.36 Hz), 3.52 (s, 2H), 3.24 (t, 2H, J = 7.2 Hz), 3.15 (t, 2H, J = 8.4 Hz), 2.87 (t, 2H, J = 7.88 Hz), 2.05-1.9 (m,2H).
Synthesis example No. 109: 2-((1-(2-(4-Cyano-3-fluorophenyl)-6-oxido-5,7-dihydrothieno[3,4-d]pyrimidin-4-yl)indolin-6-yl)oxy)-N,N-dimethylacetamide (compound No. 2-77) 109a) Ethyl 2-((1-(2-chloro-5,7-dihydrothieno[3,4-d]pyrimidin-4-yl)indolin-6-yl)oxy)acetate [0300] Caesium carbonate (5.19 g, 15.95 mmol), BINAP (0.54 g, 0.87 mmol) and palladium(ll) acetate (0.16 g, 0.72 mmol) were added under an argon atmosphere and at room temperature to a solution of 2,4-dichloro-5,7-dihydro-thieno[3,4-d]pyrimidine (3 g, 14.5 mmol) and ethyl 2-(indolin-6-yloxy)acetate (2.5 g, 11.6 mmol) in dry dioxane (80 mL). The reaction mixture was heated at 95°C for 16 h, then cooled to ambient temperature and filtered. The filtrate was concentrated and the residue purified first by flash column chromatography [dichloromethane with 0-10% ethyl acetate] and finally by trituration in acetone/THF = 1:2. White solid. Yield: 2.3 g (40% of theory) 109b) 2-((1-(2-Chloro-5,7-dihydrothieno[3,4-d]pyrimidin-4-yl)indolin-6-yl)oxy)acetic acid [0301] 1N sodium hydroxide solution (50.6 mL, 50.63 mmol) was added to the ethyl ester 109a) (6.6 g, 16.87 mmol) in 1,4-dioxane/ethanol (1:1 ; 120 mL) and the mixture was stirred at room temperature for 2 h. The solvents were distilled ofF and the remnant was diluted with water and acidified with saturated sodium hydrogen sulfate solution at 0°C. After stirring for 15 min, the precipitate was removed by filtration, repeatedly co-distilled with toluene and dried. Light yellow solid. Yield: 5.8 g (94% of theory) 109c) 2-((1 -(2-Chloro-6-oxido-5,7-dihydrothieno[3,4-d]pyrimidin-4-yl)indolin-6-yl)oxy)acetic acid [0302] m-Chloroperoxybenzoic acid (77%, 2.94 g, 13.1 mmol) in THF (20 mL) was added at 0°C to a solution of 109b) (5.6 g, 15.4 mmol) in dry THF (1000 mL). The reaction mixture was stirred at room temperature for 3 h, then poured onto brine and stirred for further 15 min. The organic layer was separated, dried over sodium sulfate and concentrated. The residue was triturated with acetone/ hexane and finally co-distilled with toluene. White solid. Yield: 4.5 g (77% of theory) 109d) 2-((1-(2-Chloro-6-oxido-5,7-dihydrothieno[3,4-d1pyrimidin-4-yl)indolin-6-yl)oxy)-N,N-dimethylacetamide [0303] HATU (6.0 g, 15.82 mmol), diisopropylethylamine (9.4 mL, 52.76 mmol) and dimethylamine (2M in THF, 13.2 mL, 26.38 mmol) were added to a solution of acetic acid 109c) (5.0 g, 13.2 mmol) in THF/DMF = 100:1 (252.5 mL). The resulting mixture was stirred at room temperature for 2 h, then diluted with dichloromethane (100 mL) and washed with saturated ammonium chloride solution, saturated sodium hydrogen carbonate solution, and brine. The organic layer was dried over sodium sulfate, the solvent was removed under vacuum and the residue was purified by flash column chromatography [methanol/dichloromethane = 1:30], White solid. Yield: 3.2 g (60% of theory) 109e) 2-((1 -(2-(4-Cyano-3-fluorophenyl)-6-oxido-5,7-dihydrothieno[3,4-d]pyrimidin-4-yl)indolin-6-yl)oxy)-N,N-dimethyl-acetamide [0304] The pyrimidine chloride 109d) (100 mg, 0.25 mmol) and 4-cyano-3-fluoro phenyl boronic acid (50 mg, 0.32 mmol) were submitted to a Suzuki reaction in analogy to the procedure for synthesis example No. 70. Light brown solid. Yield: 81 mg (65% of theory) 1H NMR (400 MHz, DMSO-d6, δ ppm): 8.35 (d, 1H, J = 8.2 Hz), 8.27 (d, 1H, J = 10.6 Hz), 8.1 (t, 1H, J = 7.4 Hz), 7.59 (s, 1H), 7.18 (d, 1 H, J = 8.1 Hz), 6.6 (dd, 1H, J = 1.8 and 7.84 Hz), 4.77-4.73 (m, 3H), 4.58-4.49 (m, 2H), 4.4-4.31 (m, 2 H), 4.06 (d, 1 H, J = 16.92 Hz), 3.16-3.07 (m, 2H), 2.94 (s, 3H), 2.79 (s, 3H).
[0305] The following compounds were obtained in an analogous manner
Compound No. 1-38: 2-((1-(2-(2-Fluoropyridin-4-yl)-6-oxido-5,7-dihydrothieno[3,4-d]pyrimidin-4-yl)indolin-6-yl)oxy)-N,N-dimethylacetamide (synthesis example No. 110) [0306] Yellow solid. Yield: 40 mg 1H NMR (400 MHz, DMSO-d6, δ ppm): 8.43 (d, 1H, J = 5.1 Hz), 8.18 (d, 1H, J = 4.9 Hz), 7.87 (s, 1H), 7.63 (d, 1 H, J = 2.1 Hz), 7.19 (d, 1 H, J = 8.3 Hz), 6.6 (dd, 1H, J = 2.2 and 8.1 Hz), 4.78-4.74 (m, 3H), 4.59-4.48 (m, 2H), 4.42-4.3 (m, 2H), 4.06 (d, 1H, J = 17 Hz), 3.2-3.08 (m, 2H), 2.94 (s, 3H), 2.79 (s, 3H).
Compound No. 2-139: 2-((1-(2-(6-Methoxypyridin-3-yl)-6-oxido-5,7-dihydrothieno[3,4-d]pyrimidin-4-yl)indolin-6-yl)oxy)-N,N-dimethylacetamide (synthesis example No. 111) [0307] Yellowish solid. Yield: 45 mg 1H NMR (400 MHz, DMSO-d6, δ ppm): 9.11 (d, 1H, J =2 Hz), 8.56 (dd, 1H, J = 2.3 and 8.7 Hz), 7.63 (d, 1H, J = 2 Hz), 7.17 (d, 1H, J = 8.1 Hz), 6.96 (d, 1 H, J = 8.7 Hz), 6.57 (dd, 1 H, J = 2.2 and 8.1 Hz), 4.78 (s, 2H), 4.72 (d, 1 H, J = 16.3 Hz), 4.53-4.43 (m, 2H), 4.37-4.26(m,2H), 4.02 (d, 1 H, J = 16 Hz), 3.94 (s,3H), 3.18-3.07 (m,2H),2.96(s,3H), 2.81 (s,3H).
Compound No. 2-78: 2-((1-(2-(4-Chloro-3-fluorophenyl)-6-oxido-5,7-dihydrothieno[3,4-d]pyrimidin-4-yl)indolin-6-yl)oxy)-N,N-dimethylacetamide (synthesis example No. 112) [0308] Light orange solid. Yield: 58 mg 1H NMR (400 MHz, DMSO-d6, δ ppm): 8.23-8.2 (m, 2H), 7.76 (t, 1H, J = 8.2 Hz), 7.6 (s, 1 H), 7.18 (d, 1H, J = 8.2 Hz), 6.6-6.58 (m, 1H), 4.77-4.71 (m, 3H), 4.56-4.44 (m, 2H), 4.38-4.18 (m, 2H), 4.04 (d, 1H, J = 16.8 Hz), 3.18-3.05 (m, 2H), 2.93 (s, 3H), 2.79 (s, 3H).
Compound No. 2-140: N,N-Dimethyl-2-((1-(2-(2-methylthiazol-5-yl)-6-oxido-5,7-dihydrothieno[3,4-d]pyrimidin-4-yl)in-dolin-6-yl)oxy)acetamide (synthesis example No. 113) [0309] Light yellow solid. Yield: 66 mg 1H NMR (400 MHz, DMSO-d6, δ ppm): 8.31 (s, 1H), 7.68 (s, 1H), 7.16 (d, 1H, J = 8.1 Hz), 6.59-6.57 (m, 1H), 4.82 (s, 2H), 4.71 (d, 1H, J = 16.3 Hz), 4.52-4.46 (m, 2H), 4.37 (d, 1H, J = 16.4 Hz), 4.32-4.26 (m, 1H), 3.99 (d, 1H, J = 16.8 Hz), 3.15-3.11 (m, 2H), 2.98 (s, 3H), 2.82 (s, 3H), 2.71 (s, 3H).
Compound No. 2-79: 2-((1-(2-(3-Fluoro-4-hydroxyphenyl)-6-oxido-5,7-dihydrothieno[3,4-d]pyrimidin-4-yl)indolin-6-yl)oxy)-N,N-dimethylacetamide (synthesis example No. 114) [0310] Yellow solid. Yield: 70 mg 1H NMR (400 MHz, DMSO-d6, δ ppm): 10.44 (s, 1H), 8.05-8.02 (m, 2H), 7.62 (d, 1H, J =2.1 Hz), 7.16 (d, 1H, J = 8.2 Hz), 7.07 (t, 1H, J = 9.1 Hz), 6.57 (dd, 1H, J = 2.2 and 8.2 Hz), 4.71-4.67 (m, 3H), 4.51-4.45 (m, 2H), 4.35-4.28 (m, 2H), 3.99 (d, 1H, J = 16.9 Hz), 3.12-3.06 (m, 2H), 2.94 (s, 3H), 2.8 (s, 3H).
Compound No. 2-80: 5-(4-(6-(2-(Dimethylamino)-2-oxoethoxy)indolin-1-yl)-6-oxido-5,7-dihydrothieno[3,4-d]pyrimidin-2-yl)thiophene-2-carboxamide (synthesis example No. 115) [0311] Light yellow solid. Yield: 45 mg 1H NMR (400 MHz, DMSO-d6, δ ppm): 8.09 (bs, 1H), 7.86 (d, 1H, J = 3.28 Hz), 7.77 (d, 1H, J = 3.44 Hz), 7.70 (s, 1H), 7.54 (bs, 1H), 7.16 (d, 1H, J = 7.92 Hz), 6.59 (d, 1H, J = 7.84 Hz), 4.81 (s, 2H), 4.74-4.7 (m, 1H), 4.52-4.47 (m, 2H), 4.4-4.29 (m, 2H), 3.99 (d, 1H, 16 Hz), 3.15-3.07 (m, 2H), 2.96 (s, 3H), 2.81 (s, 3H).
Compound No. 2-81:5-(4-(6-(2-(Dimethylamino)-2-oxoethoxy)indolin-1-yl)-6,6-dioxido-5,7-dihydrothieno[3,4-d]pyrimi-din-2-yl)thiophene-2-carboxamide (synthesis example No. 116) [0312] White solid. Yield: 0.04 g 1H NMR (400 MHz, DMSO-d6, δ ppm): 8.1 (bs, 1H), 7.84 (d, 1H, J = 3.8 Hz), 7.77 (d, 1H, J = 3.8 Hz), 7.69 (d, 1H, J = 1.68 Hz), 7.55 (bs, 1H), 7.17 (d, 1H, J = 8.08 Hz), 6.62 (dd, 1H, J = 8.24 and 1.88 Hz), 4.87 (s, 2H), 4.81 (s, 2H), 4.6 (s, 2H), 4.34 (t, 2H, J = 8.12 Hz), 3.08 (t, 2H, J = 8.04 Hz), 2.98 (s, 3H), 2.81 (s, 3H).
Compound No. 2-82: 2-((1-(2-(5-Cyanothiophen-2-yl)-6-oxido-5,7-dihydrothieno[3,4-d]pyrimidin-4-yl)indolin-6-yl)oxy)-N,N-dimethylacetamide (synthesis example No. 117) [0313] Yellow solid. Yield: 95 mg 1H NMR (400 MHz, DMSO-d6, δ ppm): 8.04 (d, 1H, J = 3.92 Hz), 7.94 (d, 1H, J = 3.92 Hz), 7.66 (d, 1H, J = 1.92 Hz), 7.16 (d, 1H, J = 8.44 Hz), 6.6 (dd, 1H, J = 8.12 and 2.12 Hz), 4.81 (s, 2H, 4.74 (d, 1H, J = 16.48 Hz), 4.54-4.5 (m, 2H), 4.48-4.28 (m, 2H), 4.02 (d, 1H, J = 16 Hz), 3.16-3.04 (2H, m), 2.98 (s, 3H), 2.82 (s, 3H).
Compound No. 2-83: 2-((1-(2-(5-Cyanothiophen-2-yl)-6,6-dioxido-5,7-dihydrothieno[3,4-d]pyrimidin-4-yl)indolin-6-yl)oxy)-N,N-dimethylacetamide (synthesis example No. 118) [0314] Yellow solid. Yield: 0.17 g 1H NMR (400 MHz, DMSO-d6, δ ppm): 8.03 (d, 1H, J = 3.88 Hz), 7.91 (d, 1H, J = 3.88 Hz), 7.65 (s, 1H), 7.17 (d, 1H, J = 8.16 Hz), 6.64-6.62 (m, 1H), 4.9 (s, 2H), 4.81 (s, 2H), 4.63 (s, 2H), 4.36 (t, 2H, J = 8 Hz), 3.08 (t, 2H, J = 8 Hz), 2.97 (s, 3H), 2.82 (s, 3H).
Compound No. 2-84: 2-((1-(2-(5-Cvanothiophen-2-yl)-6,7-dihvdro-5H-cyclopenta[d1pyrimidin-4-yl)indolin-6-yl)oxy)-N,N-dimethylacetamide (synthesis example No. 119) [0315] Light yellow solid. Yield: 43 mg 1H NMR (400 MHz, DMSO-d6, δ ppm): 8.0 (d, 1H, J = 3.88 Hz), 7.87 (d, 1H, J = 3.92 Hz), 7.76 (d, 1H, J = 2.04 Hz), 7.13 (d, 1H, J = 8.1 Hz), 6.55 (dd, 1H, J = 8.12 and 2.16 Hz), 4.8 (s, 2H), 4.39 (t, 2H, J = 8.2 Hz), 3.24 (t, 2H, J = 7.24 Hz), 3.08 (t, 2H, J = 8.2 Hz), 2.99 (s, 3H), 2.89 (t, 2H, J = 7.8 Hz), 2.82 (s, 3H), 2.03 (m, 2H).
Compound No. 2-55: 5-(4-(6-(2-(Dimethylamino)-2-oxoethoxy)indolin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-2-yl)thiophene-2-carboxamide (synthesis example No. 120) [0316] Light yellow solid. Yield: 45 mg 1H NMR (400 MHz, DMSO-d6, δ ppm): 8.05 (bs, 1H), 7.83-7.74 (m, 3H), 7.49 (bs, 1H), 7.12 (d, I H, J = 8.12 Hz), 6.53 (d, 1H, J = 8.04 Hz), 4.8 (s, 2H), 4.38 (t, 2H, J = 8.4 Hz), 3.2 (t, 2H, J = 7.28 Hz), 3.08 (t, 2H, J = 8.16 Hz), 2.97 (s, 3H), 2.87 (t, 2H, J = 7.68 Hz), 2.81 (s, 3H), 2.02 (m, 2H).
Compound No. 2-46: 2-((1-(2-(5-Fluorothiophen-2-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)indolin-6-yl)oxy)-N,N-dimethylacetamide (synthesis example No. 121) [0317] White solid. Yield: 0.08 g 1H NMR (400 MHz, DMSO-d6, δ ppm): 7.76 (d, 1H, J = 2.0 Hz), 7.54 (t, 1H, J = 4.08 Hz), 7.11 (d, 1H, J = 8.16 Hz), 6.82 (d, 1H, J = 2.84 Hz), 6.51 (dd, 1H, J = 8.08 Hz and 2.0 Hz), 4.79 (s, 2H), 4.36 (t, 2H, J = 8.28 Hz), 3.18 (t, 2H, J = 7.16 Hz), 3.07 (t, 2H, J = 8.51 Hz), 2.97 (s, 3H), 2.85-2.81 (m, 5H), 2.0 (m, 2H).
Compound No.-34: 2-((1-(2-(3-Fluoro-4-methoxvphenvl)-6,7-dihvdro-5H-cvclopentafd1pyrimidin-4-vl)indolin-6-yl)oxy)-N,N-dimethylacetamide (synthesis example No. 122) [0318] White solid. Yield: 0.12 g 1H NMR (400 MHz, DMSO-d6, δ ppm): 8.15 (d, 1H, J = 8.12 Hz), 8.05 (d, 1H, J = 12.88 Hz), 7.75 (s, 1H), 7.28 (t, 1H, J = 8.72 Hz), 7.12 (d, 1H, J = 8.08 Hz), 6.53-6.50 (m, 1H), 4.75 (s, 2H), 4.37 (t, 2H, J = 8.36 Hz), 3.91 (s, 3H), 3.18 (t, 2H, J = 7.12 Hz), 3.08 (t, 2H, J = 7.96 Hz), 2.94 (s, 3H), 2.89 (t, 2H, J = 7.92 Hz), 2.66 (s, 3H), 2.03 (m, 2H).
Compound No. 2-86: 2-((1-(2-(4-Bromo-3-fluorophenyl)-6-oxido-5,7-dihydrothieno[3,4-d]pyrimidin-4-yl)indolin-6-yl)oxy)-N,N-dimethylacetamide (synthesis example No. 123) [0319] The target compound was obtained applying the same synthesis strategy as for the preparation of examples 21 / 22. Yellow solid. Yield: 93 mg 1H NMR (400 MHz, DMSO-d6, δ ppm): 8.18-8.14 (m, 2H), 7.9-7.87 (m, 1H), 7.6 (s, 1H), 7.18 (d, 1H, J = 7.64 Hz), 6.6-6.58 (m,1H), 4.77-4.7 (m, 3H), 4.56-4.48 (m, 2H), 4.38-4.34 (m, 2H), 4.04 (d, 1H, J = 17.2 Hz), 3.15-3.1 (m, 2H), 2.93 (s, 3H), 2.66 (s, 3H).
Compound No. 2-34: 2-((1-(2-(5-Fluorothiophen-2-yl)-6-oxido-5,7-dihydrothieno[3,4-d]pyrimidin-4-yl)indolin-6-yl)oxy)-N,N-dimethylacetamide (synthesis example No. 124) [0320] Prepared according to the synthesis strategy applied for the examples 21 / 22. Light yellow solid. Yield: 0.08 g 1H NMR (400 MHz, DMSO-d6, Ő ppm): 7.65-7.62 (m, 2H), 7.14 (d, 1H, J =8.16 Hz), 6.87 (t, 1H, J = 1.52 Hz), 6.56 (dd, 1H, J = 8.2 and 2.1 Hz), 4.81 (s, 2H), 4.68-4.37 (m, 5H), 3.99 (d, 1H, J = 16.56 Hz), 3.31-3.05 (m, 2H), 2.97 (s, 3H), 2.81 (s, 3H).
Compound No. 2-36: 2-((1-(2-(3-Fluoro-4-methoxyphenyl)-6-oxido-5,7-dihydrothieno[3,4-d]pyrimidin-4-yl)indolin-6-yl)oxy)-N,N-dimethylacetamide (synthesis example No. 125) [0321] The same synthesis strategy as for the preparation of compounds according to synthesis examples Nos. 21 / 22 was used. White solid. Yield: 75mg 1H NMR (400 MHz, DMSO-d6, δ ppm): 8.19 (d, 1H, J = 8.88 Hz), 8.07 (dd, 1H, J = 12.8 and 1.8 Hz), 7.61 (d, 1H, J = 2.12 Hz), 7.32 (t, 1 H, J = 8.72 Hz), 7.17 (d, 1H, J = 8.24 Hz), 6.57 (dd, 1H, J = 8.2 and 2.25 Hz), 4.77 (s, 2H), 4.7 (d, 1H, J = 16.36 Hz), 4.53-4.44 (m, 2H), 4.35-4.26 (m, 2H), 4.01 (d, 1H, J = 16.92 Hz), 3.93 (s, 3H), 3.17-3.07 (m, 2H), 2.94 (s, 3H), 2.8 (s, 3H).
[0322] The examples in table 4 were synthesized according to the following general procedure: Tetrakis(triphenyl-phosphine)-palladium(O) (3 μίτιοΙ, 0.03 eq) was added under an argon atmosphere to a mixture of 2-((1-(2-chloro-6-oxido-5,7-dihydrothieno[3,4-d]pyrimidin-4-yl)indolin-6-yl)oxy)-N,N-dimethylacetamide(100μmol, 1.0eq.),aboronicacid (150 μίτιοΙ, 1.5 eq) and 2N sodium hydroxide solution (610 μπιοΙ, 6.1 eq) in DME (3.0 mL). The mixture was heated to 120°C for 1 h in a sealed tube under microwave irradiation. The reaction mixture was then cooled to room temperature, diluted with water (2.5 mL) and extracted with dichloromethane (2 mLx 3). The combined organic layers were concentrated under reduced pressure and finally purified by preparative HPLC.
Table 4:
(continued)
Synthesis example 167: 2-((1-(2-(5-Chlorothiophen-2-yl)-6,7-dihydro-5H-cyclopenta[d]-pyrimidin-4-yl)indolin-6-yl)oxy)-N-cyclopropylacetamide (compound No. 2-114)
[0323] Cyclopropanamine (0.14 mL, 2.04 mmol) was added to a stirred solution of methyl 2-((1-(2-(5-chlorothiophen-2-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)indolin-6-yl)oxy)acetate (300 mg, 0.68 mmol) in DMF/methanol (1:1; 10 mL) and the mixture was stirred at room temperature for 16h. A precipitating solid was filtered off, washed with ethyl acetate, and dried under vacuum. White solid. Yield: 200 mg (45% of theory). Melting range: 190-194°C LC-MS (method 3): Rt = 7.94 min, m/z: [M+H]+ = 466.8
Compound No. 2-142: 2-((1-(2-(5-Chlorothiophen-2-vl)-6,7-dihvdro-5H-cvclopenta[d1pvrimidin-4-yl)indolin-6-vl)oxv)-1-(pyrrolidin-1-yl)ethanone (synthesis example No. 168)
[0324] Compound No. 2-142 was prepared analogously to synthesis example No. 167. White solid. Yield: 70 mg. Melting range: 209-212°C LC-MS (method 3): Rt = 8.47 min, m/z: [M+H]+ = 481.2
Synthesis example No. 169: 2-((1-(2-(5-Chlorothiophen-2-yl)-6,7-dihydro-5H-cyclopenta[d]-pyrimidin-4-yl)indo-lin-6-yl)oxy)-N,N-dimethylethanamine (compound No. 3-7) 169a) 1-(2-(5-Chlorothiophen-2-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)indolin-6-ol [0325] A solution of 4-chloro-2-(5-chlorothiophen-2-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidine (10 g, 37.03 mmol, 1 eq), indolin-6-ol (5 g, 37.03 mmol, 1 eq) and sulfuric acid (6 mL, 111.0 mmol, 3 eq) in n-butanol (100 mL) was stirred at 120°C for 5 h. The solvent was evaporated under vacuum, ethyl acetate (50 mL) was added, and the precipitate was filtered off. Yield: 10 g (75% of theory)
Mass spectroscopy: m/z: [M+H]+ = 470.5 169b) 2-((1 -(2-(5-Chlorothiophen-2-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)indolin-6-yl)oxy)-N,N-dimethyl-ethanamine [0326] A mixture containing the alcohol 169a) (300 mg, 0.81 mmol, 1 eq), cesium carbonate (789 mg, 2.43 mmol, 3.0 eq) and 2-chloro-N,N-dimethylethanamine hydrochloride (291 mg, 2.0 mmol, 2.5 eq) in DMF (10 mL) was stirred at 120°C for 3 h. The reaction mixture was diluted with water and the precipitating solid was filtered off, washed with water (2 X 10mL), dried and finally purified by preparative TLC [methanol/dichloromethane = 1:20]. White solid. Yield: 100 mg (28% of theory) Melting range: 155-158°C.. LC-MS (method 3): Rt= 10.11 min, m/z: [M+H]+ = 441.1
Synthesis example No. 170: 2-((1-(2-(3-Fluoro-4-methoxyphenyl)-6-imino-6-oxido-5,7-dihydrothieno[3,4-d]pyri-midin-4-yl)indolin-6-yl)oxy)-N,N-dimethylacetamide (compound No. 2-115) 170a) 2,2,2-Trifluoro-N-(2-(3-fluoro-4-methoxyphenyl)-4-hydroxy-6-oxido-5,7-dihydrothieno[3,4-d]pyrimidin-6-yli-dene)acetamide [0327] lodobenzene diacetate (1.09 g, 3.40 mmol) was added to a stirred suspension of 2-(3-fluoro-4-methoxyphenyl)- 4-hydroxy-5,7-dihydrothieno[3,4-d]pyrimidine 6-oxide (500 mg, 1.70 mmol), 2,2,2-trifluoroacetamide (423 mg, 3.74 mmol), rhodium(ll) acetate dimer (75.0 mg, 0.17 mmol) and magnesium oxide (309 mg, 7.48 mmol) in dry 1,4-dioxane (7 mL) at 40°C. The reaction mixture was stirred at 40°C for 30 minutes and then cooled to room temperature. Silica (70-200 μπι, ~1 g) was added and the solvent was carefully removed under reduced pressure. The absorbed material was loaded on a silica flash column and purified [heptane with 0% -100% ethyl acetate] Pale blue solid. Yield: 457 mg (66% of theory)
Mass spectroscopy: m/z: [M+H]+ = 406 170b) 2-(3-Fluoro-4-methoxyphenyl)-6-oxido-6-((2,2,2-trifluoroacetyl)imino)-5,7-dihydrothieno[3,4-d1pyrimidin-4-vl trif-luoromethanesulfonate [0328] A solution of triflic anhydride (0.17 mL, 1.00 mmol) in dichloromethane (0.5 mL) was added dropwise to a cooled (0°C) solution of 170a) (325 mg, 0.80 mmol) and triethylamine (0.17 mL, 1.20 mmol) in dichloromethane (2.5 mL). The reaction mixture was stirred at room temperature for 1 h and then directly chromatographed on a silica flash column [heptane with 25% -100% ethyl acetate]. Pale solid. Yield: 252 mg (58% of theory)
Mass spectroscopy: m/z: [M+H]+ = 538 170c) N-(4-(6-(2-(Dimethylamino)-2-oxoethoxv)indolin-1-yl)-2-(3-fluoro-4-methoxyphenyl)-6-oxido-5,7-dihydroth-ieno[3,4-d1pyrimidin-6-ylidene)-2,2,2-trifluoroacetamide [0329] A solution of 170b) (250 mg, 0.47 mmol) and 2-(indolin-6-yloxy)-N,N-dimethylacetamide (204 mg, purity = 76%, 0.71 mmol) in dry acetonitril (10 mL) was stirred at room temperature for 18 h. Silica (1 g) was added and the solvent was carefully removed under reduced pressure. The absorbed material was loaded on a silica flash column and purified [heptane with 0% - 100% ethyl acetate]. Pale solid. Yield 159 mg (56% of theory)
Mass spectroscopy: m/z: [M+H]+ = 608 170d) 2-((1-(2-(3-Fluoro-4-methoxyphenyl)-6-imino-6-oxido-5,7-dihydrothieno[3,4-d1pyrimidin-4-yl)indolin-6-yl)oxy)-N,N-dimethylacetamide [0330] Potassium carbonate (70.5 mg, 0.51 mmol) was added to a stirred suspension of 170c) (155 mg, 0.26 mmol) in a blend of acetonitril (2.5 mL) and methanol (2.5 mL) at room temperature. The mixture was stirred for 1 h and then slowly poured into water (20 mL). After 5 minutes stirring, the solid was filtered off, washed with water (1 mL) and dried in a vacuum-oven at 40°C. Pale solid.
Yield 107 mg (82% of theory)
Mass spectroscopy: m/z: [M+H]+ = 512 1H NMR (400 MHz, DMSO-d6, δ ppm): 8.15 (d, J = 8.6 Hz, 1H), 8.04 (dd, J = 12.8, 1.7 Hz, 1H), 7.58 (d, J = 2.0 Hz, 1H), 7.32 (t, J = 8.7 Hz, 1H), 7.17 (d,J = 8.2 Hz, 1H), 6.59 (dd, J = 8.2, 2.2 Hz, 1H), 4.78 (s, 2H), 4.69 (q, J = 15.2 Hz, 2H), 4.54-4.46 (m, 2H), 4.39 (d, J = 15.9 Hz, 1H), 4.33 (t, J = 8.3 Hz, 2H), 3.92 (s, 3H), 3.08 (t, J = 8.1 Hz, 2H), 2.94 (s, 3H), 2.80 (s, 3H).
Synthesis example No. 171: 2-((1-(2-(3,4-Difluorophenyl)-6-oxido-5,7-dihydrothieno[3,4-d]pyrimidin-4-yl)indo-lin-6-yl)oxy)-N,N-dimethylacetamide (compound No. 2-40) 171a) 2-((1-(2-(3,4-Difluorophenyl)-5,7-dihydrothieno[3,4-d1pyrimidin-4-yl)indolin-6-yl)oxy)-N,N-dimethylacetamide [0331] Caesium carbonate (0.50 g, 1.54 mmol), BINAP (53 mg, 0.08 mmol) and palladium (ll)acetate (16 mg, 0.07 mmol) were added under an argon atmosphere and at room temperature to a solution of 4-chloro-2-(3,4-difluorophenyl)- 5,7-dihydrothieno[3,4-d]pyrimidine 6,6-dioxide (0.40 g, 1.40 mmol) and 2-(indolin-6-yloxy)-N,N-dimethylacetamide (0.30 g, 1.40 mmol) in dry dioxane (50 mL). The reaction mixture was stirred for 16 h at 100°C, then cooled and filtered through a pad of Celite®. The filtrate was concentrated and purified by flash column chromatography [dichloromethane with 0.5% methanol]. Brownish solid. Yield: 0.48 g (72% of theory) 171b) 2-((1 -(2-(3,4-Difluorophenyl)-6-oxido-5,7-dihydrothieno[3,4-d]pyrimidin-4-yl)indolin-6-yl)oxy)-N,N-dimethylacetalmidé [0332] m-Chloroperoxybenzoic acid (77 %, 53 mg, 0.24 mmol) in THF (2 mL) was added at 0°C to a solution of the thioether 171a) (150 mg, 0.32 mmol) in THF (30 mL) and the mixture was stirred for 1 h at room temperature. The reaction mixture was diluted with brine and the aqueous phase was separated and extracted with ethyl acetate (2 x10 mL). The combined organic layers were dried over sodium sulfate, the solvents were removed under vacuum, and the remnant was purified by flash column chromatography [dichloromethane with 2% methanol]. Light yellow solid. Yield: 72 mg (46% of theory) 1H NMR (400 MHz, DMSO-d6, δ ppm): 8.27-8.23 (m, 2H), 7.64-7.57 (m, 2H), 7.18 (d, 1H, J = 8.1 Hz), 6.59 (dd, 1H, J = 2.3 and 8.2 Hz), 4.77 (s, 2H), 4.72 (d, 1H, J = 16.4 Hz), 4.55-4.45 (m, 2H), 4.37-4.25 (m, 2H), 4.03 (d, 1H, J = 16.8 Hz), 3.17-3.07 (m, 2H), 2.94 (s, 3H), 2.79 (s, 3H).
Compound Nos. 2-18 and 2-141 were prepared analogously:
Compound No. 2-52: 2-((1-(2-(4-Methoxyphenyl)-6-oxido-5,7-dihydrothieno[3,4-d]pyrimidin-4-yl)indolin-6-yl)oxy)-N,N-dimethylacetamide (synthesis example No. 172) [0333] Light yellow solid. Yield: 110 mg 1H NMR (400 MHz, DMSO-d6, δ ppm): 8.33 (d, 2H, J = 8.7 Hz), 7.64 (bs, 1H), 7.16 (d, 1H, J = 8.2 Hz), 7.06 (d, 2H, J = 8.7 Hz), 6.56 (dd, 1 H, J = 2.1 and 8.1 Hz), 4.77 (s, 2H), 4.69 (d, 1H, J = 16.3 Hz), 4.51-4.43 (m, 2H), 4.35-4.26 (m, 2H), 4.0 (d, 1 H, J = 16.9 Hz), 3.16-3.07 (m, 2H), 2.93 (s, 3H), 2.80 (s, 3H).
Compound No. 2-141: 2-((1-(2-(5-Methoxypyridin-2-yl)-6-oxido-5,7-dihydrothieno[3,4-d]pyrimidin-4-yl)indolin-6-yl)oxy)-N,N-dimethylacetamide (synthesis example No. 173) [0334] White solid. Yield: 50 mg 1H NMR (400 MHz, DMSO-d6, δ ppm): 8.46-8.37 (m, 3H), 7.54 (dd, 1 H, J = 2.9 and 8.8 Hz), 7.14 (d, 1H, J = 8.2 Hz), 6.57 (dd, 1 H, J = 2.3 and 8.1 Hz), 4.86 (s, 2H), 4.78 (d, 1H, J = 16.3 Hz), 4.55-4.48 (m, 3H), 4.37-4.33 (m, 1H),4.03(d, 1 H, J = 16.9 Hz), 3.91 (s, 3H), 3.16-3.12 (m, 2H), 2.95 (s, 3H), 2.82 (s, 3H).
Synthesis example No. 174: 2-((1-(2-(3,4-Difluorophenyl)-6,6-dioxido-5,7-dihydrothieno[3,4-dlpyrimidin-4-yl)in-dolin-6-yl)oxyl-N,N-dimethylacetamide (compound No. 2-41) [0335] m-Chloroperoxybenzoic acid (77%, 0.15 g, 0.70 mmol) in THF (2 mL) was added at 0°C to a solution of the thioether 171a) (0.15 g, 0.32 mmol) in THF (30 mL) and the mixture was stirred for 1 h at room temperature. The reaction mixture was quenched with brine and the aqueous phase was separated and extracted with ethyl acetate (2 x10 mL). The combined organic layers were dried over sodium sulfate, the solvent was evaporated and the residue purified by flash column chromatography [dichloromethane with 1% methanol]. Light yellow solid. Yield: 0.11 g (68 % of theory) 1H NMR (400 MHz, DMSO-d6, δ ppm): 8.23-8.18 (m, 2H), 7.61-7.59 (m, 2H), 7.18 (d, 1 H, J = 8.1 Hz), 6.61 (dd, 1H, J = 2.0 and 8.2 Hz), 4.87 (s, 2H), 4.77 (s, 2H), 4.63 (s, 2H), 4.35 (t, 2H, J = 8 Hz), 3.08 (t, 2H, J = 8.0 Hz), 2.93 (s, 3H), 2.79 (s, 3H).
[0336] Compound No. 2-21 was prepared analogously:
Compound No. 2-21: 2-((1-(2-(4-Methoxyphenyl)-6,6-dioxido-5,7-dihydrothieno[3,4-d]pyrimidin-4-yl)indolin-6-yl)oxy)-N,N-dimethylacetamide (synthesis example No. 175) [0337] Light yellow solid. Yield: 55 mg 1H NMR (400 MHz, DMSO-d6, δ ppm): 8.29 (d, 2H, J = 8.6 Hz), 7.65 (bs, 1H), 7.16 (d, 1 H, J = 8.3 Hz), 7.06 (d, 2H, J = 8.7 Hz), 6.59 (d, 1H, J = 6.1 Hz), 4.82 (s, 2H), 4.78 (s, 2H), 4.59 (s, 2H), 4.33 (t, 2H, J = 8.3 Hz), 3.83 (s, 3H), 3.08 (t, 2H, J = 8 Hz), 2.92 (s, 3H), 2.8 (s, 3H).
Compound No. 2-143: 2-((1 -(2-(5-Methoxypyridin-2-yl)-6,6-dioxido-5,7-dihydrothieno[3,4-d1pyrimidin-4-yl)indolin-6-yl)oxy)-N,N-dimethylacetamide (synthesis example No.176) [0338] The target compound was synthesized analogously to synthesis example No. 174 with the difference that MMPP was used as oxidation reagent in the last step (see also procedure 63f). Light yellow solid. Yield: 25 mg 1H NMR (400 MHz, DMSO-d6, δ ppm): 8.45-8.33 (m, 3H), 7.55 (d, 1H, J = 2.8 Hz), 7.14 (d, 1H, J = 8.1 Hz), 6.59 (d, 1 H, J = 8.1 Hz), 4.94 (s, 2H), 4.86 (s, 2H), 4.62 (s, 2H), 4.39 (t, 2H, J = 8.4 Hz), 3.91 (s, 3H), 3.1 (t, 2H, J = 8.3 Hz), 2.95 (s, 3H), 2.82 (s, 3H). cAMP HTRF® assay to determine the activity of hPDE4B1 [0339] The inhibiting effect of the compounds on the enzyme activity of human PDE4B1 was measured by the quantification of 5’-adenosine monophosphate (5’-AMP), which is formed from 3’,5’-cyclic adenosine monophosphate (cAMP). Human recombinant enzyme, expressed in Sf9 cells, and the HTRF (homogeneous time-resolved fluorescence) detection method were used in the assay.
[0340] The test compound or water (control) was mixed with the human recombinant PDE4B1 enzyme (4.8 U) in a buffer consisting of 44.4 mM tris-HCI, 5.28 mM MgCI2, 2.64 mM DTT and 0.044% Tween 20 (pH 7.8). After adding the cAMP enzyme substrate (final concentration 40 nM), the mixture was incubated for 30 minutes at room temperature. Then a fluorescence acceptor (Dye2 marked with cAMP), a fluorescence donor (anti-cAMP antibody marked with a europium cryptate) and the non-specific phosphodiesterase inhibitor IBMX (3-isobutyl-1-methylxanthine; final concentration 1 mM) were added. After 60 minutes the fluorescence transfer, which correlates with the amount of remaining cAMP, was measured with a microplate reader (Rubystar, BMG) at λθχ = 337 nm, λΘΓΤ1 = 620 nm and λΘΓΤ1 = 665 nm. The enzyme activity was calculated from the quotient formed from the measured signal at 665 nm and that at 620 nm. The result was expressed as the percentage inhibition of enzyme activity of the control (without PDE4 inhibitor). The enzyme was omitted for measurement of the basal control. IC50 values (IC50 = concentration causing a half-maximal inhibition of control specific activity) were derived from dose response measurements with eight different concentrations (n = 2; N = 1-2).
[0341] Literature: N. Saldou et al., Comparison of recombinant human PDE4 isoforms: interaction with substrate and inhibitors, Cell. Signal. Vol. 10, No. 6, 427-440, 1998 [0342] Several compounds according to the invention are tested with above mentioned assay. The results are given below
Table 5: Percentage inhibition of PDE4B at a test substrate concentration of 1 μΜ):
[0343] The following compounds according to the invention showed an IC50 value in the following ranges: IC50 in the range from 0.1 until 1 μΜ : Compound Nos. 1-17, 1-39, 1-50, 1-60, 1-61, 1-66, 1-69, 1-70, 1-71, 1-72, 1- 73, 1-77, 1-79, 2-34, 2-54, 2-56, 2-58, 2-59, 2-60, 2-64, 2-74, 2-76, 2-86, 2-88, 2-94, 2-97, 2-103, 2-104, 2-105, 2- 111,2-112, 2-128, 2-142, 2-1 43, 2-144, 3-1,3-3, 3-4, and 3-5. IC50 below 0.1 μΜ : Compound Nos. 1-1, 1-2, 1-3, 1-5, 1-8, 1-10, 1-11, 1-12, 1-13, 1-15, 1-16, 1-18, 1-19, 2-18, 1- 20, 1-21, 1-22, 1-23, 1-24, 1-25, 1-75, 1-80, 1-81,2-18,2-20, 2-21,2-24, 2-31,2-33, 2-36, 2-37, 2-40, 2-41,2-42, 2- 45, 2-46, 2-48, 2-49, 2-57, 2-61,2-62, 2-72, 2-73, 2-77, 2-78, 2-79, 2-80, 2-81,2-82, 2-83, 2-84, 2-85, 2-87, 2-89, 2-90, 2-91,2-92, 2-93, 2-95, 2-96, 2-98, 2-99, 2-100, 2-101,2-102, 2-106, 2-107, 2-109, 2-110, 2-113, 2-115, 2-116 to 2-121,2-123, 2-124, 2-125, 2-126, 2-130, 2-131,2-132, 2-133, 2-134, 2-135, 2-136, 2-137, 2-138, 2-139, 2-140, 2-141,2-143, 2-145, 2-146, 2-147, 2-148, 2-149, 2-150, 2-151,2-152, 2-153, 2-154, 2-155, and 3-6.
Claims 1. Pyrimidine compounds of general formula (I) in which
G is a phenyl optionally substituted with at least one substituent Z or a 5- or 6-membered aromatic heterocycle optionally substituted with at least one substituent Z, wherein said phenyl or said aromatic heterocycle may be condensed with a 4-, 5-, 6- or 7-membered ring, wherein said condensed ring may be saturated, partially unsaturated or aromatic and may be substituted with at least one substituent Z; Z independently of one another is (Ci-C6) alkyl, (C-pCg) hydroxyalkyl, (C-pCg) alkoxy, (C-j-Cg) haloalkyl, (C-j-Cg) haloalkoxy, -S(CrC6) alkyl, halogen, hydroxyl or cyano or is S02(C1-C6)alkyl, CONH2, NHS02(C1-C6)alkyl, NHCO(C.|-Cg)alkyl wherein afore mentioned alkyls are branched or straight-chain and can be substituted; T is CR1R2 or S(0)x or S(0)=NH; X is 0, 1 or 2; R1 and R2 independently of one another are hydrogen, (C-pCg) alkyl, (C-pCg) alkoxy, (C-j-Cg) haloalkyl, halogen, hydroxyl or cyano, wherein the aforementioned alkyl chains are branched or straight-chain and can be substituted; n is 1 or 2; K is (CrC6) alkyl, (C-pCg) alkoxy, (C-pCg) haloalkyl, halogen, hydroxyl or cyano, wherein the aforementioned alkyl chains are branched or straight-chain and can be substituted; and m is 0, 1,2, 3 or 4; X independently of one another is (C^Cg) alkyl, (C3-C6) cycloalkyl, (C-pCg) alkoxy, (C3-C6) cycloalkoxy, (C-|-C6) haloalkyl, (CrCg) haloalkoxy, halogen, hydroxyl, cyano, carboxyl, C(0)-NH2, C(0)-NH(C1-C6)alkyl, C(0)-N((C1-C6)alkyl)2, NH2, NH(C.|-C6)alkyl, N((C1-C6)alkyl)2, N-pyrrolidinyl, N-piperidinyl, N-morpholinyl, NH-CHO, NH-CiOHC.pCgîalkyl, S(0)2-NH2, S(C1-C6)alkyl, S(0)-(C1-C6)alkyl, S(0)2-(C1-C6)alkyl, 0-(C1-C4)alkyl-CN, 0-(C1-C4)alkyl-NH-CHO, 0-(C1-C4)alkyl-NH-C(0)-(C1-C6)alkyl, or 0-(CrC4) alkyl-NtfC^-Cg) alkyl)2, or is 0-(C1-C4)aikyl-0-(C1-C4)alkyl, wherein the aforementioned alkyl chains are branched or straight-chain and can be substituted, or is a chemical grouping L-C02R3 or 0-(C.|-C4)alkyl-C0-R4 (preferably 0-CH2-C0R4) or LCONR4; R3 is hydrogen, branched or straight-chain (C.|-Cg)alkyl; R4 is NH2, NHR5, NR5R6, (C-pCg) alkoxy; R5 and R6 independently of one another is (CrC6) alkyl, (C-pCg) hydroxyalkyl, (C3-C6) cycloalkyl, (C1-Cg)alkyl(C3-Cg)cycloalkyl, (C3-C6) heterocycloalkyl, or R5 and R6, together with the nitrogen atom to which they are bound form a saturated 3- to 6-membered heterocycle, optionally substituted with branched or straight-chain (C-pCg) alkyl or hydroxyl groups, which heterocycle can optionally have at least one further heteroatom selected from O, S, and N; L is a bond, (0Γ06) alkylene, (C2-C6) alkenylene, -0-(C.|-C4) alkylene, -NH-(C1-C4) alkylene, or -NR3-(C.|-C4) alkylene, wherein aforementioned alkylenes or alkenylenes can each be substituted with one or more halogen atoms (in particular fluorine) or wherein aforementioned alkylenes or alkenylenes can be substituted with one or more (CrC6) alkyl groups (preferably methyl or ethyl), or wherein in aforementioned alkylenes or alkenylenes a CH2 unit can be replaced by an oxygen atom; p is 1,2, 3 or 4; U~V is a chemical grouping wherein ~ stands for a single or double bond, U stands for a substituted or unsubstituted carbon atom, a substituted or unsubstituted nitrogen atom or a carbonyl group, and V stands for a substituted or unsubstituted carbon atom, a substituted or unsubstituted nitrogen atom, or an oxygen atom, as well as pharmacologically tolerable salts, diastereomers, enantiomers, racemates, hydrates or solvates thereof. 2. The pyrimidine compounds according to claim 1, characterised in that U~V is selected from CR7R8-CR7R8; CR7=CR7, N=CR7, CR7=N, N=N, C(=0)-CR7R8, and C(=0)-0; and R7 and R8 independently of one another are hydrogen, (C.|-C4) alkyl, (C.|-C4) alkoxy, CHF, CH2F or CF3, (C.|-C4) hydroxyalkyl, F, Cl, Br, hydroxyl or cyano. 3. The pyrimidine compounds according to claim 1 or 2, characterised in that T is CH2, S, SO, S02, or SONH. 4. The pyrimidine compounds according to any one of claims 1 to 3, characterised in that U~V is selected from CH2-CH2, CH=CH, N=CH, CH=N, N=N, C(=0)-CH2, and 0(=0)-0. 5. The pyrimidine compounds according to any one of claims 1 to 4, characterised in that X is 0-(C1-C4)alkyl-CN, O-(C1-C4)alkyl-NH-0(O)-(C1-C6)alkyl, 0-(C1-C4)alkyl-0-(C1-C4)alkyl, L-C02R3, 0-(CrC4) alkyl-CO-R4, or LCONR4; R3 is hydrogen, branched or straight-chain (CrC4) alkyl; R4 is NH2, NHR5, NR5R6, (CrC6) alkoxy; R5 and R6 independently of one another is (CrC6) alkyl, (CrC6) hydroxyalkyl, (C3-C6) cycloalkyl (preferably as cyclopropyl), (C.|-C6)alkyl(C3-C6)cycloalkyl (preferably CH2-cyclopropyl), (C3-C6) heterocycloalkyl, or R5 and R6, together with the nitrogen atom to which they are bound form a saturated 3- to 6-membered heterocycle, optionally substituted with branched or straight-chain (CrC6) alkyl or hydroxyl groups, which heterocycle can optionally have at least one further heteroatom selected from O, S, and N; L is a bond or methylene, wherein the methylene can be substituted with one or two halogen atoms. 6. The pyrimidine compounds according to one of claims 1 to 5, characterised in that X is 0-(CrC4)alkyl-CN, 0-(C1-C4)alkyl-NH-C(0)-(C1-C6)alkyl, 0-(C1-C4)alkyl-0-(C1-C4)alkyl, L-C02R3, 0-(CrC4) alkyl-CO-R4, or LCONR4; R3 is hydrogen, branched or straight-chain (CrC4) alkyl; R4 is NH2, NHCH3, N(CH3)2, NHC2H5, NHCH(CH3)2, NHCH2CH2OH, OCH3 or one of the following groups
L is a bond or methylene, wherein the methylene can be substituted with one or two halogen atoms. 7. The pyrimidine compounds according to one of claims 1 to 6, characterised in that G is selected from thienyl, furanyl, thiazolyl, pyridinyl, pyrimidinyl, phenyl, benzothiophenyl, benzofuranyl, benzodi-oxolyl, indolyl, quinolinyl, isoquinolyl. 8. The pyrimidine compounds according to any one of claims 1 to 6, characterised in that G is selected from the following groups G1 to G47
in which the site marked with an asterisk (*) indicates the binding site at position 2 of the pyrimidine ring; Z independently of one another is CH3, OCH3, CF3, CHF2, CH2F, OCF3, OCHF2, OCH2F, SCH3, Br, Cl, F, OH or CN, or S02CH3, CONH2, NHS02CH3, NHCOCH3; and k is 0, 1,2, 3 or 4. 9. The pyrimidine compounds according to any one of claims 1 to 8, characterised in that n is 1. 10. The pyrimidine compounds according to any one of claims 1 to 8, characterised in that n is 2. 11. The pyrimidine compounds according to any one of claims 7 to 10, characterised in that if G is thienyl, furanyl, thiazolyl, pyridinyl, pyrimidinyl, benzothiophenyl, benzofuranyl, benzodioxolyl, indolyl, quinolinyl, isoquinolyl then k is 0 or 1 and if G is phenyl, then k is 1 or 2. 12. The pyrimidine compounds according to any one of claims 1 to 7, characterised in that p is 1 or 2. 13. Medicament containing at least one compound as defined in one of claims 1 to 12. 14. Compounds as defined in one of claims 1 to 12 in the presented form or in the form of their acids or bases or in the form of the physiologically tolerable salts, or in the form of their solvates, optionally in the form of their racemates, their pure stereoisomers, in particular enantiomers or diastereomers, or in the form of mixtures of stereoisomers, in particular enantiomers or diastereomers, in any mixing ratio for use as a medicament for the treatment of conditions or diseases that can be treated by inhibition of the PDE4 enzyme, wherein the conditions or diseases that can be treated by inhibition of the PDE4 enzyme are selected from the following group: inflammatory diseases of the joints, skin and eyes, gastrointestinal diseases and complaints, inflammatory diseases of the internal organs; hyperplastic diseases, respiratory or lung diseases associated with elevated mucus production, inflammation and/or obstruction of the respiratory tract, diseases of the fibrotic spectrum, cancers, metabolic diseases, psychological disorders, and diseases of the peripheral or central nervous system.
Patentansprüche 1. Pyrimidinverbindungen der allgemeinen Formel (I), in der
G ein Phenyl ist, das optional mit mindestens einem Substituenten Z oder einem 5- oder 6-gliedrigen aromatischen Heterocyclus substituiert ist, der optional mit mindestens einem Substituenten Z substituiert ist, wobei das Phenyl oder der aromatische Heterocyclus mit einem 4-, 5-, 6- oder 7-gliedrigen Ring kondensiert sein kann, wobei der kondensierte Ring gesättigt, teilweise ungesättigt oder aromatisch sein kann und mit mindestens einem Substituenten Z substituiert sein kann; Z unabhängig voneinander (C1-C6)-Alkyl, (C1-C6)-Hydroxyalkyl, (C^Cgj-Alkoxy, (C^Cgj-Halogenalkyl, (C1-C6)-Halogenalkoxy, -S(C1-C6)-Alkyl, Halogen, Hydroxyl oder Cyano oder S02(C1-C6)-Alkyi, CONH2, NHS02(C.|-Cg)-Alkyl, NHCO(C.|-Cg)-Alkyl ist, wobei vorhergehende Alkyle verzweigt oder geradkettig sind und substituiert werden können; T CR1R2 oder S(0)x oder S(0)=NH ist; X 0, 1 oder 2 ist; R1 und R2 unabhängig voneinander Wasserstoff, (C^Cgj-Alkyl, (C^Cgj-Alkoxy, (C1-Cg)-Halogenalkyl, Halogen, Hydroxyl oder Cyano sind, wobei die vorhergehenden Alkylketten verzweigt oder geradkettig sind und substituiert werden können; n 1 oder 2 ist; K (C^CgJ-Alkyl, (C^CgJ-Alkoxy, (C^Cgj-Halogenalkyl, Halogen, Hydroxyl oder Cyano ist, wobei die vorhergehenden Alkylketten verzweigt oder geradkettig sind und substituiert werden können; und m Ο, 1,2, 3 oder 4 ist; X unabhängig voneinander(C.|-Cg)-Alkyl, (C3-C6)-Cycloalkyl, (C.|-C6)-Alkoxy, (C3-C6)-Cycloalkoxy, (C-|-C6)-Ha-logenalkyl, (C1-C6)-Halogenalkoxy, Halogen, Hydroxyl, Cyano, Carboxyl, C(0)-NH2, C(0)-NH(C1-C6)-Alkyl, C(0)-N((C1-C6)-Alkyl)2, NH2, NH(CrC6)-Alkyl, N((CrC6)-Alkyl)2, N-Pyrrolidinyl, N-Piperidinyl, N-Morpholinyl, NH-CHO, NH-C(0)-(CrC6)-Alkyl, S(0)2-NH2, S(CrC6)-Alkyl, S(0)-(CrC6)-Alkyl, S(0)2-(CrC6)-Alkyl, 0-(C1-C4)-Alkyl-CN, 0-(C1-C4)-Alkyl-NH-CHO, 0-(C1-C4)-Alkyl-NH-C(0)-(C1-C6)-Alkyl, oder 0-(CrC4)-Alkyl-N((C1-C6)-Alkyl)2 ist oder 0-(C1-C4)-Alkyl-0-(C1-C4)-Alkyl ist, wobei die vorhergehenden Alkylketten verzweigt oder geradkettig sind und substituiert werden können, oder eine chemische Gruppierung L-C02R3 oder 0-(C1-C4)-Alkyi-C0-R4 (vorzugsweise 0-CH2-C0R4) oder LCONR4 ist; R3 Wasserstoff, verzweigtes oder geradkettiges (C1-C6)-Alkyl ist; R4 NH2, NHR5, NR5R6, (CrC6)-Alkoxy ist; R5 und R6 unabhängig voneinander (C.|-C6)-Alkyl, (C^CgJ-Hydroxyalkyl, (C3-C6)-Cycloalkyl, (C1-C6)-Al-kyl(C3-Cg)-Cycloalkyl, (C3-C6)-Heterocycloalkyl sind, oder R5 und R6, zusammen mit dem Stickstoffatom, an das sie gebunden sind, um einen gesättigten 3- oder 6-gliedrigen Heterocyclus zu bilden, optional mit verzweigtem/n oder geradkettigem/n (C^CgJ-Alkyl oder Hydroxylgruppen substituiert sind, wobei der Heterocyclus optional mindestens ein weiteres Heteroatom aufweisen kann, das aus O, S und N ausgewählt ist; L eine Bindung, (C^-Alkylen, (C2-C6)-Alkenylen, -0-(C1-C4)-Alkylen, -NH-(C1-C4)-Alkylen, oder -NR3-(C.|-C4)-Alkylen ist, wobei vorhergehende Alkylene oder Alkenylene jeweils mit einem oder mehr Halogenatomen (insbesondere Fluor) substituiert werden können, oder wobei vorherige Alkylene oder Alkenylene mit einer oder mehreren (C^Cgj-Alkylgruppen (vorzugsweise (Methyl oder Ethyl) substituiert werden können, oder wobei in vorhergehenden Alkylenen oder Alkenylenen eine CH2-Einheit durch ein Sauerstoffatom ersetzt werden kann; p 1,2, 3 oder 4 ist; U~V eine chemische Gruppierung ist, wobei ~ für eine Einzel- oder Doppelbindung steht, U für ein substituiertes oder unsubstituiertes KohlenstofFatom, ein substituiertes oder unsubstituiertes StickstofFatom oder eine Carbo-nylgruppe steht und V für ein substituiertes oder unsubstituiertes Kohlenstoffatom, ein substituiertes oder unsubstituiertes Stickstoffatom oder ein SauerstofFatom, sowie pharmakologisch verträgliche Salze, Diastereomere, Enantiomere, Racemate, Hydrate oder Solvate davon steht. 2. Pyrimidinverbindungen nach Anspruch 1, dadurch gekennzeichnet, dass U~V aus CR7R8-CR7R8; CR7=CR7, N=CR7, CR7=N, N=N, C(=0)-CR7R8, und C(=0)-0 ausgewählt ist; und R7 und R8 unabhängig voneinander Wasserstoff, (C1-C4) -Alkyl, (C1-C4) -Alkoxy, CHF, CH2F oder CF3, (C1-C4) -Hydroxyalkyl, F, CI, Br, Hydroxyl oder Cyano sind. 3. Pyrimidinverbindungen nach Anspruch 1 oder2, dadurch gekennzeichnet, dass TCH2, S, SO, S02, oderSONH ist. 4. Pyrimidinverbindungen nach einem der Ansprüche 1 bis 3, dadurch gekennzeichnet, dass U~V aus CH2-CH2, CH=CH, N=CH, CH=N, N=N, C(=0)-CH2, und C(=0)-0 ausgewählt ist. 5. Pyrimidinverbindungen nach einem der Ansprüche 1 bis 4, dadurch gekennzeichnet, dass X 0-(C1-C4)-Alkyl-CN, 0-(C1-C4)-Alkyi-NH-C(0)-(C1-C6)-Alkyi, 0-(C1-C4)-Aikyl-0-(C1-C4)-Alkyl, L-C02R3, 0-(C1-C4)-Alkyi-C0-R4, oder LCONR4 ist; R3 Wasserstoff, verzweigtes oder geradkettiges (CrC4)-Alkyl ist; R4 NH2, NHR5, NR5R6, (CrC6)-Alkoxy ist; R5 und R6 unabhängig voneinander (C.|-C6)-Alkyl, (C^CgJ-Hydroxyalkyl, (C3-C6)-Cycloalkyl (vorzugsweise als Cy-clopropyl), (C.|-Cg)-Alkyl(C3-Cg)-Cycloalkyl (vorzugsweise CH2-Cyclopropyl), (C3-C6)-Heterocycloalkyl sind, oder R5 und R6, zusammen mit dem Stickstoffatom, an das sie gebunden sind, um einen gesättigten 3- oder 6-gliedrigen Heterocyclus zu bilden, optional mit verzweigtem odergeradkettigen (C1-C6)-Alkyl oder Hydroxylgruppen substituiert sind, wobei der Heterocyclus optional mindestens ein weiteres Heteroatom aufweisen kann, das aus O, S und N ausgewählt ist; L eine Bindung oder Methylen ist, wobei das Methylen mit einem oder zwei Halogenatomen substituiert werden kann. 6. Pyrimidinverbindungen nach einem der Ansprüche 1 bis 5, dadurch gekennzeichnet, dass X 0-(C1-C4)-Alkyl-CN, 0-(C1-C4)-Alkyl-NH-C(0)-(C1-C6)-Alkyi, 0-(C1-C4)-Aikyl-0-(C1-C4)-Alkyl, L-C02R3, 0-(C1-C4)-Alkyi-C0-R4, oder LCONR4 ist; R3 Wasserstoff, verzweigtes oder geradkettiges (C1-C4)-Alkyl ist; r4 Nh2, NHCHg, N(CH3)2, NHC2H5, NHCH(CH3)2, NHCH2CH2OH odereine der folgenden Gruppen ist,
Leine Bindung oder Methylen ist, wobei das Methylen mit einem oder zwei Halogenatomen substituiert werden kann. 7. Pyrimidinverbindungen nach einem der Ansprüche 1 bis 6, dadurch gekennzeichnet, dass G aus Thienyl, Furanyl, Thiazolyl, Pyridinyl, Pyrimidinyl, Phenyl, Benzothiophenyl, Benzofuranyl, Benzodioxolyl, Indolyl, Chinolinyl, Isochinolyl ausgewählt ist. 8. Pyrimidinverbindungen nach einem der Ansprüche 1 bis 6, dadurch gekennzeichnet, dass G aus den folgenden
Gruppen G1 bis G47 ausgewählt ist,
in denen die Stelle, die mit einem Sternchen (*) markiert ist, die Bindungsstelle an Position 2 des Pyrimidinrings anzeigt; Z unabhängig voneinander CH3, OCH3, CF3, CHF2, CH2F, OCF3, OCHF2, OCH2F, SCH3, Br, CI, F, OH oder CN, oder S02CH3, CONH2, NHS02CH3, NHCOCH3 ist; und KO, 1,2, 3 oder 4 ist. 9. Pyrimidinverbindungen nach einem der Ansprüche 1 bis 8, dadurch gekennzeichnet, dass n 1 ist. 10. Pyrimidinverbindungen nach einem der Ansprüche 1 bis 8, dadurch gekennzeichnet, dass n 2 ist. 11. Pyrimidinverbindungen nach einem der Ansprüche 7 bis 10, dadurch gekennzeichnet, dass, wenn G Thienyl, Furanyl, Thiazolyl, Pyridinyl, Pyrimidinyl, Benzothiophenyl, Benzofuranyl, Benzodioxolyl, Indolyl, Chinolinyl, Isochi-nolyl ist, k 0 oder 1 ist und, wenn G Phenyl ist, k 1 oder 2 ist. 12. Pyrimidinverbindungen nach einem der Ansprüche 1 bis 7, dadurch gekennzeichnet, dass p 1 oder 2 ist. 13. Medikament, das zumindest eine Verbindung gemäß Definition in einem der Ansprüche 1 bis 12 enthält. 14. Verbindungen nach einem der Ansprüche 1 bis 12 in der vorliegenden Form oder in der Form ihrer Säuren oder Basen oder in der Form der physiologisch verträglichen Salze, oder in der Form ihrer Solvate, optional in der Form ihrer Racemate, ihrer reinen Stereoisomere, insbesondere Enantiomere oder Diastereomere, oder in der Form von Mischungen von Stereoisomeren, insbesondere Enantiomeren oder Diastereomeren, in jedem Mischungsverhältnis zur Verwendung als ein Medikament für die Behandlung von Zuständen oder Krankheiten, die durch Flemmung des PDE4-Enzyms behandelt werden können, wobei die Zustände oder Krankheiten, die durch Flemmung des PDE4-Enzyms behandelt werden können, aus der folgenden Gruppe ausgewählt sind: Entzündungserkrankungen der Gelenke, Flaut und Augen, Magen-Darm-Erkrankungen und Beschwerden, Entzündungserkrankungen der inneren Organe; hyperplastische Krankheiten, Atemwegs- oder Lungenerkrankungen in Verbindung mit erhöhter Schleimbildung, Entzündung und/oder Behinderung der Atemwege, Erkrankungen des fibrotischen Spektrums, Krebserkrankungen, Stoffwechselerkrankungen, psychische Erkrankungen und Erkrankungen des peripheren oder zentralen Nervensystems.
Revendications 1. Composés de pyrimidine de formule générale (I)
(1) dans laquelle : G est un groupe phényle éventuellement substitué avec au moins un substituant Z ou un groupe hétérocycle aromatique penta- ou hexagonal éventuellement substitué avec au moins un substituant Z, où ledit groupe phényle ou ledit groupe hétérocycle aromatique peut être condensé avec un noyau tétra-, penta-, hexa- ou heptagonal, où ledit noyau condensé peut être saturé, partiellement insaturé ou aromatique et peut être substitué avec au moins un substituant Z ; Z indépendamment l’un de l’autre est un groupe alkyle en C1 à C6, hydroxyalkyle en C1 à C6, alkoxy en C1 à C6, halogénalkyle en C1 à C6, halogénalkoxy en C1 à C6, -S(alkyle en C1 à C6), halogéno, hydroxyle ou cyano ou est un groupe S02(alkyle en C1 à C6), CONFI2, NFIS02(alkyle en C1 à C6), NFICO (alkyle en C1 à C6) où les groupes alkyle mentionnés ci-dessus sont ramifiés ou à chaîne linéaire et peuvent être substitués ; T est un groupe CR1 R2, S(0)x ou SO=NFI ; X vaut 0, 1 ou 2 ; R1 et R2 indépendamment l’un de l’autre sont un hydrogène, un groupe alkyle en C1 à C6, alkoxy en C1 à C6, halogénalkyle en C1 à C6, halogéno, hydroxyle ou cyano, où les chaînes alkyle mentionnées ci-dessus sont ramifiées ou linéaires et peuvent être substituées ; n vaut 1 ou 2 ; K est un groupe alkyle en C1 à C6, alkoxy en C1 à C6, halogénalkyle en C1 à C6, halogéno, hydroxyle ou cyano, où les chaînes alkyle mentionnées ci-dessus sont ramifiées ou linéaires et peuvent être substituées ; et m vaut 0, 1,2, 3 ou 4 ; X indépendamment l’un de l’autre est un groupe alkyle en C1 à C6, cycloalkyle en C3 à C6, alkoxy en C1 à C6, cycloalkoxy en C3 à C6, halogénalkyle en C1 à C6, halogénalkoxy en C1 à C6, halogéno, hydroxyle, cyano, carboxyle, C(0)-NH2, C(0)-NH(alkyle en C1 à C6), C(0)-N-(alkyle en C1 à C6)2, NH2, NH(alkyle en C1 à C6), N(alkyle en C1 à C6)2, N-pyrrolidinyle, N-pipéridinyle, N-morpholinyle, NH-CHO, NH-C(0)(alkyle en C1 à C6), S(0)2-NH2, S(alkyle en C-, à C6), S(0)-alkyle en C·, à C6, S(0)2-alkyle en C-, à C6, 0-(alkyle en C·, à C4)-CN, 0-(alkyle en C·, à C4)-NH-CHO, 0-(alkyle en C·, à C4)-NH-C(0)-(alkyle en C·, à C6), ou 0-(alkyle en C1 à C4)-N(alkyle en Ci à C6)2, ou est un groupe 0-(alkyle en C^ à C4)-0-(alkyle en Ci à C4), où les chaînes alkyle mentionnées ci-dessus sont ramifiées ou à chaîne linéaire et peuvent être substituées, ou est un groupement chimique L-C02R3 ou 0-(alkyle en C1 à C4)-CO-R4 (de préférence 0-CH2-COR4) ou LCONR4 ; R3 est un hydrogène, un groupe alkyle en C1 à C6 ramifié ou à chaîne linéaire ; R4 est un groupe NH2, NHR5, NR5R6, alkoxy en à C6 ; R5 et R6 indépendamment l’un de l’autre sont un groupe alkyle en Ci à C6, hydroxyalkyle en C1 à C6, cycloalkyle en C3 à C6, (alkyle en Ci à C6) (cycloalkyle en C3 à C6), hétérocycloalkyle en C3 à C6, ou R5 et R6, conjointement avec l’atome d’azote auquel ils sont liés forment un groupe hétérocycle tri-à hexagonal, éventuellement substitué avec des groupes alkyle en C1 à C6 ramifiés ou à chaîne linéaire ou hydroxyle, lequel groupe hétérocycle peut avoir éventuellement un autre hétéroatome choisi parmi 0, S et N ; L est une liaison, un groupe alkylène en C1 à C6, alcénylène en C2 à C6, -O-alkylène en C1 à C4, -NH-alkylène en Ci à C4 ou -NR3 (alkylène en C1 à C4), où les alkylène ou alcénylène mentionnés ci-dessus peuvent être chacun substitués avec un ou plusieurs atomes d’halogène (en particulier le fluor) ou bien où les alkylène et alcénylène mentionnés ci-dessus peuvent être substitués avec un ou plusieurs groupes alkyle en C1 à C6 (de préférence méthyle ou éthyle), ou bien où, dans les alkylène ou alcénylène mentionnés ci-dessus, un motif CH2 peut être remplacé par un atome d’oxygène ; p vaut 1,2, 3 ou 4 ; U~V est un groupement chimique dans lequel correspond à une simple ou une double liaison, U correspond à un atome de carbone substitué ou non substitué, un atome d’azote substitué ou non substitué ou un groupe carbonyle, et V correspond à un atome de carbone substitué ou non substitué, un atome d’azote substitué ou non substitué ou un atome d’oxygène, ainsi que leurs sels, diastéréomères, énantiomères, racémates, hydrates ou produits de solvatation pharmacologiquement tolérables. 2. Composés de pyrimidine selon la revendication 1, caractérisés en ce que : U~V est choisi parmi les groupes CR7R8-CR7R8 ; CR7=CR7, N=CR7, CR7=N, N=N, C(=0)-CR7R8 et C(=0)-0 ; et R7 et R8 indépendamment l’un de l’autre sont un hydrogène, un groupe alkyle en C1 à C4, alkoxy en C1 à C4, CHF, CH2F ou CF3, un groupe hydroxyalkyle en C1 à C4, F, Cl, Br, hydroxyle ou cyano. 3. Composés de pyrimidine selon la revendication 1 ou 2, caractérisés en ce que : T est un groupe CH2, S, SO, S02 ou SONFI. 4. Composés de pyrimidine selon l’une quelconque des revendications 1 à 3, caractérisés en ce que : U~V est choisi parmi les groupes CFI2-CFI2, CFI=CH, N=CFI, CFI=N, N=N, C(=0)-CFI2 et C(=0)-0. 5. Composés de pyrimidine selon l’une quelconque des revendications 1 à 4, caractérisés en ce que : X est un groupe 0-(alkyle en C1 à C4)-CN, 0-(alkyle en C1 à C4)-NFI-C(0)-(alkyle en C1 à C6), 0-(alkyle en C1 à C4)-0-(alkyle en C1 à C4), LC02R3, 0-(alkyle en C1 à C4)-CO-R4 ou LCONR4 ; R3 est un hydrogène, un groupe alkyle en C1 à C4 ramifié ou à chaîne linéaire, R4 est un groupe NH2, NFIR5, NR5R6, alkoxy en C1 à C6 ; R5 et R6 indépendamment l’un de l’autre sont un groupe alkyle en C1 à C6, hydroxyalkyle en C1 à C6, cycloalkyle en C3 à C6 (de préférence comme cyclopropyle), (alkyle en C1 à C6)(cycloalkyle en C3 à C6) (de préférence Chl2-cyclopropyle), hétérocycloalkyle en C3 à C6, ou R5 et R6, conjointement avec l’atome d’azote auquel ils sont liés, forment un groupe hétérocycle tri- à hexagonal, éventuellement substitué avec des groupes alkyle en C1 à C6 ramifié ou à chaîne linéaire ou hydroxyle, lequel groupe hétérocycle peut avoir éventuellement au moins un autre hétéroatome choisi parmi 0, S et N ; L est une liaison ou un groupe méthylène, où le groupe méthylène peut être substitué avec un ou deux atomes d’halogène. 6. Composés de pyrimidine selon l’une quelconque des revendications 1 à 5, caractérisés en ce que : X est un groupe 0-(alkyle en C1 à C4)-CN, 0-(alkyle en C1 à C4)-NH-C(0)-(alkyle en C1 à C6), 0-(alkyle en C1 à C4)-0(alkyle en C-, à C4), L-C02R3, 0-(alkyle en C-, à C4)-CO-R4 ou LCONR4 ; R3 est un hydrogène, un groupe alkyle en C1 à C4 ramifié ou à chaîne linéaire ; R4 est un groupe NH2, NHCH3, N(CH3)2, NHC2H5, NHCH(CH3)2, NHCH2CH2OH, OCH3 ou un des groupes suivants
L est une liaison ou un groupe méthylène, où le groupe méthylène peut être substitué avec un ou deux atomes d’halogène. 7. Composés de pyrimidine selon l’une quelconque des revendications 1 à 6, caractérisés en ce que : G est choisi parmi les groupes thiényle,furannyle,thiazolyle, pyridinyle, pyrimidinyle, phényle, benzothiophényle, benzofurannyle, benzodioxolyle, indolyle, quinolinyle, isoquinolyle. 8. Composés de pyrimidine selon l’une quelconque des revendications 1 à 6, caractérisés en ce que G est choisi parmi les groupes suivants G1 à G47
/10 y1D . ±
dans lesquels le site marqué avec une astérisque (*) indique le site de liaison en position 2 du noyau pyrimidine ; Z indépendamment l’un de l’autre est un groupe CH3, OCH3, CF3, CHF2, CH2F, OCF3, OCFIF2, OCH2F, SChl3, Br, Cl, F, OH ou CN, ou S02CH3, CONH2, NHS02CH3, NHCOCH3 ; et k vaut 0, 1,2, 3 ou 4. 9. Composés de pyrimidine selon l’une quelconque des revendications 1 à 8, caractérisés en ce que n vaut 1. 10. Composés de pyrimidine selon l’une quelconque des revendications 1 à 8, caractérisés en ce que n vaut 2. 11. Composés de pyrimidine selon l’une quelconque des revendications 7 à 10, caractérisés en ce que si G est un groupe thiényle, furannyle, thiazolyle, pyridinyle, pyrimidinyle, benzothiophényle, benzofurannyle, benzodioxolyle, indolyle, quinolinyle, isoquinolinyle alors k vaut 0 ou 1 et si G est un groupe phényle, alors k vaut 1 ou 2. 12. Composés de pyrimidine selon l’une quelconque des revendications 1 à 7, caractérisés en ce que p vaut 1 ou 2. 13. Médicament contenant au moins un composé tel que défini dans les revendications 1 à 12. 14. Composés tels que définis dans l’une des revendications 1 à 12 sous la forme présentée ou sous la forme de leurs acides ou de leurs bases ou sous la forme des sels physiologiquement tolérables, ou sous la forme de leurs produits de solvatation, éventuellement sous la forme de leurs racémates, leurs stéréoisomères purs, en particulier leurs énantiomères ou diastéréomères, ou sous la forme de mélanges de stéréoisomères, en particulier d’énantiomères ou de diastéréomères, en un quelconque rapport de mélange pour une utilisation comme médicament pour le traitement d’états ou de maladies qui peuvent être traités par l’inhibition de l’enzyme PDE4, où les états ou maladies qui peuvent être traités par l’inhibition de l’enzyme PDE4 sont choisis dans le groupe suivant : les maladies inflammatoires des articulations, de la peau et des yeux, les maladies et plaintes gastro-intestinales, les maladies inflammatoires des organes internes ; les maladies hyperplasiques, les maladies respiratoires ou des poumons associées avec une production de mucus élevé, l’inflammation et/ou l’obstruction du système respiratoire, les maladies du spectre fibrotique, les cancers, les maladies métaboliques, les troubles psychologiques, et les maladies du système nerveux périphérique ou central.
REFERENCES CITED IN THE DESCRIPTION
This list of references cited by the applicant is for the reader’s convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.
Patent documents cited in the description • US 2008070896 A [0002] · WO 9501338 A1 [0004] • EP 180371 A [0002] · US 20060293343 A1 [0012] [0013] • WO 2005014558 A [0002]
Non-patent literature cited in the description • SCHUDT, C. et al. PDE isoenzymes as targets for · LEE et al. Dynamic regulation of CFTR by competi- anti-asthma drugs. European Respiratory Journal, five interactions of molecular adaptors. Journa/of S/- 1995, vol. 8, 1179-1183 [0007] ological Chemistry, 2007, vol. 282, 10414-10422 • MORI, F. et al. The human area postrema and other [0010] nuclei related to the emetic reflex express cAMP · GIEMBYCZ, M.A. 4D or not 4D - the emetogenic ba-phosphodiesterases4B and 4D. Journal of Chemical sis of PDE4 inhibitors uncovered?. Trends in Phar-
Neuroanatomy, 2010, vol. 40, 36-42 [0010] macological Sciences, 2002, vol. 23, 548 [0010] • PRESS, N.J. ; BANNER K. H. PDE4 inhibitors - A · KENJI. Discovery of selective PDE4B inhibitors, review of the current field. Progress in Medicinal Bioorganic & Medicinal Chemistry Letters, 2009, vol.
Chemistry, 2009, vol. 47, 37-74 [0010] 19, 3174-3176 [0011] • ROBICHAUD, A. et al. Deletion of phosphodieste- · Remington’s Pharmaceutical Sciences. Mack Pub- rase 4D in mice shortens a2-adrenoceptor-mediated lishing Company, 1985 [0104] anesthesia, a behavioral correlate of emesis. The · N. SALDOU et al. Comparison of recombinant hu-
Journal of Clinical Investigation, 2002, vol. 110, man PDE4 isoforms: interaction with substrate and 1045-52 [0010] inhibitors. Cell. Signal., 1998, vol. 10 (6), 427-440 [0341]

Claims (14)

Αχ EP 2 98β 600 iaístromsaému európai szabadalom igénypontjainak magyar fordítása: 1. (!) általános képleté pirimídinvegyuietek:Hungarian translation of claims of EP 2 98β 600 iaístromsaému European patent: 1. Pyrimidine compound of formula (I): .... ^ valamint farmakoiögíaílag elviselhető sóik, diasziereomerjeik, enantíemerjeik, racematjsik, hidrátjaík vagy szolvátjaik, amelyekben Θ jelentése íeníiesoport, amely adott esetben legalább egy Z szubsztituensseí helyettesített vagy 5- agy 64agú aromás heterociklusos csoport, amely adott esetben legalább egy Z szubszituenssei helyettesített, ahol az említett feníí- vagy említett aromás heterociklusos csoport kondenzált lehet 4-, 5-, 6- vagy 7-tagú gyűrűvel, ahol az említett kondenzált gyűrő lehet telített, részlegesen telítetlen vagy aromás, és lehet helyettesített legalább egy Z szubsztituensseí; Z jelentése egymástól függetlenül (Ci-Cg) alkil·, (Cj-Ce) hidroxíalkil-, (Ct-Ce) alkoxl·, (CrCf,) haiogénaikik (Ci-Ce) halogénalkoxi-, ~S(CVCe) alkil, halogén, hidroxíl· vagy cíanocsoport vagy jelentése 430;?(Cr<k)aíkik -CÖNH2, -MHS02(Cr C6)alkíl, “NHCO(Ci-C(5)alkl! csoport, ahol az előzőekben említett aikilcsoportok eiágazóak vagy egyenes láncúak, és lehetnek helyettesítettek; T jelentése -CR1R2- vagy ~S{Ö)>- vagy -Β(0}~ΝΗ- csoport; X jelentése 0, t vsgv 2; R1 és R2 jelentése egymástól függetlenül hidrogén, (Cv-Cg) alkil-, (CrCg) alkoxl·, (C-rCo) halogénaikll-, halogén-, hidroxíl- vagy cíanocsoport, ahol az előzőekben említett aíkilláncok eiágazóak vagy egyenesek, és lehetnek helyettesítettek; n jelentése 1 vagy 2; K jelentése (Ci-Cg) alkil·, (Ci~Cg) alkoxl·, (Ci~Ce) halogénaikll·, halogén-, hidroxíl· vagy cíanocsoport, ahol az előzőekben említett aíkilláncok eiágazóak vagy egyenesek, és lehetnek helyettesítettek; és m jelentése 0,1,2, 3 vagy 4; X jelentése egymástól függetlenül (Cr-Cg) aíklí-, (CrCe) cikioaikii··, (C-rC«) alkoxi-, (CyCg) ciktoalkoxi-, (CrCe) halogénalkíl·-, (CrCe) haíogénalkoxl·, halogén-, hidroxíl-, ciánom karboxih -C(0}~NH2, -C(0)-NH(Ci-Ce)alkilf -C(0)"N{(CrCß}aikii)?, -NH2, -NH{Cr-Ce)alkll, ~N({CrC6} aíkjj}2, -N-pirrolidinil, -N-piperidinií, -N-morfolinil, -NHCHO. -NH-C{OHCrCe) aikií, -S(G)3~NH3, -S(CrCe)alkil, -S<OKCi-C6)afkfj, -S{0)r{Cr CejaSkil, -O-ÍCrC^aíkil-CN, ~0~(Ci-C4)aíkikNH-CHOt <y(CrC4)mmmXO)~{Cy C6}aíkil vagy ~0-{CrC.i}alkihN((Ci-Ce)alkll)í csoport, vagy jelentése -CH€VC4)alkil-0-(CrC4)alkil csoport, ahol az előzőekben említett aíkílíáncok elágazónk vagy egyenesek és lehetnek helyettesítettek, vagy jelentése -L-C02R'J vagy ~0(CV CGaikil-CÖ-R4 (előnyösen ~Q-CH2-COR4) vagy -LCONR4 kémiai csoport.; R3 jelentése hidrogén, elágazó vagy egyenes láncú (CrCß)aSkilosopori; R'1 jeíentése -NH2< -NHR5, ~NRSR® (Ci«C6) aíkoxicsoport; R5 és R6 jeíentése egymástó! függetlenül (Ci-Ce) alkík (Ch-Ce) hídroxiaikik, (Cy Ce) cikfoalkíh (Ci~Cf;)a!kil(C:rCe)dk!oa!kíl·, (Ca-Ce) heteroclkíoalkilcsoport, vagy R5 és R6 együtt a nitrogénatammal, amelyhez kapcsolódnak, telített 3-6-tagú heterociklusos csoportot alkot, amely adott esetben helyettesített elágazó vagy egyenes láncú (Ct-Cg) alkíicsoporital vagy hidroxílosaportia!, amely heterociklusos csoport adott esetben tartalmaz legalább egy további, az O, S és N közül választott heteroatomot; L jelentése vegyértékkötés, (C-rCg) aikilèn-, (C2~C&amp;) aikeniién-, -CH'CrCu) alkuién, -NH~(Ci-C*) aikílén vagy ~NR3'(Ci-C4)aikiién csoport, ahol az előzőekben említett alfelén- vagy alkeniléncsoportok mindegyike helyettesített lehet egy vagy több halogénatommaí (különösen fluorral:) vagy ahol az. előzőekben emíítetí aikílén-és aikeníléncsoportok helyettesítettek lehelnek egy vagy több (C;~C?j) alkílcsoporttai (előnyösen metik vagy etílcsoporttai), vagy aho! az előzőekben említett alkílén- és aikeníiéncsoportokban egy CMs egységet oxigénatom helyettesíthet; p jeíentése 1,2,3 vagy 4; U~V jelentése kémiai csoport, aho! - jeíentése egyszeres vagy kettős kötés, U jeíentése helyettesített vagy helyettesítetíen szénatom, helyettesített vagy helyettesítetíen nitregénatom vagy karbonilcsoport, és V jeíentése helyettesített vagy helyettesítetíen szénatom, helyettesített vagy heíyettesítetlen nitrogénatom, vagy oxigénatom.as well as pharmaceutically acceptable salts, diastereomers, enantiomers, racemates, hydrates or solvates thereof, wherein Θ is a phenyl group optionally substituted with at least one Z substituent or a 5-membered 64-membered aromatic heterocyclic group optionally substituted with at least one Z substituent; wherein said phenyl or said aromatic heterocyclic group may be fused to a 4-, 5-, 6-, or 7-membered ring, wherein said fused ring may be saturated, partially unsaturated or aromatic and may be substituted by at least one Z substituent; Z is independently (C 1 -C 8) alkyl, (C 1 -C 6) hydroxyalkyl, (C 1 -C 6) alkoxy, (C 1 -C 6) halo, (C 1 -C 6) haloalkoxy, S (CVCe) alkyl, halogen, hydroxyl or titan or is 430; (Cr < k >) alkyl is -CÖNH2, -MHSO2 (C1-C6) alkyl, " NHCO (C1-C (5) alkyl, wherein said alkyl groups are branched or straight chain, and T is -CR 1 R 2 - or - S {Ö)> - or -Β (O} - ΝΗ -; X is O, t is vg 2; R 1 and R 2 are independently hydrogen, (C 1 -C 8) alkyl- , (C 1 -C 8) alkoxy, (C 1 -C 10) haloalkyl, halo, hydroxyl or titanium, wherein the above-mentioned chain chains are branched or straight and may be substituted; n is 1 or 2; K is (C 1 -C 8) alkyl; · (C 1 -C 8) alkoxy, (C 1 -C 6) haloalkyl, halogen, hydroxy, or titanium, wherein the above-mentioned chain chains are branched or straight and may be substituted and m is 0, 1, 2, 3 or 4; X is independently (C 1 -C 8) alkyl, (C 1 -C 8) cycloalkyl, (C 1 -C 8) alkoxy, (CyCg) cyctoalkoxy, ( CrCe) haloalkyl, - (CrCe) halogenoalkoxy, halogen, hydroxy, cyano carboxyl -C (O} ~ NH2, -C (O) -NH (C1-C6) alkylf -C (O) "N {( C 1 -C 5 alkyl alkyl, -NH 2, -NH (C 1 -C 6) alkyl, N ({CrC 6} alkyl} 2, -N-pyrrolidinyl, -N-piperidine, -N-morpholinyl, -NHCHO. -NH-C (OHCrCe) alkyl, -S (G) 3-NH3, -S (C 1 -C 6) alkyl, -S <OKC1-C6) afkfj, -S (O) r {Cr CeSkyl, -O-C 1 -C 6 alkyl -CN, -O- (C 1 -C 4) alkyl or NH-CHOt <y (C 1 -C 4) mmm XO) {Cy C 6} alkyl or -O- (C 1 -C 6 alkyl) ((C 1 -C 6) alkyl) or -CH € VC4) alkyl-O- (C1-C4) alkyl, wherein the above-mentioned alkyl chains are branched or straight and may be substituted or represent -L-CO2R'J or -O (CVCGalyl-CÖ-R4 (preferably ~ Q-) CH2-COR4) or -LCONR4 chemical group; R3 is hydrogen, branched or straight-chain (C1-C6) aSkylosopor; R'1 is -NH2 <-NHR5, -NRSR® (C1-6alkyl) alkoxy; independently (C 1 -C 6) alkyl (Ch-Ce) hydroxy, (C 1 -C 6) cycloalkyl (C 1 -C f;) alkyl (C 1 -C 6) dlkyl, (C 1 -C 6) heterocycloalkyl, or R 5 and R6 together with the nitrogen atom to which it is attached forms a saturated 3-6 membered heterocyclic group optionally substituted with a branched or straight chain (Ct-Cg) alkyl group. or hydroxylaportortia, which heterocyclic group optionally contains at least one further heteroatom selected from O, S and N; L is a bond, (C 1 -C 8) alkylene, (C 2 -C &lt; c &gt;) alkenylene, -CH'CrCu) alkene, -NH- (C 1 -C 10) alkylene, or -NR 3 '(C 1 -C 4) alkylene, wherein each of the aforementioned alpha- or alkenylene groups may be substituted with one or more halogen atoms (especially fluorine) or where. alkylene and alkenylene groups referred to above are substituted by one or more (C 1 -C 8) alkyl groups (preferably methic or ethyl) or aho! in the above-mentioned alkylene and alkenylene groups, a CMs unit may be replaced by an oxygen atom; p is 1,2,3 or 4; U ~ V means chemical group, aho! is a single or double bond, U is a substituted or unsubstituted carbon atom, a substituted or unsubstituted nitrogen atom or a carbonyl group, and V is a substituted or unsubstituted carbon atom, a substituted or unsubstituted nitrogen atom or an oxygen atom. 2. Az 1. igénypont szerinti pirimidmvegyüietek, azzal jellemezve, hogy U~V jeientésèt a «CR7R8~CR?R8-; ~CR7-CR7~, -NCR7-, -CR?*N~, -N=N-, -0(=0)-CR?R8~ és a -0(=0)--0- csoport közű! választjuk; és R7 és Rs jelentése egymástól függetlenül hidrogén, {C1-C4) aikIK (CrC.*) aikoxh "CHF2, ~CH?F vagy -CFs, (C-rC^ hidroxiaikii-, F, Cl, Br, hidroxíl- vagy cianocsoport.Pyrimidium compounds according to claim 1, characterized in that U ~ V is selected from the group consisting of «CR7R8 ~ CR1R8-; ~ CR7-CR7 ~, -NCR7-, -CR? * N-, -N = N-, -O (= O) -CR? R8- and -O (= O) - 0- are in the group! is selected; and R7 and R8 are independently hydrogen, {C1-C4) alkyl (C1-C10) alkoxy "CHF2, CH2F or -CFs (C1-C4 hydroxyalkyl, F, Cl, Br, hydroxy or cyano) . 3„ Az 1. vagy 2. igénypont szerinti pirimidirwegyületek, azzal jellemezve, hogy T jelentése -CHg-, -S-, -SO-, ~S0?~ vagy -SONN- csoport.3 "Pyrimidir compounds according to claim 1 or 2, characterized in that T is -CH2-, -S-, -SO-, - S0- or -SONN-. 4, Az 1-3. igénypontok bármelyike szerinti pirímidlnvegyületek, azzal jellemezve, hogy U~V jelentését a ~CHrCH3~( -CH=CH-, -N=CH-, -CH=N-, -N*N-, ~C(=Ö)~CH2- és a -C{=0)-0- csoport közül választjuk,4, 1-3. Pyrimidyl compounds according to any one of claims 1 to 3, characterized in that U ~ V is represented by the formula -CHrCH3- (-CH = CH-, -N = CH-, -CH = N-, -N * N-, -C (= Ö) ~ CH2). - and is selected from the group consisting of -C (= O) -O-, 5. Az 1-4. Igénypontok bármelyike szerinti pirímldinvegyüietek, azzal jellemezve, hogy X jelentése -O-ÍCrC^aíkil-CN, -CHCi-C4)aika-NH-C(OHCrCe)atkH, -ö-(Cr C4)alkíhO-(CrC4)a!kik -L-CöjR3, -0~(Ci~C,Oaíkíi~Cö~R4 vagy -LCONR4 csoport; R3 jelentése hidrogén, elágazó vagy egyenes láncú (C1-C4) alkilcsoport; R4 jelentése ~NH2, 4M HR3, -NRf,R8, -(C-i-Ce) alkoxícsoport; R5 és R6 jelentése egymástól függetlenül (Ci-Cs) aikih, (CrC$) hidroxiaikii-, (Cr C5) clkloalklh (előnyösen ciklopropii-), -(Ci-Ce)alkil(C3-Ce)cikioaiki! (előnyösen -CH2-ciklopropií), (Ca-Ce) heteroclkioalkiScsoport, vagy R5 és R6 együtt a nitrogénatommal, amelyhez kapcsolódnak, telített 3-6-tagú heterociklusos csoportot alkot amely adott esetben helyettesített elágazó vagy egyenes láncú (CrCe) alkíícsoporttai vagy hidroxiícsoporttal, amely heterociklusos csoport adott esetben tartalmazhat legalább egy további, az O, S és N kézül választott heteroaiomot; L jelentése vegyérlékkötés vagy metiléncsoport, ahol a metiíéncsoport helyettesített lehet egy vagy két halogénatommal. δ.5. Pyrimidine compounds according to any one of the claims, characterized in that X is -O-C 1 -C 4 alkyl-CN, -CHC 1 -C 4) time -NH-C (OHCrCe) arkH, -O- (C 1 -C 4) alkyl (CrC 4) a! -L-C 1 R 3, -O- (C 1 -C, O-alkyl, C 4 -C 4 or -CRONR 4; R 3 is hydrogen, branched or straight-chain (C 1 -C 4) alkyl; R 4 is -NH 2, 4 M HR 3, -NR f, R 8 , - (C 1 -C 6) alkoxy; R 5 and R 6 are each independently (C 1 -C 8) alkyl, (C 1 -C 5) hydroxyalkyl, (C 1 -C 5) cl 6 alkyl (preferably cyclopropyl), - (C 1 -C 6) alkyl (C 3 -C 6); Ce) cycloalkyl (preferably -CH2-cyclopropyl), (Ca-Ce) heterocycloalkylS, or R5 and R6 together with the nitrogen to which they are attached form a saturated 3- to 6-membered heterocyclic group optionally substituted with a branched or straight chain (CrCe) an alkyl group or a hydroxy group, which heterocyclic group may optionally contain at least one further heteroatom selected by O, S, and N; methylene, where the methylene group may be substituted with one or two halogen atoms. δ. Az 1-5. igénypontok egyike szerinti pírimidínvegyüietek, azzal jellemezve, hogy X jelentése -0-(CrC4)aíkil~CN, -O~(CrC..0ölkíl~NH-C(O)-(CrCc;)alkii, ~0~{Cr C4)aIkií~0“(C1 )a 1 kü, -L-C02R3, -O-(Ci~G0aíkií-CÖ-R4 vagy -LCONR4 csoport; R3 jeíentése hidrogén, elágazó vagy egyenes láncú (CrC«} aíkilcsoport; R4 jelentése ~NH2, ~NHCH3, *N{CH3)a, -NHC2H5, -NHCH(CH3}2, -NHCH2CH2OH, -ÖCM3 vagy a következő csoportok egyike:1-5. Pyrimidine compounds according to one of Claims 1 to 5, characterized in that X is -O- (C 1 -C 4) alkyl-CN, -O- (Cr C 1-4 alkyl-NH-C (O) - (CrCc;) alkyl, ~ 0 ~ {Cr C 4) C1-6 (C1) is 1, -L-CO2R3, -O- (C1-C10 alkyl-C0-R4 or -LCONR4; R3 is hydrogen, branched or straight-chain (C1-C10) alkyl; R4 is -NH2) , - NHCH 3, * N {CH 3) a, -NHC 2 H 5, -NHCH (CH 3} 2, -NHCH 2 CH 2 OH, -ÖCM 3, or one of the following groups: JL jelentésé vegyértékkötés vagy metiíéncsoport, ahol a metííénesoporl helyettesített lehat egy vagy két haiogénatommaf.JL is a bond or a methylene group, where the methyleneopor can be substituted by one or two halogens. 7. Az 1~6. Igénypontok egyike szerinti pírí mid ín vegyü letek, azzal jellemezve, hagy G jelentését a tienik furanik tiazolík piridinik pirímidlnll-, fenik, henzoíioíenik benzofuranil-, benzodioxoíih indolík kinolíník izokínolilcsoport kézül választjuk,7. The 1 ~ 6. Pyrimidine compounds according to one of the claims, characterized in that the meaning of G is the furanyl thiazolyl pyridinyl pyrimidyl, phenoxy, benzofuranyl, benzodioxylindole quinoline, isoquinolyl group selected from the group consisting of: 8, Az 1-6, igénypontok bármelyike szerinti pírímidínvegyületek, azzal jellemezve* hogy G jelentését á következő G1 ~ G47 csoport közül választjuk:Pyrimidine compounds according to any one of claims 1 to 6, characterized in that G is selected from the group consisting of G1-G47: amelyekben a csillaggal (*) jelölt hely mutatja a pírimidingyürű 2-heSyzetéhez való kapcsolódás helyét: Z jelentése egymástól függetlenül -CH3l ~OCH3, -CFa, -CHF2, -CHZF, -GCF3, ~ ÖCHFg, ~ΟΟΗ2Ρ, ~SCH3i Br, O, F, -OH vagy ~0N csoport, vagy -S02CH3> -CONH2, -NHSO2CH3, -NHCOCH3 csoport; és k jelentése 0« 1,2,3 vagy 4.in which the place marked with an asterisk (*) indicates the site of attachment to the pyrimidine ring 2-hexyl: Z is independently -CH 3 1 -OCH 3, -CF a, -CHF 2, -CH 2 F, -GCF 3, ~ OCHFg, ~ ΟΟΗ 2ΟΟΗ, ~ SCH3i Br, O , F, -OH, or -ON, or -SO 2 CH 3> -CONH 2, -NHSO 2 CH 3, -NHCOCH 3; and k is 0? 1,2,3 or 4. 9, Az 1-8. igénypontok bármelyike szerinti pírimidinvegyületek, azzal jellemezve, hogy n jelentése 1.9, 1-8. Pyrimidine compounds according to any one of claims 1 to 4, characterized in that n is 1. 10, Az 1-8. igénypontok bármelyike szerinti pirimidinvegyüíetek, azzal jellemezve, hogy n jele ntése 2.10, 1-8. Pyrimidine compounds according to any one of claims 1 to 3, characterized in that n is a symbol 2. 11, A 7-10. igénypontok bármelyike szerinti pirimiciinvegyüíetek, azzal jellemezve, hogy ha G jelentése tienil-, furaníh tíazolil-, piridinii-, pirlmiciinih benzotíofenil··, benzofuranil-, benzodioxolil-, indolis-, kinolinil-, izokinoiiícsoport, akkor k jelentése ö vagy 1, és ha G jelentése fen ({csoport akkor k jelentése 1 vagy 2.11, A 7-10. Pyrimycin compounds according to any one of claims 1 to 3, characterized in that when G is thienyl, furanylthiazolyl, pyridinyl, pyrimycin benzothiophenyl ·, benzofuranyl, benzodioxolyl, indole, quinolinyl, isoquinyl, then k is 0 or 1, and when G is fen ({then k is 1 or 2; 12, Az. 1-7. igénypontok bármelyike szerinti pírimidinvegyületek, azzal jellemezve^ hogy p jelentése 1 vagy 2.12, Acts 1-7. Pyrimidine compounds according to any one of claims 1 to 4, characterized in that p is 1 or 2. 13, Gyógyszer, amely iegaiább egy az 1-12. igénypontok egyikéhen meghatározott vegyüietet tartalmaz.13, a medicament obtainable by one of claims 1-12; A compound as defined in any one of claims 1 to 3. 14, Az 1-12. igénypontok egyikében meghatározott vegyűíetek a bemutatott formában vagy savaik vagy bázisaik formájában vagy fiziológiásán elfogadható sók formájában, vagy szoivátjaik formájában, adott esetben racemátjaik, tiszta sztereöizomerjeik, különösen enantiomerek vagy diaszteraomerek formájában vagy sztereoízoroerek, különösen enantiomerek vagy diasztereomerek elegye! formájában, bármilyen keverési arányban, gyógyszerként vaiő alkalmazásra olyan állapotok vagy betegségek kezelésére, amelyek a PDE4 enzim gátlásával kezelhetők, ahol azok az állapotok vagy betegségek, amelyek a PDE4 enzim gátlásával kezelhetők, az ízületek, a bor és a szemek gyulladásos betegségei, gasztrointesztínáíis betegségek és panaszok, a belső szervek gyulladásos betegségei; hiperplasztikus betegségek, légúti vagy tüdőbetegségek, amelyek megnövekedett nyálkatermelődéssel társulnak, a légutak gyulladásos és/vagy elzáródásos betegségei, a íibrotikus spektrum betegségei, rákok, anyagcsere-betegségek, pszichológiai rendellenességek és a perifériás vagy központi idegrendszer betegségei köréből választottak.14, 1-12. Compounds as defined in any one of claims 1 to 3 in the form shown or in the form of their acids or bases, or in the form of physiologically acceptable salts, or solvates thereof, optionally in the form of their racemates, pure stereoisomers, in particular enantiomers or diastereomers, or stereoisomers, in particular enantiomers or diastereomers. in any form of mixing, as a medicament for use as a medicament for the treatment of conditions or diseases that can be treated by inhibition of the PDE4 enzyme, wherein the conditions or diseases that can be treated by inhibition of PDE4 are inflammatory diseases of joints, wine and eyes, gastrointestinal diseases and diseases. complaints, inflammatory diseases of internal organs; hyperplastic diseases, respiratory or lung diseases associated with increased mucus production, inflammatory and / or occlusive disease of the respiratory tract, diseases of the librotic spectrum, cancers, metabolic diseases, psychological disorders and diseases of the peripheral or central nervous system.
HUE14718916A 2013-04-16 2014-04-15 Substituted condensed pyrimidine compounds HUE034254T2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP13001993 2013-04-16

Publications (1)

Publication Number Publication Date
HUE034254T2 true HUE034254T2 (en) 2018-02-28

Family

ID=48141722

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE14718916A HUE034254T2 (en) 2013-04-16 2014-04-15 Substituted condensed pyrimidine compounds

Country Status (13)

Country Link
US (1) US9527832B2 (en)
EP (1) EP2986600B1 (en)
JP (1) JP2016516787A (en)
AR (1) AR096040A1 (en)
AU (1) AU2014253810A1 (en)
BR (1) BR112015026055A2 (en)
CA (1) CA2909464A1 (en)
ES (1) ES2642822T3 (en)
HU (1) HUE034254T2 (en)
MX (1) MX2015013936A (en)
PL (1) PL2986600T3 (en)
TW (1) TW201512189A (en)
WO (1) WO2014170020A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR101197A1 (en) 2014-07-16 2016-11-30 Gruenenthal Gmbh PYRIMIDINES 2,5-REPLACED
AR101196A1 (en) * 2014-07-16 2016-11-30 Gruenenthal Gmbh SUBSTITUTED PYRIMIDINE COMPOUNDS
AR101198A1 (en) 2014-07-16 2016-11-30 Gruenenthal Gmbh PYRIMIDINES 2,5-REPLACED AS PDE4B INHIBITORS
AR107099A1 (en) * 2015-12-22 2018-03-21 Gruenenthal Gmbh ESPIRO- [HETEROCICLOALCANE INDOLIN] COMPOUNDS AS PHOSPHODESTERASE INHIBITORS
EP3573975A4 (en) * 2017-01-25 2020-08-12 GlaxoSmithKline Intellectual Property Management Limited Compounds
US20210130339A1 (en) * 2017-01-25 2021-05-06 Glaxosmithkline Intellectual Property Development Limited Compounds
CN109761809A (en) * 2019-02-16 2019-05-17 安徽华胜医药科技有限公司 Method for synthesizing 2-bromo-2- (2-fluoro-3-methoxyphenyl) ethyl acetate by catalytic reduction of palladium on carbon
WO2026040870A1 (en) * 2024-08-23 2026-02-26 深圳湾实验室 Compound targeting phosphodiesterase subtype pde4b and use thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1238149A (en) 1984-10-30 1988-06-14 Imperial Oil Limited Closed cell phenolic foams
DE59410119D1 (en) 1993-07-02 2002-06-20 Byk Gulden Lomberg Chem Fab FLUORALKOXY SUBSTITUTED BENZAMIDES AND THEIR USE AS CYCLIC NUCLEOTIDE PHOSPHODIESTERASE INHIBITORS
NZ545717A (en) 2003-08-05 2009-12-24 Vertex Pharma Hydrogenated quinazoline derivatives as inhibitors of voltage-gated ion channels
TW200621257A (en) 2004-10-20 2006-07-01 Astellas Pharma Inc Pyrimidine derivative fused with nonaromatic ring
US20060293343A1 (en) 2005-05-18 2006-12-28 Asahi Kasei Pharma Corporation Pyrimidine derivatives
CA2702518A1 (en) * 2007-10-19 2009-04-23 Boehringer Ingelheim International Gmbh New piperazino-dihydrothienopyrimidine derivatives
MX2015009677A (en) * 2013-02-04 2015-11-25 Gruenenthal Gmbh Novel substituted condensed pyrimidine compounds.

Also Published As

Publication number Publication date
AR096040A1 (en) 2015-12-02
JP2016516787A (en) 2016-06-09
CA2909464A1 (en) 2014-10-23
MX2015013936A (en) 2015-12-11
WO2014170020A1 (en) 2014-10-23
AU2014253810A1 (en) 2015-12-03
BR112015026055A2 (en) 2017-07-25
ES2642822T3 (en) 2017-11-20
PL2986600T3 (en) 2017-12-29
US9527832B2 (en) 2016-12-27
TW201512189A (en) 2015-04-01
EP2986600B1 (en) 2017-07-05
US20160031857A1 (en) 2016-02-04
EP2986600A1 (en) 2016-02-24

Similar Documents

Publication Publication Date Title
TWI330081B (en) New compounds, their preparations and their use in treatment and/or prevention of disease associated with glycogen synthase kinase-3
EP2986600B1 (en) Substituted condensed pyrimidine compounds
CA2718528C (en) Substituted 4-hydroxypyrimidine-5-carboxamides
EP2613781B1 (en) Indazole derivatives for use in the treatment of influenza virus infection
EP3638680B1 (en) Heteroaromatic compounds as vanin inhibitors
EP3426243B1 (en) 3-phosphoglycerate dehydrogenase inhibitors and uses thereof
AU2017388376A1 (en) Poly-ADP ribose polymerase (PARP) inhibitors
TW202342458A (en) Inhibitors of parg
JP2010502617A (en) Hydantoin derivatives useful as antibacterial substances
EP2933248B1 (en) Novel renin inhibitor
CN113454081A (en) Imidazopyridinyl compounds and their use for the treatment of proliferative diseases
JP2011525927A (en) Synthesis and use of heterocyclic antibacterial agents
AU2015291477A1 (en) Novel 2,5-substituted pyrimidines as PDE inhibitors
CN112752757B (en) Tyrosine amide derivatives as RHO-kinase inhibitors
WO2017156181A1 (en) 3-phosphoglycerate dehydrogenase inhibitors and uses thereof
EP2976338A1 (en) N-(2-cyano heterocyclyl)pyrazolo pyridones as janus kinase inhibitors
WO2018021977A1 (en) Glycine metabolism modulators and uses thereof
EP3853225B1 (en) N-(5-(3-(1-((thiazol-2-yl)amino)-1-oxopropan-2-yl)phenyl)pyridin-2-yl)acrylamide derivatives as cdk7 inhibitors for the treatment of cancer
KR102783635B1 (en) Pyrido[3,2-D]pyrimidine compounds, their use in treating proliferative diseases
JP7843071B2 (en) Drak2 inhibitors, methods for producing the same, and their use
CN102939087A (en) Novel indazole derivatives or salts thereof, production intermediates thereof, antioxidants using same, uses of indazole derivatives or salts thereof
HK40058867A (en) Imidazopyridinyl compounds and use thereof for treatment of proliferative disorders